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Chapter I: The story behind embryonal and fetal genome analysis 
 
1. In vitro fertilization: a fairy tale or not? 
According to the European Society of Human Reproduction and Embryology (ESHRE), one in six couples worldwide 
are affected by fertility problems (ESHRE, 2014). Assisted reproductive technologies (ARTs) might offer a solution 
for some of these couples, depending on their reason for infertility (Table 1). An estimated 1.5 million ART cycles are 
performed worldwide per year, with in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) among 
the most common forms of ART (1). Fifty-five percent of these cycles are performed in Europe (2) and Belgium 
belongs to the top 10 most performing countries that report their ART data to the ESHRE (1) (Table 2). The overall 
number of ART cycles registered by the ESHRE continues to grow each year.  
Male infertility Female infertility 
Decreased sperm count Ovulation disorders 
Decreased sperm 
motility 
Blocked/damaged fallopian tubes 
Genetic disorders Endometriosis 
 Premature ovarian failure 
 Genetic disorders 
Table 1: Well-known causes of infertility that might benefit from IVF/ICSI 
TREATMENT CYCLES IVF ICSI FER TOTAL ART 
FRANCE 20 995 39 079 23 841 85 594 
GERMANY 12 047 39 079 23 841 7 1251 
SPAIN 3 759 3 1671                        11 736 69 699 
ITALY 8 431 47 064 6 513                  64 197 
RUSSIA 21 967                       25 751                        10 321                   62 620 
UK 21 278 24 375 11 069 6 0151 
BELGIUM 3 996 13 611 9 277 28 578 
EUROPE 139 978 312 600 139 558 640 144 
Table 2: Treatment frequencies of ART in European Countries in 2012 
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Reports from ART clinics to the ESHRE in 2012 (top-7 countries with the highest number of ART cycles performed). FER: frozen embryo 
replacement, this refers to the thawing of embryos created during an earlier cycle that were subsequently frozen and stored for later 
use (1). The number of total ART also include less frequent forms of treatments such as egg donation, in vitro maturation and frozen 
oocyte replacement. 
1.1. From follicle-stimulation to embryo transfer 
IVF is a process of fertilization by combining an egg and sperm in vitro, in a laboratory dish. Infertile couples might 
turn to IVF for several reasons: blocked/damaged fallopian tubes, decreased sperm count or motility, premature 
ovarian failure, ovulation disorders, genetic disorders or unexplained infertility etc. (Table 1). 
The IVF process consists of five basic steps. First, the oocyte production is stimulated by follicle stimulating hormone 
(FSH), to increase the number of mature eggs released at ovulation. Without stimulation, only one mature egg is 
released per menstrual cycle. Until enough follicles are mature, the ovulation is antagonized by either gonadotropin 
releasing hormone agonists or antagonists. Finale maturation is stimulated by human chorionic gonadotropin and 
within 34-36 hours after this stimulation, the ovulation takes place. The eggs are removed by a minor surgical 
procedure. Subsequently, each egg is co-incubated in vitro with a large amount of sperm. However, when the sperm 
quality is low (low sperm count or low mobility), the fertilization is performed by ICSI. Instead of co-incubation, a 
single sperm is injected directly into the egg (Figure 1). Before ICSI, the surrounding cumulus cells are removed 
from the oocyte. As male infertility is a very important reason for infertility, ICSI is performed more than 
conventional IVF (Table 1&2).  After fertilization, the embryos are grown in vitro until day 3 or day 5 after fertilization, 
before one good quality embryo is transferred to the mother.  
 
Figure 1: Conventional IVF vs ICSI 
1.2. Embryo morphology as a selection criterion  
During in vitro embryonal development, the quality of the embryo is determined by its morphology at different 
stages of development. A correlation has been shown between the embryonal morphology and the ability to grow 
to the blastocyst stage (3). A good embryo selection method is important to maximize the success of the transfer 
and thereby avoid the need to transfer more than one embryo (4). Transferring more than one embryo risks the 
occurrence of multiple pregnancies with its complications.  
The morphology of the embryo can be scored at the pro-nuclear, cleavage and blastocyst stage. An embryo is in 
the pronuclear stage before the genetic material of the egg and the sperm have fused. The pronuclei are the nuclei 
Holding pipette 
Needle 
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of the sperm and egg cell during the process of fertilization. They should appear together, centrally in the oocyte 
and have approximately the same size. Within these pronuclei, nucleoli are visible at the pronuclear junction. A Z-
score (Z1-Z4) is appointed to the embryo depending on the size, number and distribution of these nucleoli. Each 
nucleus should have a similar number (between 3 and 7) and size of nucleoli (3). Embryos with a low Z-score will 
result in better quality cleavage stage embryos and blastocysts (5).  
 
Figure 2: Morphology of the pronuclei stage embryo 
Left: a normal distribution of nucleoli (nucleolus precursor bodies (NPBs)); Right: abnormal distribution of NPBs. PN: pronuclei; PB: polar 
body; ZP: Zona pellucida.  
At day 3 after fertilization, the embryo is at the cleavage stage and consists of 6 to 8 cells. Scoring at this stage is 
most commonly used. This scoring is based on the number and size of the blastomeres and the grade of cytoplasmic 
fragmentation (6-9) (Figure 3). Nevertheless, the specific grading system differs between centers.  However, the 
number of blastomeres has the highest predictive value (7, 9), because embryos dividing either too fast or too slow 
may have metabolic or chromosomal defects (8-14). 
 
Figure 3:  Morphology of the cleavage stage embryo (15) 
Top: optimal cleavage stage development; Bottom FLTR: Uneven cleavage, multinucleated blastomeres, high fragmentation. 
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Towards day 5 or 6 the embryo develops into a blastocyst. A blastocyst consists of an inner cell mass (ICM), which 
subsequently forms the fetus, a blastocoel, and the trophectoderm (TE), which will form the placental interface 
(Figure 4a). The Gardner grading system is frequently used to grade blastocysts based on the developmental stage, 
the ICM and the trophoblast (16). The developmental stage is graded from one to six, with six being the stage were 
the blastocyst is released from the zona pellucida. This process is called hatching (Figure 4b). The ICM and the TE 
get each a score from A to C, based on how compact the cells are (17) (Figure 4b). The blastocyst stage is the final 
stage before implantation takes place. During implantation the embryo adheres to the uterus wall.  
 
Figure 4a: Schematic representation of a blastocyst 
The fluid-filled cavity represents the blastocoel 
 
 
Figure 4b: Grading blastocyst morphology 
Top: Developmental stages of the blastocyst: first the blastocoel grows (grade 1-3), than blastocyst expansion occurs (grade 4) until the 
zona pellucida ruptures and hatching begins (grade 5) 
Down: The black arrows indicate the ICM, the white arrow show the TE. Grade A is a good quality embryo, Grade B is also good quality 
but ICM and/or TE cells are less compact, while grade C is a bad quality embryo (17) 
Although IVF is a widespread treatment, with the current state-of-the-art technology, the clinical pregnancy rate 
per transfer is only 33.8%, and 32.3% for ICSI (1). Obviously, embryo selection based on morphology alone does not 
predict the developmental potential of the embryo (18-20).  
1.3. Preimplantation genetic diagnosis and screening 
A lot of embryos suffer from genetic abnormalities during development that might impede with further 
development or result in birth defects (13, 21, 22). The prevalence of malformation in a pregnancy is approximately 
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2.5-3.2% of births and thereby, an estimated 8 million infants worldwide are born each year with a major birth 
defect (23). If diagnosis is performed before implantation, a non-affected embryo could be selected before embryo 
transfer. For couples with a known balanced or unbalanced chromosomal rearrangement, preimplantation genetic 
diagnosis (PGD) can be offered during ART to select against unbalanced rearrangements in the embryo (24). Early-
stage embryos also suffer from a high rate of spontaneous (mosaic) chromosomal aberrations and aneuploidy, 
reducing the embryo survival, implantation potential and hence the success rate of ART (25). Couples producing 
such embryos might benefit from preimplantation genetic screening (PGS). Both PGD and PGS analyze the genetic 
makeup of the embryo to select an embryo without genetic abnormalities for transfer to the woman. The big 
difference between PGD and PGS is the targeted patient population. PGD was originally developed to avoid the 
repeated choice for pregnancy termination in couples whose potential offspring is at risk for a specific severe 
Mendelian disorder, structural chromosomal aberration or mitochondrial disorder. PGS is often used for women 
suffering from recurrent implantation failure or repeated miscarriage. Those patients do not carry a specific genetic 
abnormality, but produce embryos with a general low quality genetic makeup.  
PGD/PGS is performed by the isolation of cells at day 3 or day 5 after fertilization or the isolation of a non-
functioning haploid polar body after meiosis I, before fertilization. At day 3, cleavage stage biopsy is performed by 
the isolation of one or two blastomeres through a hole in the zona pellucida (Figure 5).  Cells isolated at day 5, the 
blastocyst stage, are isolated from the TE after hatching. During this blastocyst biopsy, 4 to 6 trophoblasts are 
isolated for diagnosis.  
 
Figure 5: Cleavage stage biopsy. A) Hole in zona pellucida B) Isolation through micromanipulation (26). 
1.3.1.  PGD/PGS for chromosomal aberrations  
Embryos can suffer from structural or numerical abnormalities or even both. Structural abnormalities are 
mutations such as: translocations, inversions, deletions, duplications or insertions. They occur when a part of the 
chromosome is missing, multiplied or has switched places with another part. The latter is otherwise known as a 
chromosomal rearrangement arising by the simultaneous breakage of two chromosomal segments that rejoin 
within the same or a different chromosome (Figure 6). If no chromosomal parts are lost, this is a balanced 
rearrangement. A carrier of such balanced chromosomal rearrangement is phenotypically normal and the problem 
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will only arise during gametogenesis. A couple of which one of the partners is a carrier, might experience difficulties 
to conceive or give birth to a child with birth defects. Such a parental rearrangement might cause the gain or loss 
of certain chromosomal parts in some of the gametes, as illustrated in figure 6. Such insertions or deletions of 
chromosomal parts are referred to as copy number variants (CNVs). A numerical abnormality is the loss or gain of 
a complete chromosome that might arise during meiotic or mitotic divisions of the gametes or the embryo. The 
loss or gain of a chromosome, known as an aneuploidy, is the most frequent form and is the most common cause 
of miscarriages and implantation failure during IVF treatment. Numerical abnormalities are often only discovered 
by screening, except for Klinefelter syndrome which is a known indication for PGD.  
 
Figure 6: Chromosomal rearrangements 
A couple carrying a chromosomal rearrangement and their possible offsprings. They have a 50% chance for an affected 
child, 25% chance the child is normal and 25% the child is a carrier.  
The way a genetic analysis for chromosomal abnormalities in PGD was performed, changed over the years. 
Fluorescence in situ hybridization (FISH) was one of the first methods used for PGD (27). FISH is a technology that 
visualizes metaphase chromosomes by hybridization of fluorescent probes. However, it evaluates only a small part 
of the chromosomes in an embryo, at a relatively low resolution and it is rather labor intensive. Later, array 
Comparative Genomic Hybridization (aCGH) replaced FISH, enabling simultaneous screening for aneuploidies of all 
chromosomes, as well as large insertions, deletions and unbalanced translocations (28). In aCGH, the fetal DNA and 
a reference DNA sample are first labeled with each a different fluorescent dye (for instance Cy3/green color for 
fetal DNA and Cy5/red color for the reference). Both are then hybridized simultaneously to a microarray coated 
with single-stranded DNA probes (29). These probes can vary in size, but for PGD the bacterial artificial 
chromosomes (80000-200000bp) or BAC-arrays are most commonly used. After hybridization, the fluorescent 
pattern on the microarray will indicate the regions with either a deletion or insertion. A red signal would indicate 
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the presence of a deletion in that part of the fetal DNA and a green signal would indicate a duplication. ACGH has 
long been the state-of-the-art method in PGD for chromosomal abnormalities. However, massively parallel 
sequencing (MPS) is now claiming that position, showing a better resolution, lower cost and better signal-to-noise 
ratio compared to aCGH (30-32). The resolution of an aCGH is limited by the distance between the probes, which is 
fixed for a certain type of microarray. During MPS, the reads are distributed randomly across the whole genome 
and the number of reads will readily change the resolution. MPS allows sequencing different samples on a single 
run, which is referred to as multiplexing. In this respect, MPS is more flexible and presumably cheaper than aCGH.  
As only a small number of cells can be isolated from an embryo, the DNA of the cells will need to be amplified 
before performing genetic testing. One cell only contains 6 picogram (pg) of DNA and genetic testing, such as aCGH 
and MPS, will require nanograms (ng) of DNA. However, amplification of the DNA might introduce bias in the DNA 
sequence during amplification (33). More details about this amplification will be discussed below. However, some 
methods for genetic testing have been developed, circumventing the need for amplification. For instance, the 4-
hour quantitative real-time PCR-based chromosome screening technology uses a more targeted approach. The cells 
undergo a targeted multiplex PCR for 96 loci and these loci are subsequently interrogated on qPCR. Although, an 
amplification is still performed, this targeted approach will improve the success of amplification at each loci 
compared to a whole genome amplification (WGA) (34). Nevertheless, this remains a targeted approach that will 
probably never obtain the resolution possible by MPS.  
1.3.2.  PGD for single gene disorders 
Single gene disorders (SGDs) or Mendelian disorders can also be analyzed through PGD. SGDs are, in contrast to 
multifactorial disorders, caused by a mutation in a single gene. They are inherited according to the Mendelian model. 
Five main modes of inheritance exist: autosomal recessive, autosomal dominant, X-linked recessive, X-linked 
dominant and mitochondrial. In recessive disorders, two abnormal copies of the gene are essential to manifest the 
disease. A person with only one abnormal copy is known as a carrier or heterozygote. Two heterozygotes trying to 
have a child will have a 1 in 4 chance of having an affected offspring. The most common recessive SGD among 
Caucasians in Europe is cystic fibrosis and it was also the first SGD to be diagnosed by PGD (35). In dominant 
disorders, one abnormal copy of the gene is sufficient to manifest the disease. An affected individual has a 50% 
chance to transfer the defective gene to his offspring. Recessive X-linked disorders will mainly affect male 
offsprings if carried by the mother, as they will not have a normal copy to compensate for the defective one. In 
contrast, dominant X-linked disorders will mainly affect females, if the male partner was affected. Mitochondrial 
disorders are only passed on by females, as the male mitochondrial DNA will not enter the fetus. 
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Some individuals do not know they carry a mutation for a SGD and only discover that after having an affected child 
or an affected family member. Those couples could rely on PGD to select a non-affected embryo for transfer. 
However, some mutations occur spontaneously (de novo), during gamete formation or during embryogenesis and 
those mutations will only be discovered through screening by PGS.  
In most SGDs, the disease-causing gene can be mutated in various ways, which makes it harder to develop a 
universal diagnostic method for each SGD. For instance, more than 1000 different mutations can cause cystic 
fibrosis. Previously, the specific mutation was first determined in the parents or an affected family member and an 
individual targeted PCR was developed for each case. However, a PCR reaction can suffer from allelic dropouts 
(ADOs), especially when amplifying a low lumber of cells. ADO can seriously compromise the reliability of PGD, as 
a heterozygous embryo could be diagnosed as affected or unaffected depending on which allele would fail to 
amplify. The introduction of multiplex marker PCR led to some advances in the diagnosis of SGDs (36-38). Markers 
are determined by identifying family-specific polymorphisms that are linked to the mutation in that family. 
Changing the focus from one locus to multiple loci diminishes the problems occurring by contamination or ADO (37, 
38). A large multicenter study showed a higher validity and diagnostic value for multiplex PCR-based PGD than the 
singleplex (39). More recently, researchers began to develop SNP-array-based technologies, allowing the 
simultaneous analysis of (more than) one SGD and chromosome abnormality screening (40-45). However, these 
technologies are time consuming, costly, extremely complex and did not demonstrate the ability to detect all types 
of aneuploidies. Another recent advance in SGD diagnosis is the introduction of MPS. The cost and timescale might 
be reduced by multiplexing amplicons from different PCR reactions on a single sequencing run (46). Still, this 
approach also requires a specific test per couple. 
1.3.3.  Cleavage stage versus blastocyst biopsy  
Genetic analysis in PGD/PGS is performed on a small number of cells, isolated from the embryo. As mentioned 
above, three types of biopsy exist. Cleavage stage biopsy has long been the preferred isolation method (47), but in 
most fertilization centers a shift towards blastocyst biopsy was recently observed (48, 49). Although, the isolated 
TE cells during blastocyst biopsy are destined for the placenta, it was shown that the TE is an excellent predictor 
for the genetic makeup of the ICM (50). It was shown that the isolation of cells from a cleavage stage embryo, has 
an impact on the viability of the embryo and embryo implantation (48, 51, 52). Blastocyst biopsy will not have such 
an impact, as the fetal-determined cells remain untouched during isolation (53).  
The amount of cells available for diagnosis is important to overcome PCR failure, ADOs, non-uniform amplification 
of the DNA and cell cycle discrepancies (49, 54). Therefore, as only one or two blastomeres are isolated at cleavage 
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stage, this might result in a diagnostic failure (49). The isolation of more cells during TE biopsy will lead to better 
amplification and hence, a more confident genetic diagnosis (54).  
Furthermore, it has been shown that cleavage stage embryos show a higher rate of mosaicism for numerical and 
structural chromosomal aberrations (55). Mosaicisms arise when some cells from the same embryo have a different 
genetic make-up. Since only one or two cells can be biopsied on day 3, the mosaicism might be missed and this 
might influence the accuracy of PGD (56). Mosaicisms might also occur in blastocysts, but more cells are isolated 
during blastocyst biopsy, increasing the detection potential. In terms of mosaicisms, the TE is shown to be 
representative for the embryo, as the mosaic level is not higher for the TE compared to the ICM (18, 57). However, 
more research needs to be performed to understand the full extent of mosaicisms.  
Embryos selected for biopsy on day 5 carry a lower risk of being aneuploid (18, 19). Genomic activation of the 
embryo sets in at day 3 and thereby DNA-damage and -response pathways will be activated. This will lead to the 
loss or repair of some or even most of the abnormal embryos (58-60). Due to this natural selection against genomic 
abnormal embryos, genetic testing is needed for fewer, high quality embryos at the blastocyst stage. This makes 
genome-wide chromosome analysis on day 5 embryos more appropriate.  
However, a TE biopsy can only occur at day 5 and embryos should be transferred by day 6 the latest. TE biopsy, 
combined with PGD, hampers a fresh embryo transfer and implies vitrification of the embryos. Nevertheless, the 
cryopreservation methods have improved a lot over the recent years (61-63) and it was recently shown that embryo 
transfer after freezing and in a natural menstrual cycle leads to better IVF outcomes than fresh transfer in a 
stimulated cycle (63, 64). All of these issues make TE biopsies the preferred approach for PGD.  
2. Prenatal diagnosis: invasive or non-invasive?  
The concept of prenatal diagnosis is older than the concept of PGD, and dates back to the sixties. Prenatal diagnosis 
is performed to obtain information about the genome of the fetus during pregnancy and thereby discover possible 
genetic abnormalities. A prenatal ultrasound without genetic testing might lead to differential diagnosis (65). The 
fetal phenotype does not always reflect the fetal genotype, as a genetically abnormal fetus might not always show 
abnormalities on ultrasound. Sex determination and trisomy 21 detection were among the first indications for 
prenatal genetic testing. Today, we are able to diagnose big and small chromosomal abnormalities and SGDs at 
high resolutions. Efficient prenatal genomic-based diagnosis will be important to make an advised reproductive 
decision (66) or to prepare the future parents for the disability of their future child. Similar to PGD, a couple can 
perform a genetic analysis based on familial history or screen for de novo abnormalities. Based on the DNA material 
collected for diagnosis, three types of prenatal diagnosis exist.  
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2.1. Invasive cell-based prenatal diagnosis 
The state-of-the-art methods for prenatal diagnosis are amniocentesis and chorionic villus sampling (CVS). The 
first amniocentesis procedures date back to the late 1960s and were only performed on the highest risk patients 
(67). As ultrasound guidance was non-existing, the procedure was performed essentially blindly and thereby later 
in pregnancy (68). Nowadays, amniocentesis is performed in the second trimester, after week 13 and collects a 
small amount of amniotic fluid from the amniotic sac surrounding the fetus. The fluid is collected by inserting a 
fine needle through the abdomen into the uterus, guided by ultrasound (Figure 7). This fluid contains fetal cells for 
genetic testing, and other substances to check the overall fetal health. An amniocentesis is performed in women 
with an abnormal ultrasound, a family history for certain birth defects or a previous affected child. CVS is performed 
in the first trimester, between week 10 and 12 and collects chorionic villi from the placenta. The villi are the part 
were the placenta meets the uterus and are derived from the outer layer of the blastocyst (TE). The villi can be 
retrieved through the cervix (transcervical) or the abdominal wall (transabdominal) (Figure 7). The indications for 
CVS and amniocentesis are similar, but CVS will detect genetic problems earlier in pregnancy. 
 
Figure 7:  Schematic representation of the two types of CVS vs amniocentesis 
During these invasive tests, a large amount of cells is collected. This circumvents the need for WGA and thereby 
leads to a more accurate diagnosis of small variations. Previously, prenatal diagnosis was performed by generating 
a karyotype from the isolated DNA. However, the resolution for such analyses is rather limiting (69) and some small 
CNVs might be missed. The development of array-based techniques has improved the detection of small variants 
as compared to the standard karyotyping (70, 71). Microarray analysis will provide additional clinically relevant 
information over karyotyping in 6 % of the cases with an abnormal ultrasound (69). However, balanced 
chromosomal translocations are not detected by array, as there is no loss or gain of genetic material. Nevertheless, 
such balanced translocations will have no consequences for the current pregnancy, unless it occurs in an important 
gene region.  
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Nevertheless, invasive prenatal testing is not without risks. Amniocentesis and CVS induce, respectively, a 0.81% and 
2.2% risk for a miscarriage (72). However, these numbers should be interpreted with caution, as it is likely that 
pregnancy loss can also originate from other pregnancy-related and maternal factors (72, 73). 
2.2. Non-invasive cell-free prenatal diagnosis 
A recent evolution in prenatal diagnosis is the introduction of non-invasive prenatal testing (NIPT).  In 1997, cell-
free fetal DNA (cffDNA) was discovered in the maternal blood circulation (74). CffDNA is fetal DNA circulating freely 
in the maternal blood stream, derived from the cytotrophoblasts making up the placenta (75). This cell-free DNA 
can be isolated from the cell fraction of a maternal blood sample. The non-invasive nature of the method makes it 
an attractive alternative for the invasive methods. However, less than 7% of the cell-free DNA found in the blood is 
from the fetus (76), which makes it difficult to separate from the maternal DNA. Therefore, most commercially 
available NIPT tests only offer screening for trisomy 21, 13 and 18 (T21, T13 and T18). As long as not all chromosomal 
abnormalities are detectable with NIPT (77), the diagnosis by NIPT will not parallel the diagnosis by CVS or 
amniocentesis.  
Since the introduction of NIPT, the amount of invasive prenatal procedures has plummeted (78-80). Giving the 
limited conditions tested with cell-free NIPT, this decrease might have led to fewer serious genetic conditions 
detected (81). There is also a small chance for false positive results after cell-free NIPT (82). Therefore, NIPT should 
only be used as a screening method, as an alternative for ultrasound imaging and maternal serum marker screening 
(83). Integrating this technique into prenatal screening might have the potential to decrease the amount of 
invasive procedures due to a false positive ultrasound and serum screening (84).  
2.3. Non-invasive cell-based prenatal diagnosis 
The presence of fetal cells in maternal blood during pregnancy was already described in the 70s (85-87). Different 
types of fetal cells are present in the maternal bloodstream and three types have been the subject of research for 
prenatal diagnosis: fetal leukocytes, fetal nucleated red blood cells and trophoblasts. Over the past years, many 
attempts have been made to use these fetal cells present in the blood for fetal diagnosis (81). Still, none of them 
is ready for routine clinical practice.  
2.3.1.  Leukocytes 
Fetal leukocytes were amongst the first fetal cells discovered in the maternal blood of pregnant women (87). They 
discovered the presence of Y chromosome signals in both the maternal blood and the isolated leukocytes (86-88). 
However, fetal leukocytes were shown to persist in the maternal bloodstream for many years after giving birth 
(86, 88-91). Therefore, during a second pregnancy, leukocytes from the previous pregnancy might interfere with a 
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correct diagnosis of the current pregnancy. This implied the need for a short-lived fetal cell type, with limited 
replicating capacity, in the maternal bloodstream.  
2.3.2.  Nucleated red blood cells 
The presence of immature erythrocytes in pregnant women was already demonstrated in 1957 by fetal hemoglobin 
labeling (92). However, it took a longer time to prove the fetal nature of these cells. As these cells were nucleated, 
Y-chromosome staining was used to show their fetal nature (93). Some research groups showed the possibility to 
enrich these cells from maternal blood (94-97), and thereby they became the most popular cell types for prenatal 
diagnosis. However, lacking a specific fetal marker, the majority of the enriched cells were still of maternal origin 
(98-102). A large multicenter clinical project in 2002 by Bianchi et al. failed to show a high sensitivity for detecting 
fetal aneuploidy and failed to diagnose female fetuses (103). This complicates the use of these cells for prenatal 
diagnosis. This and their rather fragile nature, tempered the initial popularity of these cells for prenatal diagnosis.  
2.3.3. Trophoblasts 
Trophoblasts first line the outer layer of the blastocyst and develop into a large part of the placenta. These cells 
are in close contact with the maternal circulation (104). Extravillus trophoblast cells invade into the maternal tissue 
during placenta formation and this tumor-like behavior will transform the arteries. During this natural process, 
uninuclear endovascular trophoblasts might breach through the maternal circulation. It has been demonstrated 
that trophoblasts are consistently present in the maternal circulation from week 5 of gestation (105) (Figure 8), 
but are rapidly cleared after pregnancy (105). They can be distinguished from other blood cells by their large cell-
size (105) and detected by an epithelial cell marker, cytokeratin, not present on other cells in the blood (106, 107). 
This makes these cells attractive for use in prenatal diagnosis. One to six trophoblasts are present per milliliter of 
mother’s blood (107, 108). Some promising work has already been done to prove the potential of trophoblasts in 
prenatal diagnosis (105, 109, 110).  




Figure 8: Kinetics of circulating fetal trophoblastic cells (CFTCs) 
14 pregnant women during their first trimester from 5 to 12 weeks of gestation. A) Number of CFTCs per ml of blood. B) Mean and 95% 
confidence interval of CFTC number per ml of blood (105). 
 
3. Whole genome amplification: a necessary evil 
For applications, such as PGD and prenatal diagnosis, only limited genetic material is available. One cell contains 
only six pg of DNA, but analysis technologies such as aCGH and MPS demand nanograms to micrograms of DNA. An 
amplification of the genome will be essential to obtain reliable information about CNVs, aneuploidies or mutations 
present in the genome. WGA will amplify the entire genome, resulting in microgram quantities of amplified 
products. WGA might be compared with making a couple of copies from the genome of the cell. This is a critical 
component for obtaining genetic information, as the introduction of bias during amplification might influence the 
downstream results (111-114).  
Multiple methods have been developed, each with their specific strength and bias introduction (115-117). Different 
types of amplification bias exist. Some methods might cause representation bias, by a preferential amplification of 
certain regions opposed to others, and thereby the representation of the original genome after amplification will 
be incorrect. Others will introduce ADOs, which occurs when a supposedly heterozygous locus appears as 
homozygous due to the failure to amplify one of the loci. Nucleotide errors can also be introduced and they might 
introduce or mask a mutation present in the original genome. Another important contributing factor is the source 
of input material, as some WGA methods might act differently with degraded, fixed or colored DNA (118).  It is 
important to bear in mind that, to date, no WGA method is perfect. Therefore, the intended application and source 
material are an important factor to determine the method for amplification.  
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The existing WGA technologies are divided in 4 categories. They all made modifications to the classical PCR, that 
will give them their typical strengths and weaknesses.    
3.1. Once upon a time 
The first attempts to amplify genomic DNA were based on a standard PCR reaction, but with reduced specificity, 
allowing for a general amplification of the DNA. The two most widely used methods were: primer extension 
preamplification-PCR (PEP-PCR) and degenerate oligonucleotide primed-PCR (DOP-PCR) (116, 119). PEP-PCR uses a 
mixture of 15-base random oligonucleotides to perform repeated primer extensions (119) at a low annealing 
temperature. Although, random bases will increase the amplification yield, it also decreases the fidelity (120). As 
random primers are used, a high amount of primers is added to be able to cover each part of the genome. This 
might lead to primer-dimer formation, a well-known problem for PEP-PCR (121). As a consequence, less primers are 
available for the amplification reaction, thereby reducing the amplification efficiency. 
To improve priming, DOP-PCR employs primers with an internal stretch of degenerate bases, flanked with specific 
sequences and uses an increasing annealing temperature (116). The degenerate part of the primers is a mix of 
similar sequences where some positions contain bases that can bind to any other base pair. These short base 
sequences can match easier across the DNA (122), but not completely random because of the presence of the 
specific region (Figure 9). Nevertheless, the specific bases at 3’ can result in over-amplification of regions with a 
perfect match for this region (123). The annealing temperature starts low, to allow for many aspecific binding sites 
across the genome. Subsequently the temperature is increased, to prime more specific, only at the fragments 
previously tagged with the primers (124). 
However, both PCR-based methods results in loss of signal and the introduction of nucleotide errors (125).  




  Figure 9: Schematic representation of DOP-PCR 
3.2. Multiple displacement amplification 
Multiple displacement amplification (MDA) based methods are isothermal, in contrast to the previous thermally 
cycled WGA (126, 127). These methods use the Phi29 polymerase, which exhibits strand displacement activity (128, 
129) and 3’-5’ exonuclease activity. Strand displacement occurs when the polymerase encounters other nucleotide 
sequences on the same strand. The polymerase will displace this sequence and thereby create a new single 
stranded sequence, which is available again for priming and extension (Figure 10). Due to its 3’-5’ exonuclease 
activity, Phi29 is also a high fidelity and high processivity polymerase, resulting in low error rates, longer reads and 
higher yields during amplification. In the end, a network of sequences has been created by hyper-branching, 
covering a bigger part of the genome, with a lower error rate (130). 
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Figure 10: Schematic representation of the multiple displacement amplification (MDA) technology 
Comparable to PEP WGA, MDA-based methods use also a random primer, leading to high yields, but low fidelity 
(126, 131). The most well-known commercially available MDA kits are: GenomiPhi (GE Healthcare Life Sciences) and 
REPLI-g (Qiagen).  
3.3. Hybrid WGA methods 
Previous methods were all based on an exponential amplification of the DNA. All errors introduced during 
amplification will thereby also be amplified exponentially. Hybrid methods perform a semi-linear amplification. 
First a pre-amplification is performed of only a few cycles, using a MDA-based amplification (Figure 11). The 
generated amplicons can form loops, as they have complementary parts with a constant sequence, at both ends. 
As a consequence, they are no longer available as template during this pre-amplification step.  Thereby, a more 
homogeneous template is created for further exponential amplification with universal primers (132, 133). Two 
recent examples of such hybrid WGA are: PicoPLEX/SurePlex (Rubicon Genomics Inc., MI 48108, USA / BlueGnome 
Ltd., Mill Court, Great Shelford, Cambridge, UK) and Multiple Annealing and Looping Based Amplification Cycles 
(MALBAC) (Yikon genomics, Beijing, China). Both methods are similar, but with some discrepancies in the primer-
sequence. PicoPLEX will use self-inert degenerative primers, whereas MALBAC uses random primers. However, their 
primers are both flanked with complementary ends for the looping formation,  MALBAC primers are more focused 
on the formation of these loops (133), whereas PicoPLEX primers are more focused on a good primer distribution 
across the genome (132).  
 
Figure 11: Schematic representation of hybrid WGA technologies 
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3.4. Ligation-based WGA 
The most recent example of ligation-based WGA is Ampli1 (Silicon Biosystems, Castel Maggiore, Italy). The template 
is fragmented through a restriction enzyme, prior to amplification. This will create sticky ends for the ligation of 
adaptors. Subsequently, sequence-specific primers (complementary to the adaptor sequence) will bind and thereby 
start amplification (134). As the primers will bind to only one specific sequence, the binding efficiency is constant 
for all primers, in contrast to degenerate primers. However, the amplified fragments are shorter, rendering it less 
useful for applications where linkage information is important. In contrast, Ampli1 will perform better on degraded 
material (135) than WGA methods creating longer amplicons (118). 
 
Figure 12: Schematic representation of ligation-based PCR 
3.5. The importance of the downstream application 
All WGA methods are in some way trying to minimize the introduced bias, but no WGA method, to date, is perfect. 
However, the impact of the bias on the resulting data could be reduced by selecting the ideal WGA for this 
application or starting material. For instance, MDA-based methods use a high fidelity polymerase, which makes 
them more preferable for SNP detection than hybrid methods using Taq polymerase. The high fidelity polymerase, 
Phi29, has a 3’-5’ proofreading activity with an error rate between 1*10-6 - 10-7 (136). Due to the proofreading activity, 
the polymerase has an exonuclease activity, allowing the removal of erroneously inserted bases. Taq polymerase 
lacks this proofreading activity and thereby the error rate increases to 2*10-4 (137, 138). However, the phi29 
polymerase will underrepresent regions close to the template termini and tends to over-amplify the first amplified 
fragments, rendering a non-uniform amplification (130).  In contrast, hybrid methods will perform a more balanced 
amplification than the hyper-branching MDA methods, due to their semi-linear nature. Therefore, hybrid methods 
will result in a better CNV profile (130).  
Some WGA methods have difficulties to amplify degraded material. For instance, due to hyper-branching, MDA will 
be more sensitive to template fragmentation, as the opportunities for hyper-branching and priming will be 
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decreased on each short molecule (118). As the polymerase is already sensitive to template termini, the problem of 
underrepresentation will enlarge with more template termini, as in the case with fragmented DNA (127, 139).  
Fixative agents are sometimes used to limit biological or chemical degradation of your template. In many non-
invasive cell-based prenatal settings, fixation becomes more important (105, 110). However, these fixatives have 
also shown to damage the DNA (140-143). The most widely used fixative is formaldehyde and it is known to break 
inter-chain hydrogen bonds in AT-rich regions of a double-stranded template. Formaldehyde will further react with 
the free bases (144), which could lead to DNA fragmentation (144). This renders formaldehyde fixed samples also 
less preferable templates for some WGA methods. Therefore, Ampli1 or other WGA methods creating short 
fragments might be more preferable for fixed templates. 
4. Low-pass whole-genome sequencing 
4.1. DNA sequencing in general 
DNA sequencing is used to determine the precise order of nucleotides within a DNA molecule. DNA consists of four 
basic types of nucleotides, based on their present nitrogenous base: Adenine (A), Cytosine (C), Guanine (G) or 
Thymine (T). DNA occurs as a double-stranded molecule in nature. Each base will form a pair through hydrogen 
bonds with a complementary base (A-T or G-C) on the opposite DNA-strand (Figure 13). All humans carry DNA in 
their cells and the precise order of these bases in their DNA will be unique for every person, except for homozygous 
twins. 
 
Figure 13: Nucleotide formations in the DNA structure 
The human DNA consists of three billion base pairs. To sequence the complete human genome at a single base pair 
resolution, a very high sequencing coverage is required. The sequencing coverage is the average number of times 
each nucleotide is sequenced. This will depend on the number of reads created during the sequencing run, the 
length of these reads and the assumption that reads are distributed randomly across the genome (145). The breadth 
of coverage is different from the sequencing coverage, as this is the percentage of target bases that are sequenced 
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a given number of times. For instance, a genome sequenced at a coverage of 30X, with a breadth of coverage of 
95% at 30X, will indicate that 5% of the bases failed to reach the 30X coverage. Obviously, a higher coverage 
inevitably requires a higher cost, as the read number or read length will increase. Therefore, it is important to 
consider the desired coverage for the downstream application before sequencing.  
To detect large CNVs or aneuploidies, a deep sequencing at a single base pair resolution is not required. Low pass 
or shallow whole-genome sequencing will be more cost effective to detect these large CNVs (Figure 14). In contrast 
to deep sequencing, the coverage is low in low-pass sequencing. Still, this will be enough to detect the real CNVs, 
as the absence of big genomic parts will not be the result of the random read distribution.  
               
Figure 14:  Shallow sequencing vs deep sequencing 
4.2. First generation sequencing 
F. Sanger developed the first DNA sequencing method in 1975 (146). Sanger sequencing has been the dominant 
sequencing technique for several decades. It is based upon the random incorporation of dNTPs and chain-
terminating dideoxycucleotides (ddNTPs) during in vitro DNA replication. This is an example of sequencing by 
synthesis (SBS), as the sequence is determined by re-synthesis of that sequence. The ddNTPs lack a 3’ OH group, 
which impedes further incorporation of nucleotides. Thereby, a mixture of complementary DNA strands of variable 
length are synthesized and they are subsequently size-separated using capillary electrophoresis. The four different 
ddNTP types were initially labeled, each to a unique fluorochrome. Therefore, every last nucleotide of a fragment 
can be identified by its label and thereby listing all fragments by size will identify the complete sequence. Sanger 
sequencing allows for long read sequencing, up to 1000bp and longer, but in terms of large-scale sequencing it 
will be too expensive (147-149).  
4.3. Second-generation sequencing 
By the mid-1990s, several second-generation sequencing methods, also called next-generation sequencing or MPS 
methods, made their appearances. They are able to generate an enormous amount of sequencing data during a 
single sequencing run and this at an affordable price. Multiple samples can be sequenced in parallel on one run, 
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several competitors entered the market for second generation sequencing, nowadays Illumina and Ion Torrent 
mainly dominate this market.  
4.3.1. Illumina sequencing 
The standard workflow for Illumina sequencing consists of three main parts: a library preparation, followed by 
clonal amplification and sequencing (149-151). During library preparation, the DNA is prepared to be compatible 
with the sequencing system. In the case of Illumina, the DNA should be able to bind to the probes on the flowcell. 
These probes are short identical single stranded sequences. Different types of library preparation methods exist, 
depending on the source material and the desired application (genomic sequencing, targeted sequencing…). 
However in general, the core steps for library preparation are: i) fragmentation/sizing of the DNA to the desired 
length, ii) making all fragments completely double-stranded and iii) attach adapters to the end of the fragments.  
For CNV detection in PGD or prenatal samples, the source material is WGA material or genomic DNA. In such settings, 
three well-known library preparation methods are available for genome-wide Illumina sequencing. TruSeq 
(originally from Illumina) and NEBnext Ultra (generic version from New England Biolabs) are two examples of 
library preparation methods that rely on a fragmentation step independently from the library preparation protocol. 
In those settings, physical fragmentation is often performed by acoustic shearing of the DNA with, for instance, a 
Covaris instrument (Covaris, Woburn, MA). A third library preparation method, Nextera (Illumina), has an integrated 
enzymatic fragmentation step, called tagmentation. The DNA is fragmented and simultaneously tagged with 
adaptor sequences using a transposase enzyme. This will decrease preparation and handling time during library 
preparation, but enzymatic fragmentation is less precise than physical fragmentation (152).  
Only the fragments with adaptors attached to the end will bind to the flowcell (Figure 15). Most library prep 
methods will enrich for these fragments using an enrichment PCR. However, PCR will introduce bias during 
amplification and therefore the reliability of the library preparation might increase by omitting this step. Illumina 
has already developed such a PCR-free library preparation method (TruSeq PCR-free library prep). 
 
Figure 15: Adaptor-ligated fragment for Illumina sequencing.  
An insert is a fragment with an unknown sequence; P5 and P7 are probe binding sites for flowcell binding; the sequencing primers are 
the primer binding sites used during the actual sequencing-step and index 1 & 2 are barcodes that will identify the individual samples 
during analysis. All molecules derived from one sample carry the same index sequence. For single-end sequencing only prime-site 1 is 
introduced, paired-end sequencing will need both sites. Similar for single and dual indexing.  
 
Chapter I: The story behind embryonal and fetal genome analysis 
35 
 
After library preparation, the adaptor-ligated fragments are denatured and immobilized on the flowcell for 
subsequent clonal amplification by an isothermal bridge PCR (Figure 16). First, the immobilized probe is used as a 
primer to create the complement of each fragment, whereupon the original strands are washed away. Subsequently, 
these single stranded fragments will form bridges by binding to a complementary probe using their free end. The 
probe sequence is again used as a primer for the replication of these fragments, after which the new and old 
fragments are separated by a denaturation step. This bridge formation will be repeated until clusters are created, 
consisting each of a 1000 identical copies of a single DNA molecule.  
 
Figure 16: Schematic illustration of bridge amplification during Illumina sequencing 
Finally, the sequence of each single molecule is determined during a sequencing-step. The sequencing starts from 
the sequencing primer binding site at the 3’ side of the created fragments. Illumina also uses the SBS technology, 
as the sequence is determined by a step-by-step incorporation of a fluorescent nucleotide complementary to the 
single-ended fragment (Figure 17). Similar to Sanger, a chain-termination principle is used and four differentially 
labelled nucleotides were added simultaneously, competing each cycle for incorporation. Different from Sanger is 
the reversibility of the chain-termination and the absence of non-fluorescent labelled nucleotides. The 
incorporation of a fluorescent labelled nucleotide can be detected immediately, as for each molecule a complete 
cluster of fragments lights-up simultaneously.  After detection, the blocking group and fluorescent label are 
removed and another cycle is initiated. At the end of this sequencing process, a sequencing read is created for each 
cluster/molecule. 
 
Figure 17: The sequencing by synthesis technology by Illumina 
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The number of cycles will determine the length of these reads, but at this point the read length is limited to 300bp 
(153). Different commercial kits are available for sequencing at specific read lengths, performing single or paired-
end sequencing. Single-end sequencing is performed as described above, creating one read per molecule starting 
from the sense strand. For paired-end sequencing, the whole process is repeated starting from the anti-sense 
strand. In this way, two reads are created per molecule, each starting from another side. This will increase the 
coverage of the genome and is more preferable when longer fragments are sequenced. Illumina offers different 
sequencing platforms, ranging from benchtop sequencers (MiniSeq, MiSeq and NextSeq series) to production-scale 
sequencers (HiSeq and NovaSeq series). The choice for a specific sequencer series depends on the size of sample 
genome, the aimed sequence depth and the amount of samples to sequence at a certain depth. More samples per 
run will result in less sequence coverage/depth per sample, but also a lower price per sample.  
4.3.2. Ion Torrent sequencing 
The Ion Torrent semiconductor technology from Life Technologies translates simple chemical changes to digital 
information on a semiconductor chip. The standard workflow also consists of a library preparation, clonal 
amplification and sequencing. The adaptor-ligated fragments are linked to 3-micron diameter beads, known as Ion 
Sphere particles. The fragments are further clonally amplified by emulsion PCR on the beads and those beads are 
loaded on a semiconductor chip, each in separate wells. During the sequencing-step, each of the four nucleotides 
is introduced sequentially, as they do not carry a blocking group. If the correct base is introduced, a hydrogen ion 
will be released and change the charge. This will, subsequently, change the pH and this pH change will be detected 
proportional to the number of bases incorporated (Figure 18).   
 
Figure 18: semiconductor sequencing by the Ion Torrent technology 
Ion Torrent has four different sequencing platforms: The Ion Proton, the Ion Personal Genome Machine, and the Ion 
S5 and S5 XL systems. None of them is able to reach the capacity of Illumina, but they can create reads up to 400bp 
and with the S5 systems even up to 600bp. Ion Torrent’s biggest downside is the difficulty to sequence 
homopolymer DNA stretches. As no blocking group is present, more nucleotides of the same type can be introduced 
during one cycle. Unfortunately, the signal does not increase proportionally with the number of bases introduced 
and after eight bases, the signal will no longer represent the correct number of bases. 
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4.4. Third generation sequencing 
Recently, single-molecule technologies have been introduced. They promise to sequence high throughput, without 
the need for the clonal amplification step. The two most well-known single-molecule instruments are: The MinION 
from Oxford Nanopore and the PacBio RS from Pacific Biosciences (CA, USA). Pacific Biosciences (CA, USA) developed 
the Pacbio RS with the single molecule real-time sequencing technology to create true long reads of ±20kb. Zero-
Mode Waveguides allow for real-time monitoring of base incorporation without the need for clonal amplification 
of the single molecule. This approach does not only result in unobstructed views of the sequence, it also reduces 
the degree of bias introduced. Nevertheless, the Pacbio instrument is very expensive, takes up a lot of space and 
requires multi-mg sample input. Another company engaged in long read sequencing, called Oxford Nanopore, has 
developed a low-cost, portable instrument to create true long reads. The MinION, as the instrument is called, 
consists of 512 pores to each fit a single DNA molecule. Common read lengths during Nanopore sequencing range 
from 6000 to 48000 bases (154). Similar to the PacBio, the bases are monitored in real-time without clonal 
amplification, but the identification and detection of the bases is different. An ion current flows through the pore 
and is partly blocked when a stretch of bases enters the pore. The fraction of the ion current that is blocked depends 
on the nucleotide within the pore (155-157). Nevertheless, this MinION has some drawbacks, as it is not yet 
commercially available, has a lower base-calling accuracy than conventional methods and whole-genome 
sequencing (WGS) is not yet possible.  
4.5. Data analysis 
Based on the hypothesis that there is a correlation between depth of coverage of a genomic region and the copy 
number (CN) of that region, the detection of CNVs, after low-pass MPS, might be performed using ‘Depth of coverage’ 
(DOP) analysis methods (158). Different types of DOP methods exist, but it would lead us too far to list all of these 
possibilities in this dissertation. QDNASeq and ReadDepth are examples of DOP methods that are not using a 
reference to call CNVs and are both correcting for GC content and mappability. They divide the genome in non-
overlapping fixed size parts, so called windows/bins (159, 160). The size of these windows will determine the 
minimum size of the CNVs which can be detected. Generally, CNVs three to five times the size of the windows can 
be detected. First, the number of reads mapped to each window is determined. As this reads number is influenced 
by certain factors, such as GC-content and mappability, the number of reads mapped per window is normalized 
according to these factors. After GC-content and mappability normalization, read counts are also median-
normalized by dividing the number of reads in each window by the median number of reads across all windows. 
As CNVs are assumed to be rare, the median number of reads across all windows is a fair estimate of the expected 
number of reads per window for a perfectly diploid genome. As such, the median-normalized read counts represent 
a measure for the deviation from diploidy for each window and a CN estimate is calculated using the following 
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formula: CN= 2(read count/median read count). Then, a circular binary segmentation (CBS) algorithm (161) is applied 
which groups windows into larger contiguous regions with an equal CN. The mean of read counts of the windows 
contained in the segments are used as an estimator of the copy number of the whole segment. After this 
segmentation, CNVs are called when the segment’s log2(CN/2) surpasses a certain threshold. Based on literature 
review and own experience a threshold of +/- 0.35 performs well (161). The ideal window size for a specific sample 
will depend on its variance in read distribution across the genome. Bigger window sizes will smoothen the variance, 
lowering the chance of detecting false CNVs, but also lowering the resolution for CNV detection. A bigger variation 
in read distribution across the genome might indicate the presence of bias in the genome. Samples with a bigger 
variation might benefit from such larger window sizes, as this will avoid the detection of false CNVs. Nevertheless, 
too much smoothing, in samples with a very low amount of variance, might result in undetected CNVs. Therefore, 

























Chapter II: Aims and overview 
This dissertation consists of three parts. In the first main part we focus on CNV detection after shallow MPS on a 
limited amount of cells, as would be performed in a PGD-like setting using MPS. The second part is focused on 
another aspect of PGD, the SGDs. In the last part, we focus no longer on PGD, but on cell-based non-invasive prenatal 
diagnosis. More specific, the possibility to determine fetal identity of an isolated cell using short tandem repeat 
(STR) profiling.  
One of the main goals of this dissertation was to show the possibility to apply shallow MPS for CNV detection in 
PGD and add evidence that MPS is a valuable and efficient substitute for state-of-the-art aCGH technology. As only 
4 to 6 trophoblast cells are available to perform PGD, amplifying the DNA of those cells without introducing bias, 
will be an important first step in our workflow. The WGA method chosen to amplify the DNA must be able to 
reproduce a reliable representation of the CNVs present in the original cells. Therefore, in Chapter III, two prominent 
WGA methods, PicoPLEX/SurePlex (Rubicon Genomics Inc., MI 48108, USA / BlueGnome Ltd., Mill Court, Great Shelford, 
Cambridge, UK) and MALBAC (Yikon genomics, Beijing, China), were compared for their ability to amplify a limited 
number of cells for CNV detection after shallow MPS. SurePlex is the standard WGA method for PGD using aCGH and 
MALBAC was, at that time, a new WGA method using a similar technology as SurePlex. They are both hybrid PCR 
methods resulting in a semi-linear amplification. As a standard library preparation method also includes a PCR-
step, two different library preparation methods were compared, one with and one without the PCR-step. The study 
was designed to resemble a possible workflow for CNV detection in PGD using MPS and to thereby discover which 
WGA method would be most suitable in such setting. 
Subsequently, a large clinical study was initiated to evaluate the use of shallow MPS for CNV detection in PGD on 
trophectoderm cells of blastocysts and compare the results with the state-of-the-art technology in terms of 
accuracy. ACGH was the state-of-the-art technology in PGD, but in terms of cost, resolution, accuracy and flexibility, 
shallow MPS could possibly outperform aCGH. This study is described in Chapter IV. SurePlex amplified DNA material 
of 47 embryos was analyzed after shallow MPS for the presence of CNVs and aneuploidies of ≥3Mb and the outcome 
was compared to previous aCGH results. Sequencing was performed using both Illumina (NextSeq) and Ion Torrent 
(Ion Proton) sequencing as most clinical genetic labs should have access to one of these benchtop sequencers. 
After this study, our first main goal, to introduce shallow MPS in PGD, should be accomplished. 
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CNA analysis starting from a limited amount of DNA has also several other applications. Therefore, the complete 
workflow used in Chapter IV has been described in detail in Chapter V, including some tips and tricks to guarantee 
the success.  
Although SurePlex has been successfully applied for PGD, a resolution of < 3Mb was hampered by WGA 
representation bias introduced during amplification. In the meantime, we were also approached by several 
commercial partners to test their new WGA methods for CNV detection after single cell MPS. Therefore, our next 
goal was to find a WGA method that was able to amplify single cells without representation bias for CNV analysis 
after shallow MPS. In Chapter VI, the TruePrime WGA method (Sygnis, Heidelberg, Germany) was compared in this 
context to previous SurePlex results. TruePrime uses a new type of amplification technology, as no artificial primers 
are added to the reaction. A DNA primase, TthPrimPol, will synthesize primers for the Phi29 DNA polymerase. 
Subsequently, Phi29 polymerase performs polymerization and strand displacement as in a classical MDA. The non-
artificial primers, which could lead to a lower representation bias, combined with the high-fidelity of Phi29, could 
theoretically lead to an ideal WGA method. However, TruePrime WGA seemed unsuitable for CNV detection after 
MPS on a limited number of cells.  
In Chapter VII, two new methods, DOPlify (Reproductive Health Science, Thebarton, Australia) and PicoPLEX DNA-
Seq (Rubicon Genomics Inc., MI 48108, USA) , were compared to two older WGA methods, Ampli1 (Silicon Biosystems, 
Castel Maggiore, Italy) and REPLI-g (Rubicon Genomics Inc., MI 48108, USA). Thereby, four of the main types of WGA 
were tested in one study. DOPlify is an advanced DOP-PCR based WGA method, PicoPLEX DNA-Seq is a hybrid PCR 
method based on the SurePlex WGA principle, Ampli1 is a ligation-based method and REPLI-g is a MDA method. They 
were compared in a similar setting as the studies described above, except for the library preparation. In Chapter III 
we demonstrated that a PCR-free library preparation improved the CNV analysis and therefore all samples in the 
current study were prepped using a PCR-free library preparation. After this study, we hope to accomplish our goal 
with at least one WGA method, amplifying single cells without bias influencing CNV analysis at a 3Mb resolution 
after shallow MPS.  
Another goal in this dissertation was to simultaneously analyze several monogenetic disorders in PGD using MPS. 
Current procedures for monogenetic PGD are time consuming, as for each mutation a specific test is designed. A 
test, applicable to all patients, simultaneously testing for multiple disorders would be more efficient. The TruSight 
One sequencing panel might be such a test, as it has been applied to screen for different monogenetic disorders in 
prenatal diagnosis using CVS. This panel simultaneously captures more than 4800 genomic regions associated with 
certain monogenic disorders and analyzes them on a single sequencing run. In contrast to PGD samples, CVS 
samples contain a lot of cells and thereby do not need amplification before analysis. The TruSight panel was 
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optimized for such bulk DNA samples and might therefore perform differently on WGA samples. In Chapter VIII, 
SurePlex, MALBAC, Ampli1 and REPLI-g were used to amplify the DNA of three-cell samples and the amplification 
products were prepped with the TruSight panel. DOPlify and PicoPLEX DNA-Seq did not exist yet and were therefore 
not included. The study should show if a reliable detection of SNVs is possible using the panel after amplification 
of only three cells.  
The final part of this dissertation is focused on the preparation of genetic analysis tools applicable in cell-based 
prenatal diagnosis. Current state-of-the-art prenatal diagnostic methods are invasive and carry some risks for the 
fetus. The isolation of fetal cells from maternal blood, cell-based NIPT, would be a non-invasive alternative. Similar 
to PGD, only a limited number of fetal cells is available in one blood sample. Therefore, our workflow, previously 
developed for CNV detection in PGD, could also be applied in cell-based NIPT. As no specific marker for fetal cells 
is available, the fetal origin of the isolated cells should be determined in another way before genetic analysis. In 
Chapter IX, STR-analysis is proposed to identify the genetic origin of a single cell. The DNA of this cell is also needed 
for the genetic diagnosis, such as CNV analysis. Therefore, WGA is inevitable. Similar to CNV analysis, the used WGA 
method might influence the STR results. We compared SurePlex, Ampli1, DOPlify and REPLI-g for their suitability to 
detect STR markers after single cell amplification.  
However, genetic analysis in cell-based NIPT cannot always be performed on-site or immediately upon blood 
retrieval. The widely used EDTA blood tubes demand blood processing within 4 hours, otherwise the cell quality 
might drop, hampering fetal cell isolation. Cell-free DNA BCT (cfDNA) tubes (Streck, Nebraska, USA) are designed to 
prevent lysis of nucleated blood cells by fixation of the cells. This fixation step might have an influence on the DNA 
of the cell and the performance of the WGA method. In Chapter X, we demonstrated the use of BCT reagents from 
Streck as a fixative for STR and CNV analysis of a single cell after amplification. The influence on the performance 
of SurePlex, Ampli1, DOPlify and REPLI-g was analyzed. A WGA method suitable for cell-based NIPT, should be able 
to amplify a single cell to determine the genetic identity of a cell and perform a reliable detection of CNVs after 
amplification of a single cell. After this study, we should have the tools for a possible genetic analysis of single 
fetal cells isolated in the context of cell-based NIPT.  
Chapter XI provides a general conclusion of this dissertation. In Chapter XII, the broader international context of 
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Current whole genome amplification (WGA) methods lead to amplification bias resulting in over- and under-
represented regions in the genome. Nevertheless, certain WGA methods, such as SurePlex and subsequent aCGH 
analysis, make it possible to detect copy number alterations (CNAs) at a 10 Mb resolution. A more uniform WGA 
combined with massively parallel sequencing (MPS), however, could allow detection at higher resolution and lower 
cost. Recently, MALBAC, a new WGA method, claims unparalleled performance. Here, we compared the well-
established SurePlex and MALBAC WGA for their ability to detect CNAs in MPS generated data and, in addition, 
compared PCR-free MPS library preparation with the standard enrichment PCR library preparation. Results showed 
that SurePlex amplification led to more uniformity across the genome, allowing for a better CNA detection with 
less false positives compared to MALBAC amplified samples. An even more uniform coverage was observed in 
samples following a PCR-free library preparation. In general, the combination of SurePlex and MPS led to the same 
chromosomal profile compared to a reference aCGH from unamplified genomic DNA, underlining the large potential 
of MPS techniques in CNA detection from a limited number of DNA material. 
2. Introduction 
Today, massively parallel sequencing (MPS) techniques undergo a rapid and continuous evolution and improvement 
in accuracy, speed, and cost efficiency. An important factor determining the success of the sequencing of limited 
numbers of starting material is the whole genome amplification (WGA) protocol. Bias introduced during this 
amplification process may lead to misinterpretations of the genomic profile. Especially when very low amounts of 
DNA have to be amplified, such as DNA from single cells, some WGA methods will lead to a disproportionate 
amplification of genomic regions. This results in false positive or false negative copy number changes and allelic 
dropouts and will be of great importance for applications with the purpose of detecting copy number changes in 
the genome. An example of such application is pre-implantation genetic diagnosis (PGD) to select an embryo fit 
for implantation based on the DNA analysis of 4-7 trophectoderm cells. State-of-the-art PGD, using array 
Comparative Genomic Hybridization (aCGH), allows to determine the aneuploidy in the embryo as well as copy 
number alterations (CNAs), such as deletions, duplications and unbalanced translocations of size larger than 10Mb. 
Nowadays, MPS techniques are being introduced in this field (32, 162-164) which rises the opportunity to increase 
the resolution at a reasonable price. Oncogenetics is another field where a faithful analysis of a limited number of 
DNA is of great interest. Analyzing the genome of individual cells is important to dissect cancer evolution and to 
provide the potential to considerably change both cancer research and clinical practice (165). 
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A number of commercially available WGA kits have already been individually tested for single cell sequencing, 
including degenerate oligonucleotide primed PCR (166) and primer extension PCR (119, 167). However, these 
resulted in allelic drop out (ADO) or preferential amplification of one of both alleles (125). Another technique, 
PicoPLEX/SurePlex (Rubicon Genomics Inc., MI 48108, USA / BlueGnome Ltd., Mill Court, Great Shelford, Cambridge, 
UK) which is the current standard WGA method for PGD aCGH, is based on the use of specific self-inert degenerative 
primers in the formation of an in vitro molecular library that can be amplified by PCR utilizing flanking universal 
priming sites. Based on the company brochures, an ADO rate limited to 10% can be expected, which is a major 
improvement over previous PCR-based methods. Recently, a new method, Multiple Annealing and Looping Based 
Amplification Cycles (MALBAC) (Yikon genomics, Beijing, China) was developed. According to their patent, this 
method would lead to less amplification bias compared to the SurePlex procedure (WO 2012166425 A2). As the 
name suggests, loops are formed from the first generated amplicons, which ensures that these amplicons are no 
longer available as template during this first amplification round. During a second amplification step, these loops 
will form a more homogeneous template for PCR amplification. In this way, a semi-linear amplification takes place. 
Ning et al. (2014) compared MALBAC with two other WGA methods, Multiple Displacement Amplification (MDA) and 
a GenomePlex PCR-based method, and concluded that MALBAC had the best genome coverage with excellent 
reproducibility (168). In general, it has been shown that each WGA method has its own advantages and 
disadvantages and that the best method should be selected based on its intended application. A recent article, for 
instance, suggested that MDA would be better for single nucleotide polymorphism (SNP) detection while MALBAC 
would be better for CNA detection (130).  
On top of the representation bias introduced by WGA, MPS library preparation can also introduce additional bias 
due to the enrichment PCR amplification of adapter-ligated fragments. Extra cycles of amplification could lead to 
extra representation bias in the results. 
The goal of this study was to compare commercial SurePlex and MALBAC WGA protocols for their ability to produce 
optimal MPS data for aneuploidy screening and copy number analysis from a limited number of cells. Samples 
consisting of 1, 3 or 5 cells, in triplicate, were collected from the Loucy lymphoblastoid cell line using 
micromanipulation. The samples were amplified using both WGA methods and Illumina library preparation and 
sequencing was performed on these WGA products. Subsequent enrichment PCR or PCR-free MPS library 
preparation was performed in parallel to compare the representation bias. For the different WGA and sequencing 
library preparation methods, the variability in distribution of the reads across the genome and the ability to 
correctly detect chromosomal aneuploidies and large CNAs was compared using the bioinformatics tool ReadDepth 
(159). The final MPS results were compared to a 180K aCGH profile (Agilent technologies) of unamplified genomic 
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DNA of the Loucy cell line which was determined prior to the experiments to serve as a reference performance 
standard.  
3. Material and methods 
3.1. Experimental design 
This study was performed on cells derived from the female Loucy cell line (ATCC CRL-2629; (169)). A reference 180K 
aCGH profile (Agilent Technologies) from unamplified genomic DNA from this cell line was obtained prior to the 
start of the experiments, i.e. before handling and isolation of the samples (Figure 1). The sequencing results will be 
compared to this reference aCGH profile for CNAs of 3Mb and larger. The cell line was grown in suspension which 
allowed isolation of individual cells. The influence of two commercially available WGA kits (MALBAC and SurePlex) 
on the ability to detect CNAs in a MPS approach was assessed. For each amplification method, a total of 12 samples 
was used. Triplicates of samples with 1, 3 or 5 cells were prepared with a standard enrichment PCR based Illumina 
sequencing library preparation (Figure 2a). Secondary, triplicates of samples with 3 cells were prepared with a PCR-
free Illumina sequencing library preparation (Figure 2b). 
 
Figure 1: 180K aCGH of genomic DNA from the female Loucy cell line 
This profile shows all CNAs detected in the female Loucy cell line up to a resolution of 50 kb. Red bars indicate deletions and blue bars 
indicate insertions. The deletions in chromosomes X, 5, 6, and 16 and duplication in chromosome 13, all with a size of >3Mb, were the 
ones expected to be detected by the sequencing results.  
3.2. Growth and isolation of cells 
The cells were grown in Roswell Park Memorial Institute (RPMI-1640) medium (Life technologies, Carlsbad, USA), 
supplemented with 10% fetal bovine serum (Life technologies, Carlsbad, USA). For optimal growth they were kept 
at a temperature of 37°C and a 5% CO2 level. A known amount of cells was isolated with an ergonomic denuding 
handle from STRIPPER (Origio, Måløv, Denmark) and MXL3-100 needles with a diameter of 100 µm (Origio, Måløv, 
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Denmark). A serial dilution with sterile phosphate buffered saline (PBS) (Life technologies, Carlsbad, USA) spots to 
the desired amount of cells for isolation was performed on a Petri dish (5.5cm) under an Axiovert 25 light 
microscope (Zeiss, Jena, Germany).  All cells were collected in a maximum volume of 1µl for the MALBAC samples 
and 2.5µl for the SurePlex samples, as this is required for optimal lysis of the cells, according to manufacturer’s 
instructions. Immediately after collection, all samples were snap frozen in liquid N2. 
 
Figure 2: Experimental design  
a) Experiment comparing SurePlex and MALBAC WGA methods. B) Experiment to investigate effect of enrichment PCR during library 
preparation for both SurePlex and MALBAC amplified samples. 
3.3. MALBAC WGA 
Cell lysis and amplification was performed, using the MALBAC kit (Yikon genomics YK001A/B version 1302.1, Jiangsu, 
China), following manufacturer’s instructions. As a positive control, 1µl of male control DNA (9948; Promega; 10ng/µl) 
was used at a concentration of 30pg/µl. The blank was 1µl of PBS. All samples were purified according to the 
manufacturer’s protocol of the Genomic DNA Clean & Concentrator kit (version 1.0.0, Zymo Research, Irvine, USA) 
with 5 X binding buffer. Concentration was measured using Qubit dsDNA High Sensitivity Assay kit (Life technologies, 
Carlsbad, USA). 
3.4. SurePlex WGA 
Cell lysis and amplification was performed following manufacturer‘s instructions using the SurePlex Amplification 
system (Bluegnome, Cambridge, United Kingdom). As a positive control, 2.5µl of female control DNA (G1521; 
Promega; 187ng/µl) was used at a concentration of 25pg/µl. The blank was equal to 2.5µl of PBS. Purification and 
concentration measurements were done in the same way a described above.  




One of the three cell samples, amplified by SurePlex, was also analyzed using a 1Mb BAC array (Bluegnome) 
(Supplementary fig. S1). The CNAs observed on this array should also be observed on the reference array profile. 
The aCGH was performed according to the 24Sure Protocol (Bluegnome) with a male genomic DNA sample as 
reference.  
3.6. Illumina library preparation 
Hundred ng of the WGA products was fragmented to an average size distribution of 200bp with the S2 Focused 
Ultrasonicator with Adaptive Focused Acoustics (AFA) technology (Covaris, Woburn, USA). All samples were diluted 
in Tris-EDTA buffer (TE-buffer) to a volume of 130 µl in microTUBES (Covaris, Woburn, USA). The programmed 
guidelines for fragmentation to 200bp were followed (Duty cycle of 10%, Intensity of 5 and 200 cycles/burst), but 
the fragmentation time was prolonged to 190sec based on previous experience.  
Subsequently, libraries of the fragmented samples were created using NEBNext Ultra DNA Library Prep (Chapter 
2B, New England Biolabs, Ipswich, USA), following manufacturer’s protocol with modifications as described here. 
After incubation with the USER enzyme, a DNA purification step (Zymo Genomic DNA Clean & Concentrator) was 
included before the size selection step. Size selection was performed with the E-Gel iBase Power system (Invitrogen) 
using an E-gel EX 2% agarose gel and a 1kb Plus DNA ladder (Thermo Fisher Scientific, Waltham, USA). For all samples, 
fragments with a size of ±300bp were cut from the gel and DNA was recovered using the Zymoclean gel DNA 
recovery kit (Zymo research). The size selected DNA samples were then subjected to an enrichment PCR using 
NEBNext Multiplex Oligos for Illumina (Index Primers Set 1 and 2) according to the protocol, with addition of tRNA 
to minimize the loss of DNA via tube interaction. The quality of the different samples was assessed with the Agilent 
High-Sensitivity DNA kit (Bioanalyser, Agilent Technologies, California, USA). 
The PCR-free libraries were created entirely according to the TruSeq DNA PCR-free HT sample preparation kit 
(Illumina), which does not require an enrichment PCR. For each sample, the entire amount of WGA product was 
used as starting material, which was on average 700ng. This is lower than the 1µg input required by the protocol. 
From here onwards, these samples are called ‘PCR-free’ samples. 
Before sequencing the samples, the amount of sequence-able library fragments was determined by performing a 
qPCR according to the Sequencing Library qPCR Quantification kit (Illumina, San Diego, USA). Samples were diluted 
to 10nM with elution buffer (EB buffer) (QIAGEN, Hilden, Germany). The control template used for the standard 
curve was a PhiX control library (10nM).  
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Finally, single-end index 75bp sequencing was performed on a high output flowcell on a NextSeq500 (Illumina, 
California, USA). 24 samples with each a different index were multiplexed on one flowcell. Samples were pooled at 
2nM each and diluted to a final concentration of 2.3pM. Sequencing of 24 samples at 75 bp on a NextSeq500 should 
lead to an average genome coverage of 0.4X per sample (16M reads /sample).  
3.7. Data analysis 
The FastQ files imported from Basespace (Illumina), were quality controlled using FastQCv0.10.1 (Babraham 
bioinformatics). This revealed a disproportionate oscillation of the percentage of the bases in the first 30bp of the 
reads. The disproportionate oscillation in the percentage of bases was more pronounced in the SurePlex amplified 
samples (Supplementary fig. S2). In addition to trimming these 30 bp, TruSeq adapters and low quality read ends 
with Phred quality score < 20 were trimmed with Cutadapt v1.4.2.   
Reads with minimum length of 30 bp were subsequently aligned to the human genome hg19 using the Burrow-
Wheeler-Aligner (BWA) v0.7.5a algorithm and non-uniquely mapping reads were removed with SAMtools v0.1.19 
and BEDtools v2.17.0 (170, 171). CNA detection was performed using the bioinformatics tool ReadDepth (159), which 
performed best in a recent comparison of different CNA detection methods (172).  For this, the genome sequence 
was divided into non-overlapping windows or bins of 1Mb in size and the number of reads per bin was calculated. 
The number of reads per bin was corrected for bias introduced by the inability to map reads into repetitive regions 
of the genome by using mappability tracks created via self-alignment of the reference genome. Additionally, the 
mappability corrected read numbers per bin were normalized for GC-content. For this, the average read depth for 
bins with GC content was calculated in intervals of 0.1% before using LOESS smoothing to fit a regression line to 
this data. Finally, bins were median normalized. The number of reads per bin was scaled using a correction value 
equal to the difference between the median read depth and the average read depth of that bin and in such way 
that the correction was neutral with respect to the total number of reads. Bins with a similar amount of reads were 
detected using a circular binary segmentation algorithm (alpha value of 0.01 and min.width value of 2) and 
considered as one segment. Based on an estimated amount of copy-number gain or loss in the genome (both 5%; 
standard settings determined by the authors of the ReadDepth tool yielding a good performance (159)) and an 
overdispersion factor equal to 5 (for which the observed and modeled distributions were most similar), three 
different negative binomial distributions were modeled for monosomic, diploid or trisomic regions, respectively. 
The two values at which the three peaks of these distributions were maximally separated were considered as 
thresholds for monosomic and trisomic regions. Estimated copy numbers for segments that exceeded these 
thresholds were flagged as CNAs. Copy numbers were estimated under the assumption that for a diploid genome 
the majority of the genome is copy number two. The copy number of other regions was subsequently estimated 
based on the segment ratio relative to two. 
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Comparing the yield after amplification and library preparation between the different groups was performed using 
t-test statistics. The variance in number of reads per 1Mb bin across the genome was compared between MALBAC, 
SurePlex and the PCR-free samples by means of a mean-scaled first order estimator. In more detail, GC-content 
and mappability normalized count data per bin was divided by the average number of reads per bin, thus correcting 
for possible differences in sequencing depth. We then estimated the variance across bins as the running sum of the 
squared difference between the mean scaled number of reads of one bin and the previous bin divided by the total 
number of bins, which is the same for all samples. The variance due to counting statistics in profiles, normalized so 
that the mean value is 1.0, is equal to 1/N, where N is the average number of reads per bin (neglecting small effects 
due to copy number aberrations and counting corrections). As such, the difference between the variance of the copy 
number profile, estimated by the first-order estimator, and the variance due to counting statistics (1/N) for that 
profile gives a measure of the noise contribution from the entire sample handling, preparation and analytical 
process, independent of sequencing depth. The difference in percentage of reads mapped in the different groups 
was analyzed by a one-way ANOVA on the arcsine transformed data, followed by a Bonferroni’s multiple 
comparison post-hoc test. When the prerequisites for valid ANOVA testing could not be met, an ANOVA on ranks 
followed by post-hoc Dunn’s method was performed instead. P-values <0.05 were considered significant. Numbers 
given after ‘±’ symbol in results indicates standard deviation. The sensitivity was defined as the number of true 
positive calls divided by all positive results for the cell line (true positive + false negatives). The positive predictive 
value (PPV) was defined as the number of true positive calls divided by the number of positive calls (false positive 
+ true positive). Raw sequencing data are deposited in the NCBI Sequence Read Archive under project accession 
number SRP051311. 
4. Results 
4.1. Evaluation of Loucy cell line stability 
As a reference for our DNA samples, a 180K aCGH profile of unamplified genomic DNA of the Loucy cell line was 
used (Figure 1). The 180K arrays have an average resolution of ±50kb. The resolution aimed by the MPS analysis is 
to find CNAs of 3Mb in size or larger. This resolution was chosen in view of performing PGD using MPS. Currently 
the resolution for PGD is 3-10Mb. However, some small CNAs are not well-defined at this resolution. Opting for a 
higher resolution could include these CNAs as well. 3Mb was considered a minimum because the variation caused 
by the WGA was a limiting factor at lower bin sizes. BAC aCGH analysis was performed on amplified DNA at a 
resolution of 10Mb (Supplementary fig. S1). If the 180 aCGH profile was filtered for CNAs > 3Mb in size, both profiles 
showed a similar pattern, confirming that the cell line was not altered after manipulation. According to the 180K 
aCGH profile, the following chromosomal aneuploidies and CNAs were called within the resolution range of the 
subsequent sequencing results (>3Mb): a deletion of an entire X-chromosome, a distal deletion of ±72Mb on 
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5q21.3q35.3, a distal deletion of ±45Mb on 6q22.31q27, a ±26Mb duplication of 13q33-q33.3 and deletions of 
respectively 13Mb and 3Mb on 16p13.3-p13.12 and 16q24.2q24.3. These CNAs were used as a reference for comparison 
with the MPS analyses. 
4.2. Yield after WGA and library preparation 
Figure 3 compares the WGA product yield of both tested WGA methods. The final volume of all samples was the 
same. Both WGA methods resulted in a similar yield after amplification of the samples containing 1 cell. The yield 
after amplification with SurePlex was significantly higher than the yield after MALBAC amplification when started 
from samples of 3 (34.7±6.1 ng/µl vs. 19.9±2.1 ng/µl) or 5 cells (31±4.8 ng/µl vs. 17.7±5 ng/µl).  
For the libraries that were prepared using enrichment PCR, there was no significant difference in the amount of 
sequence-able fragments measured by qPCR for MALBAC or SurePlex amplified samples (14.8±3.7 nM and 18.5± 6.3 
nM for MALBAC and SurePlex amplified samples, respectively). In contrast, for the PCR-free library preparations, a 
significant difference was detected between the samples with MALBAC (1.1±0.6 nM) and SurePlex amplification 
(4.6±1.5 nM). 
 
Figure 3: Average yield after MALBAC and SurePlex amplification for the different amounts of starting material used. 
The difference between MALBAC and SurePlex within each group was tested with a t-test. One-tailed p-values are #: p =0.000305; *: 
p=0.00352. 1 cell N=6; 3 cell N=9; 5 cell N=6. 
4.3. Sequencing quality 
With a density of 140K/mm3 and a total (passed-filter) read count of 324.76M, the run quality was within 
expectations with 87% passing the quality threshold of 30, a Full width at half maximum (FWHM) of 3 and a 1.66% 
alignment of the PhiX control. After adaptor and quality trimming and mapping of the reads, an average of 
12,708,048 reads of ±30bp was mapped per sample, resulting in an average coverage of 0.1X per sample. The PCR-
free SurePlex prepped samples had a lower number of reads mapped, compared to the other samples. While all 
other samples contributed on average to 14,013,601 reads per sample, these samples only had 3,569,175 reads on 
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average mapped per sample (coverage of 0.03X). To allow comparison between PCR-free libraries and enrichment 
PCR amplified libraries, the latter were randomly down-sampled to a comparable raw read count. 
4.4. Difference in read mapping between MALBAC and SurePlex. 
When comparing the mapping results within each protocol from the samples with a different number of input cells, 
no significant differences were detected in the relative number of uniquely, non-uniquely and unmapped reads 
(p>0.05). A significantly higher percentage of reads, generated from the samples amplified with MALBAC, mapped 
uniquely compared to the percentage of uniquely mapped reads from samples amplified with SurePlex (82.8± 1.4% 
vs 76.1± 1.6 %, respectively) (Figure 4). This also holds true for the MALBAC and SurePlex amplified samples that 
were not enriched by PCR during library preparation (81.1 ± 2.4% vs 69.8 ± 2.3%, respectively). The percentage of 
uniquely mapped reads was significantly higher in the SurePlex amplified samples compared to the SurePlex 
amplified samples prepared without enrichment PCR. No significant difference was found for the MALBAC samples 
prepared with enrichment PCR versus the PCR-free MALBAC amplified samples. 
The distributions of the GC content per read showed, for both MALBAC and SurePlex amplified samples, a higher 
mean GC-content than the GC-content in the human genome, around 46% and 45% vs 42.4% for MALBAC and 
SurePlex, respectively (Supplementary fig S3). Omission of the enrichment PCR during library preparation resulted 
for both amplification protocols in slightly lower average GC-contents (43% for both MALBAC and SurePlex), yet the 
distributions were less well-shaped (Supplementary fig S3). 
 
Figure 4: Scheme of read mapping after different amplification methods 
MALBAC amplified samples have more uniquely mapped reads compared to SurePlex amplified samples. Samples were combined for the 
different starting amounts. Statistical analysis was performed with a one-way ANOVA followed by a Bonferroni t-test for multiple 
comparison. When comparing the percentages of non-uniquely mapped samples, the equal variance test failed. Here an ANOVA on ranks 
was performed followed by Dunn’s method for multiple comparison. #: p<0.001 and *: p<0.05. 
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4.5. Read distribution across the genome 
The variance in read distribution across the genome was significantly different between MALBAC and SurePlex 
amplified samples. The number of reads per 1Mb bin in MALBAC amplified samples varied more across the genome 
as compared to SurePlex amplified samples. This was the case for 1 cell, 3 cells and 5 cell samples (Table 1). The 
variability in mapping had the consequence that a lot of bins, in the MALBAC amplified samples, fell outside of the 
range expected for diploidy, even in regions where the Loucy genome is diploid. This was not observed in the 
SurePlex amplified samples, were a more smooth read distribution was observed. 
  






Table 1: Estimates of variance (mean and standard deviation) and statistical differences in variance for the different tested conditions. 
“no PCR” indicates the absence of an enrichment PCR during library preparation. 
4.6. Detection of chromosomal aneuploidy and copy number variants 
The first way to detect CNAs is using an algorithm such as used by ReadDepth. Next to this, CNAs can also be 
represented as a graphical profile (Figure 5), allowing a more manual interpretation. The choice for 1Mb bins 
allowed us to detect CNAs at least 3Mb in size. Analysis of the MALBAC amplified samples resulted in many false 
positive CNA calls random across the genome, which were not observed on the reference aCGH profile (Table 2; 
Supplementary Table 1). Only one of the MALBAC amplified samples resulted in detection of all CNAs that were 
present according to the aCGH reference (Table 2; Supplementary Table 1). Most of the samples missed more than 
one of the expected CNAs. On the other hand, of all samples amplified with SurePlex, only two gave an incomplete 
detection of the CNAs and only a few false positive CNAs were detected. Figure 5 shows the CNA profiles of two 3-
cell samples amplified with either SurePlex (Figure 5a) or MALBAC (Figure 5b). The profile of the SurePlex samples 
is smoother and the expected CNAs are clearly observed. The CNA profiles of all samples used during this 
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experiment are shown in Supplementary fig. S4. These results show a sensitivity for calling the correct CNA equal 
to 59.3% ±22.2% (mean ± standard deviation) for MALBAC amplified samples and 94.4% ±11.8% for SurePlex 
amplified samples. The difference between both methods, is also reflected in the PPV, with a PPV of 42% ±12.3% 







Table 2:  Number of expected calls and false positives made by all samples.  
Expected calls were: deletions in chromosomes X, 5, 6, 9 and 16 and duplication in chromosome 13 as expected by array. Calls were of 
3Mb and bigger expected. Calls were summed for the samples that started with the same amount of cells. 
 
Number of 
Expected CNA calls according 
to reference array (≥3Mb) (18) 
False positive calls (0) 
3X 1cell 3cell 5cell 1cell 3cell 5cell 
MALBAC 9 10 13 16 13 14 
SurePlex 13 18 18 6 4 5 
No-PCR 
MALBAC 
 9   8  
No-PCR 
SurePlex 
 14   0  




Figure 5: Samples amplified with SurePlex are better suited for detection of aneuploidies and CNAs. 
A) All aCGH-verified deletions in chromosomes X, 5, 6, 9 and 16 and duplication of 13 are only detected in SurePlex amplified samples. B) 
MALBAC amplified samples show, because of their bigger variability, false positives. Each dot on the plots represents an equally sized 
bin of 1Mb. Separate chromosomes (from 1 to 22 and X) are colored green/black alternatingly. The X-axis indicates log2(copy number / 2), 
estimated based on the number of reads per bin. A log2(copy number / 2) equal to zero corresponds to a copy number of 2, as would be 
expected for a diploid genome. Theoretically for an insertion a log2 (copy number/2) of 0.5 is expected, whereas for a deletion a log2 
(copy number/2) of -1 is expected. The red and green horizontal lines represent the threshold for detection of insertion or deletion, 
respectively. The brighter red line combines the bins with equal means. 
4.7. The influence of a PCR-free library preparation on read distribution and CNA detection 
The variance in read distribution across the genome was significantly different between enrichment PCR 
amplified and PCR-free samples. The number of reads per 1Mb bin in the PCR-free SurePlex samples varied 
less across the genome compared to enrichment PCR amplified SurePlex samples (Table 1). The detection of 
CNAs was comparable at this resolution, yet slightly more consistent in PCR-free SurePlex samples compared 
Chapter IV: Shallow whole genome sequencing is well suited for detection of chromosomal aberrations in human blastocysts 
56 
 
to enrichment PCR amplified SurePlex samples (Figure 6). Although the X-chromosome monosomy was not 
called by ReadDepth, on the graphical profiles it can be distinguished. MALBAC amplified samples with 
subsequent PCR-free library preparation also resulted in improved MALBAC variation, but still a lot of false 
positive CNAs were detected in these libraries. CNA calling in SurePlex amplified samples with PCR-free library 
preparation has a PPV of 100% (±0%; mean ± standard deviation) and a sensitivity of 77.8% (±9.6%). CNA calling 
in the MALBAC amplified PCR-free library preparation samples has a PPV of (50% ± 26.8%) and a sensitivity of 
(50% ± 33%). 
Figure 6: Omitting enrichment PCR during library preparation leads to smoother CNA profiles 
As a result of the decreased variation, copy number estimation is more consistent across chromosomes, for instance in chromosome 1, 4 
and 8 (red circles). This will be an important benefit if screening at higher resolutions is performed. To allow direct comparison, 
‘SurePlex PCR’ samples were randomly downsampled to obtain a similar number of raw reads as ‘SurePlex no-PCR’ samples. 




SurePlex amplification has already proven its efficiency in combination with the 24Sure aCGH protocol for PGD 
purposes. During aCGH, amplification bias could partially be overcome by using the same WGA method for both 
sample and reference. However, due to the rather random nature of the bias introduced by WGA, the possibility of 
bias cannot be completely eliminated (173). Because of the nature of the detection of aneuploidies and CNAs from 
MPS data, it is not necessary to sequence a reference with the samples every time. This, however makes it even 
more important to obtain an unbiased amplification. De Bourcy et al.  (2014), observed that PCR-based methods 
like MALBAC and NEB-WGA, are better suited for CNA detection than MDA methods because of their low variability.  
NEB-WGA is similar to the SurePlex WGA method used in this study, while the MALBAC WGA method of De Bourcy et 
al. (2014) is comparable, yet not entirely similar, to the MALBAC WGA method used in this study. In the present study, 
MALBAC (Yikon Genomics) and SurePlex (Bluegnome), both commercial kits, were compared for their usability in 
CNA detection in a more complex, say diploid human genome, setting that has to our knowledge not been done 
before.  
The reference aCGH used for this study was performed with unamplified genomic material, thus avoiding the bias 
introduced by WGA. The resolution aimed by the sequencing during this study, is in the range of state-of-the-art 
PGD with aCGH. With 1Mb bins, CNAs of 3Mb and larger should be successfully detected by ReadDepth. However, as 
stated in the results, some smaller CNA can also be called if the variation in that specific region is low. We were, 
for instance, able to detect a deletion of 2.5 Mb at chromosome 9 (q34.11q34.12), which was also detected, and thus 
confirmed, on the 180K and 1Mb aCGH. In the sequencing results this particular deletion was called as a 3Mb CNA 
because sequencing is only accurate down to 1Mb.  
Based on raw read count, an average genome coverage of approximately 0.3x was obtained for most samples. This 
theoretical calculation of the coverage gives an indication of how much of the human genome could theoretically 
be covered with a certain number of reads of a given length. However, after adaptor and quality trimming and 
mapping of the reads, an actual coverage of approximately 0.1X was obtained, except for the PCR-free SurePlex 
samples, for which a coverage after mapping of only 0.03X was obtained. It was shown that MALBAC amplified DNA 
samples yielded a significantly higher amount of uniquely mapped reads compared to SurePlex amplified samples. 
If these uniquely mapped reads are distributed uniformly along the genome, this would indicate that the MALBAC 
amplified samples cover the reference genome better, potentially increasing the accuracy in which CNAs can be 
detected. However, the distribution of the reads along the different bins in every chromosome was not uniform for 
the MALBAC amplified samples (Table 1). Indeed, the variance in read counts per 1Mb bin across the genome was 
Chapter IV: Shallow whole genome sequencing is well suited for detection of chromosomal aberrations in human blastocysts 
58 
 
significantly higher compared to the SurePlex samples, suggesting that certain loci in the genome must be over- 
or under-amplified during MALBAC amplification.  
MALBAC has been reported to have strong GC biases (168). Indeed, when studying the distribution of the GC-content 
per read, MALBAC seems to prefer more GC-content rich regions for amplification. Yet, this bias seems also to be 
prevalent in the reads originating from SurePlex amplified samples. Enrichment PCR during library preparation 
seems to amplify this GC bias effect, i.e. GC-bias is less pronounced in samples that did not undergo enrichment 
PCR compared to samples that did. However, where usually a clear Gaussian distribution can be expected, the 
distribution for the samples that were not enriched by PCR is less well-shaped, i.e. no clear maximum/mean can be 
distinguished.  
Bias caused by over- or underrepresentation of certain parts of the genome, will most likely lead to false 
interpretations of the copy number status of chromosomal regions. This means that the variability in read 
distribution across the whole genome is directly related to the suitability to detect CNAs. The smaller the variation, 
the bigger the possibility that a value lying outside the threshold barriers is a true CNA. The thresholds for diploidy 
were redefined for every sample based on their negative binomial distribution, but did remain comparable between 
the samples. Variations in copy number were called if the number of alleles exceeded these boundaries. For only 
one of the MALBAC amplified samples, the MPS-CNA profile was similar to the reference aCGH profile. For SurePlex 
amplified samples on the other hand, all the expected CNAs were detected in the majority of the samples (7 out of 
9). The variability between different bins in the MALBAC samples was too high to distinguish whether regions were 
actually underrepresented because they were deleted in the original genome or because of amplification bias. In 
addition, for the MALBAC amplified samples, quite some false positive results were called that were not visible on 
the reference array. For instance, chromosome 19 aberrations, a false positive recurrently appearing on aCGH (174), 
was called for almost all MALBAC amplified samples, but for none of the SurePlex amplified samples. Moreover, 
calls made for the MALBAC amplified samples were not very consistent across the three replicates, especially for 1 
and 3 cell samples. Although such inconsistency was also observed across the replicates of the 1 cell samples 
amplified with SurePlex, less false positive calls were made compared to the MALBAC amplified samples. In the two 
cases that not all expected CNAs were called, the correct profile could still be deducted from the graphical profile. 
The opposite does also occur, where in one SurePlex amplified 3 cell sample a duplication in chromosome 20 was 
called by ReadDepth, but on the graphical profile this could not be observed. These observations suggest that for 
good practices both calls made by the ReadDepth algorithms and manual visual inspection of the graphical profiles 
should be considered. Nowadays, aCGH profiles in PGD are interpreted and corrected based on recurrent artifacts, 
i.e. aberrations that are present in most profiles but which are known not to have any impact on the correct 
development of the embryo. Such artifacts may result from the used technique and are frequently observed around 
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telomeric and centromeric regions of the chromosome. In this study however, information of such artifacts was not 
available and thus not taken into account to correct the calls. Nevertheless such information could be obtained by 
sequencing multiple normal, non-aberrant genomes and screening for recurrent aberrations. In general, this study 
shows that even without a reference genome the expected calls can be made, although a few false positives were 
also called.  
The inconsistency observed between different replicates of 1 cell samples could possibly be explained by the cell 
cycle status of the amplified cells. More evidence is growing that cells that are in S-phase give a more scattered 
profile because of the replication status of the DNA (54). Samples containing multiple cells could contain cells that 
are in a different cell cycle status, which diminishes the influence of the individual cell status.  
In the PCR-free MALBAC and PCR-free SurePlex amplified samples, similar overall differences could be observed 
between both WGA methods. The PCR-free MALBAC amplified samples had again a significantly higher amount of 
uniquely mapped reads but at the same time also a significantly higher variance in read counts per bin across the 
genome. This suggests that the enrichment PCR did not cause the difference observed between the two 
amplification methods. However, omitting the PCR shows an even lower, significant, variance in read distribution 
across the genome. Still, the difference with the normal diploid parts on the graph was obvious. Also the graphical 
profile is smoother without the use of enrichment PCR. This might become even more important to detect CNAs at 
a higher resolution and thus smaller bin size. Generally, these results suggest that at least part of the bias in MPS 
data for CNA detection could be eliminated by avoiding an enrichment PCR during library preparation.  
Although the detection of CNAs was performed with ReadDepth, other bioinformatics tools exist for calling CNAs 
without the need of a reference genome. Some of them are described in the review of Duan et al., who compare six 
different tools in different settings (172). ReadDepth seemed to perform best in most of the conditions tested in 
this review (172). However, the tool described by Baslan et al., which should be more specific for single cell analysis 
(175), was not considered in this review. Although this tool is quite similar to ReadDepth, it might be expected that 
in a setting with higher resolution, and thus much less reads per bin, where the bias introduced by WGA will be 
more prominent, the tool might perform better in calling CNAs compared to ReadDepth. Another recently published 
tool, QDNAseq, might also have that advantage over ReadDepth, as it uses a blacklist to filter chromosomal regions 
with anomalous behavior, such as satellites, centromeric and telomeric repeats, reducing the noise level of the 
data (160). 
6. Conclusion 
In conclusion, we observed that for CNA detection, the SurePlex protocol is better suited than the MALBAC procedure. 
MALBAC amplified samples show a high non-uniformity across the genome, which leads to false positive CNAs. This 
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is especially true when starting from single cells. SurePlex amplification has shown its value for single cell 
chromosomal CNA detection, although for PGD purposes a minimal 3 cell starting amount is recommended. It has 
also been shown that omitting enrichment PCR during library preparation, will lead to a more uniform coverage of 
the genome. This may become more important if sequencing depth is being increased to increase resolution.  
7. Supplementary information 
Supplementary figure S1  
1Mb aCGH profile of the Loucy cell line determined from a 3 cell sample amplified with SurePlex. The profile confirms the 
profile determined prior to the start of the experiments. CNAs of 3Mb and more can be detected on this profile. Since the 
reference genome used for this array was a male genome, the X chromosome deletion was observed as normal while the Y 
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Supplementary figure S2: Sequence content across all bases 
The percentage of each base at the different bp positions on the reads is shown in this graph. A) For the MALBAC samples a 
slightly irregular pattern is observed for the first 10 bases. The last base shows a skewed pattern and will be trimmed. B) The 
SurePlex samples have a very irregular pattern for the first 30 bases indicating that the adapter probably consists of mainly 




























Chapter IV: Shallow whole genome sequencing is well suited for detection of chromosomal aberrations in human blastocysts 
62 
 
Supplementary fig. S3: Distribution of GC content per read  
 
MALBAC and SurePlex seem to prefer more GC-content rich regions for amplification. Enrichment PCR during library 
preparation seems to amplify this GC bias effect, i.e. GC-bias is less pronounced in samples that did not undergo enrichment 
PCR compared to samples that did. However, where usually a clear Gaussian distribution can be expected, the distribution for 
the samples that were not enriched by PCR is less well-shaped, i.e. no clear maximum/mean can be distinguished. The red 
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Supplementary fig. S4: Overview of the CNA profiles of all samples 
 
The CNA profiles of all samples used in this study are shown here. These CNA profiles are similar to the profiles shown in 
figure 6. The very low copy number of the last part of chromosome 9 will fall out of the range of these graphs, but is present 
in al SurePlex samples. 

















Supplementary table S1: List of all CNAs detected by ReadDepth 
CNAs given in grey are the ones that are expected to be detected. The CNAs given in de white columns are false positive 
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Preimplantation genetic diagnosis (PGD) for chromosomal rearrangements is widely used to avoid transferring 
embryos with genomic aberrations. Currently, genomic microarrays are predominantly used for the detection of 
unbalanced structural abnormalities and aneuploidies in embryos from parents at risk. In this study we evaluate 
whether massive parallel sequencing (MPS) can be used in PGD for detecting chromosomal abnormalities. 
15 patients with a balanced structural rearrangement were included in the study: 8 reciprocal translocations, 3 
Robertsonian translocations, 2 inversions and one insertional translocation. In total, 6 normal embryos and 41 
abnormal embryos were included in the cohort. Low coverage MPS on a NextSeq 500 (Illumina) and Ion Proton 
(Life Technologies) instrument was performed in parallel for 47 trophoblast amplified samples. All aberrations 
previously detected with aCGH could be readily detected in the MPS data and were called correctly. The smallest 
detected abnormality was a 5 Mb deletion/duplication hence equaling or even exceeding the resolution of the 
routinely used microarrays. Thereby, this study demonstrates that MPS on a NextSeq 500 or Ion Proton instrument 
can both be applied for the detection of chromosomal abnormalities in PGD embryos and MPS can serve as a more 
cost-effective and flexible technology for PGD compared to aCGH.  
2. Introduction 
Chromosomal abnormalities in early embryonic development can give rise to implantation failure, early 
spontaneous abortions and/or fetuses with multiple congenital anomalies. For couples with a known balanced or 
unbalanced chromosomal rearrangement, preimplantation genetic diagnosis (PGD) can be offered to select against 
unbalanced chromosomal aberrations in the embryo during assisted reproductive technology (ART) (24). At the 
same time, it is well established that early stage embryos suffer from a high rate of (mosaic) aneuploidy, reducing 
embryo survival, implantation potential and hence the success rate of ART (25). 
In the past, Fluorescent In Situ Hybridization (FISH) has been widely used to screen for chromosomal imbalances 
in the embryos (27). With FISH, the chromosomes involved in the translocation can be evaluated for unbalanced 
rearrangements at the single cell level. However, for every single case, an individual laboratory genetic work-up is 
needed to optimize the protocol before starting the PGD procedure (27, 176).  
In recent years, array Comparative Genomic Hybridization (aCGH) has replaced FISH for PGD in translocation carriers. 
ACGH is a valuable technology in the context of PGD, since all chromosomes can be interrogated in a single 
experiment. There is no need for optimization of the PGD test in advance and besides chromosomal aberrations 
due to the (balanced) chromosomal rearrangement in the parent, also other aneuploidies or large copy number 
variations (CNV) can be detected. ACGH and other comprehensive screening methods such as real-time PCR and 
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SNP-arrays, allow improved embryo diagnosis before transfer to the uterus and have proven their clinical utility 
(20, 61, 177, 178).  
Embryonic aneuploidy detection is not only valuable in a PGD setting. Recent evidence suggests that also patients 
with normal karyotypes who have recurrent miscarriages can benefit from comprehensive chromosome screening 
of the embryo (20). Currently, randomized controlled trials (RCTs) are ongoing to evaluate the use of 
preimplantation genetic screening (PGS) in those patients and these studies might prove that comprehensive 
chromosome screening could increase the implantation and pregnancy rate (20, 61).  
Although aCGH proved its value, its rather limited resolution and the relative high cost are a disadvantage (32). For 
cryptic chromosomal rearrangements, the current resolution of approximately 10 Mb can be shortcoming. These 
issues could be addressed using massively parallel sequencing (MPS). Shallow or low-pass whole genome 
sequencing is used when no full genome coverage is needed. This technique can be used for detection of aneuploidy 
and/or chromosomal imbalances.  The rapid development, dropping costs, and the possibility of screening at higher 
resolution, make MPS an attractive alternative to further increase the success rate of PGD and/or PGS after ART. 
Some proof of concept studies have shown the possibilities of shallow whole genome sequencing in a PGD/PGS 
setting (32, 163, 164, 179). However, most of these studies focused on aneuploidy detection and the resolution 
remained rather limited.    
A recent important evolution in PGD is the time point for embryo biopsy. While cleavage stage biopsy, taking one 
or two blastomeres from the embryo on day 3, has long been the gold standard, recently a shift towards blastocyst 
trophectoderm biopsy on day 5 has occurred.   
The present study evaluates the use of MPS for PGD on trophectoderm cells of blastocysts, making a comparison 
with aCGH in terms of accuracy. With this study, we aim to add evidence that MPS is a valuable and efficient 
substitute for aCGH, with the potential of being more cost efficient, and with a resolution that is more appropriate 
for PGD in translocation carriers.  
3. Materials and methods 
3.1. Study design 
In the present study, 15 patients with a balanced structural chromosomal rearrangement were enrolled. The 
aberrations included 8 reciprocal translocations, 4 Robertsonian translocations, 2 inversions and one insertional 
translocation (Table 1). Maternal age ranged from 27 to 41 years (mean 33,5 years). Retrieved oocytes underwent 
intracytoplasmic sperm injection (ICSI) and trophectoderm biopsies were performed on day 5 or 6. After WGA of 
the DNA from the trophectoderm cells, 24sure+ aCGH was performed for PGD. DNA amplified material from 47 
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embryos that were found abnormal with aCGH or did not implant after transfer were selected for MPS. In this 
validation study we evaluated whether MPS is able to detect small but relevant chromosomal aberrations in a PGD 
setting. The 47 embryos were selected from a larger clinical cohort of 141 embryos in total and were specifically 
selected based on different sizes of the involved translocated segments and aneuploidy of different chromosomes. 
This study cohort represents a variety of clinical relevant chromosomal aberrations in a PGD setting.  
After aCGH, we analyzed the remaining amplified DNA with shallow whole genome sequencing on both an Illumina 
NextSeq500 platform and an Ion Proton sequencer. Results from MPS were subsequently compared with the 
previously generated aCGH results (Figure 1).  
The aCGH analysis was performed between September 2014 and December 2014. Ion Proton and NextSeq500 
sequencing was performed simultaneously at the beginning of 2015. 
Our institutional review board approved this study (EC/UZG/2015/0108) and informed consent was obtained from 
all patients included in this study.  
 
Figure 1: Schematic overview of the experimental design of this study. 
After whole genome amplification of trophectoderm biopsies, routine microarray analysis was performed. Remaining amplified DNA was 
used to sequence samples on a NextSeq 500 and Ion Proton sequencer in parallel. 
3.2. Oocyte retrieval and blastocyst biopsy 
Controlled ovarian hyperstimulation of this study’s patients was performed according to age, anti-Müllerian 
hormone levels and previous response. The gonadotrophins used were either a recombinant follicle stimulating 
hormone (FSH) (Gonal F, Merck Serono) or a urinary FSH (Menopur, Ferring Pharmaceuticals) at daily doses between 
150 and 300 U. When an agonist protocol was followed, 0.1 mg triptorelin (Decapeptyl, Ipsen) was administered 
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subcutaneously for 7 days starting on cycle day 1, and gonadotrophins were started on cycle day 3. In case an 
antagonist protocol was necessary, gonadotrophins were started on cycle day 3, and 0.25 mg cetrorelix (Cetrotide, 
Merck Serono) was injected subcutaneously as a daily dose from the 6th day of stimulation until the day of oocyte 
maturation triggering. The course of stimulation was followed by ultrasound monitoring. As soon as 50% of the 
follicles were > 10-18 mm in diameter, oocyte maturation and retrieval was performed according to 
Vandekerckhove et al. 2014 (180). 
After ICSI, oocytes were cultured in 25µl drops of IVF-cleavage-medium (COOK) in the microwells of Embryoslides 
(Vitrolife) and overlaid with 1,2 ml of mineral oil. Embryoslides were placed in the EmbryoScope (Fertilitech) at 
37°C in 5% O2 and 6% CO2. On the 3rd day of embryo development, the zona pellucida was breached using a series 
of laser pulses (Zilos-TK, Hamilton Thorne) to assist trophectoderm herniation and the medium of the microwells 
was refreshed with IVF-blastocyst-medium (COOK). On the 5th or 6th day of development, good quality blastocysts, 
according to the criteria of Gardner and Schoolcraft (181) (>grade 3BB) with herniating trophectoderm underwent 
laser-assisted biopsy (Zilos-TK, Hamilton Thorne) using a 28-32 µm inner diameter biopsy micropipette (Origio). 
The biopsied cells (min. 1 cell and max. 9 cells; average, 4.3 cells) were washed with PBS (AMRESCO, USA) and 
polyvinylpyrrolidone (COOK), placed in 0.2 ml sterile PCR tubes and kept in -20°C until genetic screening. Embryos 
were vitrified on the day of the biopsy with the Vitrification Freeze kit (Irvine Scientific, USA). 
3.3. SurePlex WGA 
Cell lysis and amplification of 47 biopsied blastocyst samples, was performed following manufacturer‘s instructions 
using the SurePlex Amplification system (Illumina Bluegnome, Cambridge, United Kingdom). 2.5µl of control DNA 
(G1521; Promega, USA; 187ng/µl) was used at a concentration of 25pg/µl. The blank was equal to 2.5µl of PBS. 
Evaluation of amplification was performed on a Labchip GX (CaliperLife Sciences) instrument. All samples for 
sequencing were purified according to the manufacturer’s protocol of the Genomic DNA Clean & Concentrator  kit 
(version 1.0.0, Zymo Research, Irvine, USA) with 5X binding buffer. Samples that were analyzed with aCGH were not 
purified. Concentration was measured using Qubit dsDNA High Sensitivity Assay kit (Life technologies, Carlsbad, 
USA). 
3.4. ACGH 
The WGA products were processed following manufacturer’s protocol (Illumina, Bluegnome) and hybridized on 
24sure+ arrays. A male reference sample was used for all tested embryos.  
Briefly, amplified samples and reference DNA were labeled with Cy3 and Cy5 fluorophores, respectively, during 4 
hours at 37°C. After combining sample and reference with Cot1 DNA, the mixture was precipitated for minimum 20 
minutes at -80°C. The pellets were resuspended in pre-warmed hybridization buffer and hybridized on a 24sure+ 
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array for 16h (overnight) at 42°C. After washing, microarrays were scanned on an Agilent G2565CA microarray 
scanner. Data were analyzed using the BlueFuse Multi software (Illumina) and visualized in ViVar (182). 
3.5. Fragmentation 
One hundred ng of the purified WGA product was fragmented to an average size distribution of 200bp with the S2 
Focused Ultrasonicator with Adaptive Focused Acoustics (AFA) technology (Covaris, Woburn, USA). All samples were 
diluted in Tris-EDTA buffer (TE-buffer) to a volume of 130µl in microTUBES (Covaris, Woburn, USA). The guidelines 
for fragmentation to 200bp were followed (duty cycle of 10%, intensity of 5 and 200 cycles/burst), but the 
fragmentation time was prolonged to 190sec based on previous experience. Subsequently, samples were divided 
in two aliquots, one for Illumina sequencing and one for Ion Proton sequencing. 
3.6. Sequencing on NextSeq500 
Libraries of the fragmented samples were created using NEBNext Ultra DNA Library Prep (Chapter 2B, New England 
Biolabs, Ipswich, USA), following manufacturer’s protocol with modifications as described here. After incubation 
with the USER enzyme, a DNA purification step (Zymo Genomic DNA Clean & Concentrator) was included before the 
size selection step. Size selection was performed with the E-Gel iBase Power system (Invitrogen) using an E-gel EX 
2% agarose gel and a 1kb Plus DNA ladder (Thermo Fisher Scientific, Waltham, USA). For all samples, fragments with 
a size of ±300bp were cut from the gel and DNA was recovered using the Zymoclean gel DNA recovery kit (Zymo 
research). The size selected DNA samples were then subjected to an enrichment PCR using NEBNext Multiplex Oligos 
for Illumina (Index Primers Set 1 and 2) according to the protocol, with addition of tRNA to minimize the loss of 
DNA via tube interaction. The quality of the different samples was assessed with the Agilent High-Sensitivity DNA 
kit (Bioanalyser, Agilent Technologies, California, USA).  
Before sequencing the samples, the amount of sequence-able library fragments was determined by performing a 
qPCR according to the Sequencing Library qPCR Quantification kit (Illumina, San Diego, USA). Samples were diluted 
to 10nM with elution buffer (EB buffer) (QIAGEN, Hilden, Germany). The control template used for the standard 
curve was a PhiX control library (10nM). Finally, single-end index 75bp sequencing was performed on a high-output 
flowcell on a NextSeq500 (Illumina, California, USA). Samples with different indexes were pooled at 4nM each and 
diluted to a final concentration of 2.3pM. 24 samples were multiplexed on one flowcell. The complete protocol from 
library construction to data analysis takes 23 hours. 
3.7. Sequencing on Ion Proton 
Library construction was performed according to the Ion Plus Fragment Library Kit (Life Technologies). Briefly, end-
repair of the amplified DNA was performed with T4 DNA polymerase and T4 polynucleotide kinase. Ion Proton 
compatible adapters with barcodes were ligated to the WGA DNA using DNA ligase. Libraries were amplified using 
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Platinum PCR SuperMix High Fidelity in a thermal cycler (5 min 95°C, [15 sec 95°C, 15 sec 58°C, 1 min 70°C] 9 cycles). 
Libraries were purified using Agencourt AMPure XP beads (Beckman Coulter). After the amplification double size 
selection was performed using Agencourt AMPure XP beads (Beckman Coulter) for removal of residual adaptors 
and primers. Libraries were quantified with the Ion Library Quantitation Kit (Life Technologies). Template 
preparation and PI chip loading was performed on Ion Chef (Life Technologies) using 60 pM of equimolar pooled 
libraries. Six samples were pooled on one PI chip and sequenced on an Ion Proton instrument using 400 flows. The 
complete protocol from library construction to data analysis takes 26 hours. 
3.8. Data analysis 
Reads were aligned to the human genome hg19, assembly GRCh37, using the Burrow-Wheeler-Aligner Maximal 
Exact Matches (BWA-MEM) v0.7.5a-r405 algorithm (183) and converted to BAM files using SAMtools v0.1.19 (170). 
Subsequent data analysis for CNV detection was performed using QDNAseq (160). This tool is implemented in R 
(184) and normalizes, after removal of non-uniquely and poorly mapped reads, the number of reads mapped in 
non-overlapping, fixed size windows for bias in GC-content and mappability simultaneously. Moreover, QDNAseq 
uses a “blacklist” of genomic regions. This blacklist, based on the ENCODE Project Consortium (185), contains 
information on chromosomal regions with anomalous behavior, especially regions with known repeat elements, 
such as satellites, centromeric, and telomeric repeats. QDNAseq uses the blacklist to exclude these regions from 
the analysis. After GC-content and mappability normalization, read counts are median normalized, after which a 
circular binary segmentation algorithm detects breakpoints between the windows, and groups them between 
breakpoints in segments with equal copy number. 
Different window sizes (100kb, 250kb, 500kb and 1Mb) were evaluated for CNV detection. Each genome profile (line 
view and chromosome view) was manually checked for aberrations.  
To determine the minimum number of reads necessary to detect CNVs successfully, raw reads were randomly 
downsampled to levels 2-10 times lower than the original number of raw reads. This downsampling was performed 
using the seqTK toolkit (https://github.com/lh3/seqtk). For each sample, another random seed was used.  
The profiles of all samples used in this study can be found online in ViVar (182), a platform for the automated 
analysis and visualization of microarray and sequencing data. For this study, we incorporated the QDNAseq 








4.1. MPS specifications 
Twenty-four samples were pooled on one NextSeq500 run, whereas 6 samples were combined on a single Ion 
Proton PI chip. This resulted in an average of 11 and 10 million uniquely mapped reads per sample for NextSeq 500 
and Ion Proton, respectively. An average coverage of 0.3x resp 0.4x per sample was obtained (mean read length 
NextSeq500 = 75 bp, mean read length Ion Proton = 123 bp). 
4.2. Aberrations detected with MPS 
MPS results for the 47 analyzed samples were evaluated in ViVar and interpretation of the genomic profiles (line 
views) was performed with knowledge of the parental karyotype, but blindly from the earlier generated aCGH 
results (Table 1).  
The genetic diagnosis of all samples was the same for aCGH and both MPS technologies. The chromosomal changes 
detected by MPS were concordant with those detected by aCGH in all embryos, as all structural and numerical 
aberrations identified by aCGH were also identified by MPS, hence the sensitivity is 100%. Vice versa, no new 
aberrations have been detected with MPS giving a specificity of 100%. 
The 500kb window size during QDNAseq analysis proved to give the most appropriate resolution for our analysis. 
While the 1Mb window smoothed the signals to much, hampering the proper detection of smaller aberrations, the 
250kb windows and smaller windows resulted in the identification of several smaller aberrations that were 
recurrent across different unrelated samples, probably due to artefacts during the WGA. 
Results from NextSeq500 and Ion Proton sequencing were concordant: QDNAseq line views are almost 
indistinguishable between both technologies, independent of the chosen window size (See example in Figure 2). 
All aberrations were detected by both technologies. The size of these aberrations was also identical between the 
two technologies. For an overview of all samples, following link to ViVar can be used: ViVar: http://cmgg.be/ViVar/. 
Five of the 47 analyzed embryos, gave a normal profile without any detectable structural or numerical aberration. 
The other 42 embryos showed one or several abnormalities. In total, 54 structural abnormalities (31 deletions and 
23 duplications) were detected in 27 embryos.  Additionally, 17 monosomies and 16 trisomies were observed in 25 
embryos. Twenty-three embryos showed a duplication together with a deletion in concordance with an unbalanced, 
derivative chromosome related to the parental rearrangement. Of these, 9 embryos showed additional 
aneuploidies or copy number aberrations together with the unbalanced translocation. Of note, and in line with 
previous studies, 19 embryos did not show the expected parental rearrangement, but showed aneuploidies or copy 
number aberrations of/in chromosomes not involved in the parental rearrangement, illustrating the importance of 
whole genome analysis.  




Table 1: Chromosomal aberrations present in study cohort 
Although all structural aberrations could be detected by both aCGH and MPS, MPS showed a slightly higher 
resolution and signal-to-noise ratio. Accordingly, the smaller aberrations could be identified more clearly as 
illustrated in Figure 3. The examples in Figure 3 are further discussed in detail in the discussion section of this 
article.  




Figure 2: Comparing aCGH and MPS profiles for chromosomal aberrations. 
Genomic profiles from Patient 2 embryo 8 generated with (A) NextSeq500 sequencing, (B) Ion Proton sequencing and (C) aCGH. The blue 
color indicates a duplication or trisomy, while the red color indicates a deletion or monosomy. All sequencing results were analyzed with 
a female reference while a male reference was used in the aCGH experiments. The aCGH profiles were analyzed with a 1Mb distance 
between the probes, which leads to a smoother line compared to the 500kb windows from sequencing results. 
4.3. Resolution limited by number of reads or by WGA amplification bias? 
The average number of reads per sample was higher than actually needed for correct detection of the aberrations 
present in the samples. The minimal number of reads that would still lead to the same result can be imputed by 
random selection of reads across the genome (downsampling of the sequencing reads). With only 1/10th of all reads 
remaining, all aberrations could still be detected. Even the very small duplication as shown in figure 3b, is still 
detected after a 10x downsampling. We can conclude that with ±1.6 million reads we still achieve the resolution 
necessary for this sample set (4.5 Mb resolution) (Supplementary figure 1). Although it is expected that a higher 
read count will lead to a higher resolution, we saw an increase in false positive results (see above) when reducing 
the analysis window to a size that is required to call copy number aberrations at a higher resolution. This shows 
that the minimal resolution for detection of chromosomal aberrations is probably limited by the WGA and not by 
the number of reads. 




Figure 3: The resolution and signal-to-noise is more appropriate for MPS analysis. 
(A) Sequencing (top) and aCGH (bottom) profile of chromosome 6 from Patient 10 embryo 1. The 6q23.2q24.3 duplication due to the 
paternal insertional translocation (46,XY,ins(14;6)(q23.2;q23.2q24.3)) is more clearly detected on the MPS profiles than on the array 
profile. (B) Sequencing (top) and aCGH (bottom) profile of chromosome 9 from Patient 2 embryo 7. The 4.5 Mb duplication on 
chromosome 9 is unequivocally apparent in the MPS data whereas less obvious in the array profile. The abnormalities were highlighted 
with red arrows. 
5. Discussion 
In the present study we evaluated the use of MPS in PGD for chromosomal aberrations. We thoroughly compared 
aCGH data from 47 embryos with data generated on the same amplified samples using shallow whole genome 
sequencing on both an Illumina and Ion Torrent instrument. All aberrations previously detected with aCGH could 
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be identified by MPS. There was no difference in the detection capacity between the NextSeq500 and Ion Proton 
instrument.  
Microarrays are widely used in PGD and are considered the gold standard for the detection of chromosomal 
aberrations in embryonic samples. However, a major drawback of microarrays is the high cost per sample. We show 
that multiple PGD samples can be multiplexed in one MPS run. The PGD samples could also be multiplexed with 
sequencing libraries from other samples such as NIPT and exome sequencing samples. MPS technology and 
workflows can thus be flexibly applied to a range of samples. Depending on the sample throughput, MPS can be a 
cost-effective alternative compared to aCGH. Furthermore, we show that less sequencing reads than generated in 
this validation study can be used to obtain the same resolution.  
According to our downsampling experiment, the minimal amount of sequencing reads to obtain a 4.5Mb resolution 
in PGD (smallest aberration present in our data set), is 1.6 million reads per sample. This number of reads is much 
higher compared to what is needed in MPS experiments on non-amplified DNA for copy number analysis. Probably 
due to the amplification bias introduced by the WGA protocol more reads are needed to obtain a similar resolution 
(186). Although several new WGA methods have been described, we –and others- have shown that the SurePlex 
method used in this study introduces the least amplification bias (187) (Chapter III). Although MPS is a technique 
that allows scaling, the WGA is currently the limiting factor in achieving higher resolution copy number profiles 
when starting from a single or a limited number of cells. According to the binomial distribution, higher read counts 
would lead to higher resolutions. However, looking at a higher resolution by using smaller windows introduced 
artefacts originating from WGA representation bias.  
This validation study nicely demonstrates that for some samples the resolution of the commonly used BAC arrays 
is suboptimal. Although current WGA methods limit the resolution in both aCGH and MPS, with MPS the resolution 
can be increased (e.g., by lowering the analysis window size) for patients with known cryptic aberrations while 
restricting the analysis to the chromosomal segments of interest to avoid false positive results genome-wide. 
Illustrative are two different cases (Patient 2 and 10) in the present study. Both patients had a small balanced 
rearrangement in one of the parents. In Patient 10, embryo 1 has a 16.5 Mb duplication on chromosome 6 due to an 
insertional translocation in the father-46,XY,ins(14;6)(q23.2;q23.2q24.3). This couple was enrolled for PGD following 
a pregnancy where amniocentesis showed an aberrant prenatal microarray profile with a 16.5 Mb duplication on 
chromosome 6. Only with knowledge of this previous prenatal result, the insertion could be detected in the embryo 
by aCGH. The duplication is not called automatically by the BlueFuse software and although the 24sure+ arrays 
have a higher coverage of BAC probes near the telomeres and centromeres, the resolution in between is rather 
limited. The duplication is, however, clearly visible in the MPS data (Figure 3a). Another example of a small relevant 
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aberration is observed in Patient 2 embryo 7, where the terminal duplication of 4.5 Mb on the p-arm of chromosome 
9 is only vaguely detectable by aCGH, but is very clearly revealed by sequence analysis (Figure 3b). Those two 
examples show that for some cases the resolution of the commonly used microarrays can be a limiting factor for 
PGD.  
Concerns are raised about the ideal resolution for preimplantation analysis (36). The detection of Variants Of 
Unknown Significance (VOUS) should be avoided at this time, as this can potentially lead to discarding normal 
embryos. We therefore chose to limit the resolution of our analysis to ±3 Mb. Larger aberrations are very likely to 
be pathogenic and selecting against these larger aberrations can enhance conceiving a normal pregnancy. 
Depending on the parental karyotype and the imbalances involved, one could however adjust sequencing depth to 
obtain the needed resolution. The window size used during data analysis is another important element influencing 
the resolution of CNV detection. While smaller windows will be able to detect smaller CNVs, the amount of false 
positive calls will also increase. In the present study, we noticed that artefacts were apparent in smaller window 
sizes (100kb and 250kb windows).  Of note were two recurrent artefacts that were present in several embryonic 
samples from different cases using the smaller window sizes: a duplication at 10q22.2q23.1 and a deletion in 
17q22q24.1. Both aberrations were present in the NextSeq 500 and Ion Proton data. These aberrations are very 
likely the result of a bias in the genomic representation introduced by WGA. Therefore, for clinical use of MPS in 
PGD we consider 500kb as the most appropriate window, giving the best trade-off between sensitivity and 
specificity. The 500kb moving window allowed clear detection of all clinically relevant aberrations, yet excluding 
false positive calls.  
MPS is a labor-intensive technique and library construction is quite a lengthy protocol that consists of multiple 
steps. Automation of the library preparation can diminish the hands-on time and increase the throughput. MPS for 
PGD with fresh embryo transfer can, however, be problematic due to the limited available timeframe. The 
introduction of trophectoderm biopsy and major improvements in cryopreservation, using the closed blastocyst 
vitrification system, are revolutionary innovations for PGD (61-63). First, more time available to perform the genetic 
analysis and potentially discuss difficult cases. Upon failure of the sequencing, the MPS protocol can be easily 
repeated or even a re-biopsy can be considered. Dimitriadou et al. showed that the quality of aCGH results on single 
cells is dependent on the phase in the cell cycle (54). ACGH on S-phase cells shows a more fluctuating profile than 
cells in the G-phase, which can lead to misdiagnosis. More cells can be biopsied from blastocysts which leads to a 
better and more uniform amplification. Cell cycle discrepancies are smoothed, ultimately leading to better results 
and hence, a more confident genetic diagnosis (54). An additional advantage of trophectoderm biopsy is the 
decreased risk of damaging the embryo. It has been shown that taking more than one cell from a cleavage stage 
embryo decreases the survival rate of the embryo, whereas this is not the case for trophectoderm biopsy (48, 61). 
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Furthermore, it has been shown that cleavage stage embryos contain more aneuploidies and show a higher rate 
of mosaicism for numerical and structural chromosomal aberrations (55). This can lead to both false positive and 
false negative results (58). This makes genome-wide chromosome analysis on day 3 embryos less meaningful. 
Genomic activation of the embryo sets in at day 3 and in this way DNA damage and response pathways will be 
activated. This will lead to the loss of some or even most of the abnormal embryos (58-60). Due to this natural 
selection against genomic abnormal embryos, genetic testing is needed for fewer, high quality embryos at the 
blastocyst stage. Although we use day 5 biopsy in this study, there is still a low chance of mosaicism for 
aneuploidies or structural abnormalities in the embryo. Since only a few cells are biopsied, mosaic embryos could 
potentially be missed. If the mosaicism is present in the biopsied cells, it is possible to detect mosaicism with aCGH 
as well as sequencing, depending on the percentage of abnormal cells vs normal cells. Although trophectoderm 
biopsy, combined with PGD, hampers fresh embryo transfer and implies vitrification of the embryos, it was recently 
shown that embryo transfer after freezing and transfer in a natural menstrual cycle leads to better IVF outcomes 
than fresh embryo transfer (63, 188). All these issues make trophectoderm biopsies the preferred approach for PGD 
for chromosomal aberrations.  
This study also shows that shallow whole genome sequencing enables the unambiguous identification of 
aneuploidies and copy number aberrations in embryonic samples. Randomized control trials are currently being 
performed to evaluate whether aneuploidy screening shows added value in ART (19). The used technologies can be 
easily implemented for PGS and will allow reliable detection of aneuploidies of all chromosomes. 
Furthermore we show, for the first time, that both Illumina (NextSeq500) and Ion Torrent (Ion Proton) sequencing 
technologies can both be used for the detection of chromosomal aberrations in embryos. Most clinical, genetic 
laboratories have access to one of these benchtop sequencers and the used protocols can be easily implemented. 
We could not determine any difference between both MPS techniques, and as such, they can be used equally. We 
prove that all aberrations detected by aCGH are also detectable by MPS, even the smaller ones and this for 42 
abnormal samples.  For the data analyses, QDNAseq or other published read depth algorithms can be used (159, 
175). Due to the ease of use and the incorporation of the blacklisted regions, we prefer the QDNAseq algorithm. 
6. Conclusion 
We demonstrated that shallow whole genome sequencing on trophectoderm biopsies is a preferable alternative 
for the detection of chromosomal structural and numerical abnormalities in PGD embryos. MPS results are 
completely concordant with current aCGH techniques and provide slightly higher signal-to-noise ratio and 
resolution. The resolution of the MPS assay can be scaled by generating more or less reads, but resolution of <3Mb 
is hampered by WGA representation bias. 
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Link to data: 
ViVar: http://cmgg.be/ViVar/ 
7. Supplementary information 
Supplementary figure 1: Only 1/10nd of the reads is needed for detecting the chromosomal aberrations of 4.5 Mb and more.  
 
To determine the minimum number of reads necessary to detect copy number aberrations successfully, raw reads were 
randomly downsampled to levels, respectively, 2 to 10 times lower than the original number of raw reads. (7) Original genomic 
MPS profile of Patient 2 embryo 7, (1) Genomic MPS profile of Patient 2 embryo 7 with the 10x less reads. All aberrations from 
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Shallow whole genome sequencing has recently been introduced for genome-wide detection of chromosomal copy 
number alterations (CNAs) in preimplantation genetic diagnosis (PGD), using only 4–7 trophectoderm cells biopsied 
from day-5 embryos. This chapter describes the complete workflow, starting from whole genome amplification 
(WGA) on isolated blastomere(s), up to data analysis for CNA detection. The process is described generically and 
can also be used to perform CNA analysis on a limited number of cells (down to a single cell) in other applications. 
This unique description also includes some tips and tricks to increase the chance of success. 
2. Introduction 
Massively parallel sequencing (MPS)-based preimplantation genetic diagnosis (PGD) has been the subject of 
several studies in recent years (30, 32, 163, 179). Those studies show the advantages of MPS over current methods, 
such as array Comparative Genomic Hybridization (aCGH), for detecting chromosomal aberrations in PGD (30, 32, 
163). Although aCGH proved its value, its rather limited resolution and the relative high cost are a disadvantage 
(32). Shallow or low-pass whole genome sequencing can address these issues (30) (Chapter IV). Chapter IV 
concluded that shallow whole genome sequencing on trophectoderm biopsies is a preferable alternative for the 
detection of chromosomal structural and numerical abnormalities in PGD embryos (30). MPS-based PGD was able 
to detect chromosomal aberrations, equal or larger than 3Mb, in 47 blastocysts of 15 patients with a better 
resolution and signal-to-noise ratio compared to aCGH-based PGD (30) (Chapter IV). Although no large clinical 
trials on the long-term clinical advantages of embryo selection using MPS have been reported yet, a few cases of 
birth of a healthy baby are known (31, 32).  
Embryo implantation fitness is determined using only 4–7 trophectoderm cells biopsied from day-5 embryos (48, 
55, 58). Whole genome amplification (WGA) is needed to amplify the DNA from those cells before downstream 
analysis. Especially with such low amounts of input DNA, some WGA methods will lead to unbalanced amplification 
with over- and under-representation of genomic regions. Bias introduced during this amplification process, may 
lead to misinterpretations of the genomic profile (187) (Chapter III). Choosing the correct method for amplification 
depends on the application (130): PCR-based methods are better suited for chromosomal aberration detection 
compared to multiple displacement amplification (MDA) methods, because they give a more balanced genomic 
amplification. In Chapter III, two state-of-the-art PCR-based WGA methods were compared to study their 
applicability for copy number alteration (CNA) detection using MPS (187). In this study, PicoPLEX/SurePlex (Rubicon 
Genomics Inc., MI 48108, USA / BlueGnome Ltd., Mill Court, Great Shelford, Cambridge, UK) proved to be better suited 
for CNA analysis using MPS compared to Multiple Annealing and Looping Based Amplification Cycles (MALBAC) 
(Yikon genomics, Beijing, China). SurePlex WGA is more uniform across the genome, leading to less false positive 




and false negative CNAs. SurePlex WGA has been successfully applied in clinical MPS-based PGD with correct 
detection of CNAs with a resolution of 3Mb (30) (Chapter IV). 
CNA analysis starting from a limited number of DNA has several applications. Therefore, a detailed description of 
this method is useful. In this chapter, the workflow is described in detail as it would be executed for PGD. The 
general techniques described are from standard protocols, but important changes to these standard protocols were 
introduced to optimize the results. The note section, listing some tips and tricks, is important to increase the chance 
of success. The complete procedure, starting from a few cells and ending up with a CNV profile of the DNA, has 
never been described in such great detail before. The workflow, as described, has proven its success in detecting 
CNV up to 3Mb starting from 4-6 blastocysts.  
The protocol starts with WGA on a few cells. Based on previous results, the SurePlex WGA kit was the method of 
choice for WGA (187) (Chapter III). SurePlex might be replaced with another WGA method, but this might have a 
significant influence on the results. The genomic coverage, sequence error rate, yield, and representation bias might 
differ, possibly leading to more/less accurate CNA detection and/or a higher/lower CNA detection resolution. 
Changing from SurePlex to PicoPLEX should not influence the results, since both kits basically have the same 
underlying method. The amplified DNA is fragmented to fragments of 200bp using sonication. Subsequently, 
Illumina sequencing libraries are prepared from the fragmented DNA using NEBNext Ultra 2 library preparation kit. 
This kit is suited for DNA input amounts as low as 500pg. The needed library preparation method depends on the 
downstream sequencing technology. In this protocol, Illumina NextSeq500 sequencing is described.  Ion Torrent 
sequencing will show similar results as demonstrated in chapter IV (30).   
3. Materials 
3.1.  Whole genome amplification 
1. DNA Lo-bind 0.2ml or 1.5ml tubes. 
2. Filter tips 
3. Positive control (genomic DNA at a known concentration): diluted to 30pg/µl in Molecular Bio-grade water 
(Note 1). 
4. Phosphate Buffered Saline (PBS). 
5. SurePlex/PicoPLEX WGA kit for single cell whole genome amplification, Rubicon Genomics, store at -20°C 
(Note 2).  
6. Thermocycler with heated lid at 105°C. 
7. Purification kit: Genomic Clean &Concentrator, Zymo Research, store at room temperature. Binding buffer and 
Wash buffer are provided.  
8. Benchtop microcentrifuge. 
9. Thermomixer at 65°C. 




10. Quality control using capillary gel electrophoresis: Agilent High-Sensitivity DNA kit (lab-chip), Bioanalyser 
2100, Agilent Technologies. 
11. Concentration measurement: Qubit dsDNA High Sensitivity Assay kit. 
3.2. Fragmentation of purified WGA product 
1. DNA Lo-bind 0.2ml tubes. 
2. Filter tips 
3. Fragmentation of DNA by sonication: Covaris S2 Focused Ultrasonicator with Adaptive Focused Acoustics 
technology (Covaris). 
4. MicroTUBES (Covaris) 
5. 1/5 X Tris-ethylenediaminetetraacetic acid (EDTA) buffer: 0.5ml 20 X TE buffer, 49.5ml molecular bio-grade 
water. 
3.3. Library preparation 
1. DNA Lo-bind 0.2ml or 1.5ml tubes. 
2. Filter tips 
3. All buffers mentioned during the downstream protocol are derived from the NEBNext Ultra II kit, Bioké. Store 
at -20°C. (Note 3) 
4. Thermocycler with adjustable heated lid.  
5. Thermomixer for 0.2 and 1.5ml tubes. 
6. Purification kit: Genomic Clean & Concentrator (Zymo Research), store at room temperature. Binding buffer 
and Wash buffer are provided.  
7. Benchtop microcentrifuge. 
8. Size selection: E-Gel 2% EX agarose gel, 1kb plus DNA ladder and E-gel ibase power system (Thermo Fisher 
Scientific). 
9. Purification from gel: Zymoclean gel DNA recovery kit, Zymo Research, store at room temperature. 
10. Dark Reader blue light Transilluminator 
11. 10ng/µl yeast tRNA 
12. Purification after enrichment PCR: magnetic beads, Agencourt AMPure XP beads, store at 4°C, magnetic 
particle concentrator (MPC). 
13. 80% ethanol: 40ml 100% ethanol with 10ml molecular bio-grade water. This can be kept at 4°C for two weeks. 
3.4.  Library quality control and quantification 
1. Quality control using capillary gel electrophoresis: Agilent High-Sensitivity DNA kit (lab-chip), Bioanalyser 
2100, Agilent Technologies. 
2. Quantification of adapter-ligated fragments: Sequencing library qPCR quantification guide (Illumina) 
3. Illumina sequencing kit (Note 4).  
4. Method 
Carry out all procedures at room temperature unless otherwise specified. 
 




4.1. Whole genome amplification 
1. Isolate the necessary amount of cells in less than 2.5µl of cell medium or PBS in a 0.2ml tube (Note 5).  
2. Dilute with the appropriate volume of Cell Extraction Buffer to achieve a total sample volume of 5µl (Note 6). 
3. Prepare a positive and negative control. Take 2.5µl of PBS as negative control and take 2.5µl of the diluted 
positive control.  
4. Prepare an extraction cocktail for at least 5 samples (positive and negative control included) (Note 7). 
Combine 24µl of Extraction Enzyme Dilution Buffer and 1µl of Cell Extraction Enzyme in a 0.2ml tube and mix 






5. Prepare a pre-amp cocktail for at least 5 samples. Combine 24µl of Pre-Amp buffer and 1µl of Pre-Amp Enzyme 
in a 0.2ml tube and mix by flicking the tube. Add 5µl of the cocktail to each sample (Note 8). Incubate the 









6. Place the samples on ice before use. 
7. Prepare the Amplification Cocktail as instructed. Combine 34.2µl nuclease-free water/sample, 25µl 
Amplification buffer/ sample and 0.8µl Amplification enzyme/sample in a 0.2ml tube. Mix by flicking the tube 






8. Vortex the samples and spin down 
9. Purify the samples on spin columns. As an efficient example, Zymo Genomic Clean and Concentrator has been 
described below. 
10. Place nuclease-free water at 65°C in a thermomixer. 
11. Add 375µl Binding buffer to each sample and transfer this mix to the spin column (Note 9).  
12. Centrifuge at 11000 RPM for ± 25sec. 
13. Discard the flow-through and pat the collector tube dry. Re-use the same collector tube. 
14. Wash the spin columns with 200µl Wash buffer. 
15. Centrifuge at 11000 RPM for ± 25sec. 
12 cycles 
14cycles 




16. Repeat step 14. 
17. Centrifuge at 11000 RPM for ± 1min (Note 10). 
18. Transfer the spin columns to a new 1.5ml tube. 
19. Elute the DNA in ±32µl of the pre-warmed molecular biology grade water (Note 11) and incubate for 1min at 
room temperature.  
20. Centrifuge at 11000 RPM for ± 35sec. 
21. Remove the spin column and store the 1.5ml tubes at -20°C or perform a quality/quantity check before storing. 
Measure the concentration with Qubit (Note 12). Analyze the sample on a high sense Agilent lab-chip (Note 
11).  
4.2.  Fragmentation of purified WGA product 
1. Dilute ±100ng of the WGA product with 1/5 TE buffer in 130µl in microTUBES. 
2. Adjust the settings of the Covaris S2 for a 200 bp fragmentation:  duty cycle of 10%, intensity of 5, 200 
cycles/burst and a treatment time of 190s (Note 14). 
4.3. Library preparation  
1. Make sure the heated lid of the thermocycler is set on 75°C. 
2. Add 7µl of End repair reaction buffer to empty 0.2ml tubes. Transfer 50µl of each fragmented sample into a 
0.2ml tube with buffer. Add 3µl of End prep enzyme mix to each sample and mix by flicking the tube. Incubate 





(During incubation, put a thermomixer at 20°C and pre-program another thermocycler at 37°C with a heated lid at 
47°C. Make sure the temperature of the thermocycler is already at 37°C when the samples are inserted. If DNA 
input was less than 100ng, dilute the adapter to a finale concentration of 1.5µM (Note 15).) 
3. Add 30µl ligation master mix, 1µl ligation enhancer and 2.5µl diluted adapter to each sample in this respective 
order (Note 16). Mix by flicking the tube and incubate 15min at 20°C in a thermomixer. 
4. Add 3µl USER enzyme to each sample and incubate 15min at 37°C in a thermocycler with heated lid at 47°C. 
5. Purify the samples on spin columns, such as described above. Place nuclease-free water at 65°C in a 
thermomixer. 
6. Add 482.5µl Binding buffer to each sample and transfer this mix to a spin column (Note 9).  
7. Follow step 12-18 as in part 4.1. 
8. Elute the DNA in ±22µl of the pre-warmed nuclease-free water (Note 17) and incubate for 1min at room 
temperature. 
9. Centrifuge at 11000 RPM for ± 35sec and remove the spin column (Note 18). 
10. Perform size selection using E-gel EX 2% agarose gels. Dilute the DNA ladder ¼ in 20µl water. Add all samples 
individually to a separate gel-slot, alternated with a ladder every 3 or 4 samples. Choose the 1-2% gel program 
on the ibase (10min) and run the gel. 




11. Remove the gel from its case and visualize using a Dark Reader blue light transilluminator. Cut the gel at the 
desired height to retrieve the DNA (Note 19). 
12. Dissolve the gel in 300µl ADB buffer (Zymo gel purification) at 55°C in a thermomixer for at least 10min. When 
the gel is completely dissolved, purify on spin columns as described above in 4.1. However, change the elution 
volume to 17µl.  
13. Next, enrich the samples carrying adapters.  Each sample is assigned an index (Note 20). Transfer the samples 
to a 0.2ml tube and add 1µl of tRNA (Note 21).  Add 3µl of the assigned index primer and 3µl of universal 
primer to each sample. Finally, transfer 25µl of HF 2X PCR master mix to each sample. Mix by flicking the tube 




5 min 65°C 
Hold 4°C 
While waiting: put the magnetic beads at room temperature. 
14. Purify the sample using magnetic beads (Note 23). Mix the samples with 45µl beads and leave at room 
temperature for 6min. 
15. Put on a MPC until the liquid is clear and remove supernatant 
16. Wash the beads with 200µl 80% ethanol while on MPC and wait 30sec before removing supernatant. 
17. Repeat step 18 
18. Make sure all supernatant has been removed, in order to facilitate the air-drying process. Air-dry the samples 
until cracks are visible between the beads (Note 24). 
19. At 22µl nuclease-free water to each sample and remove from MPC. Mix well until sample and beads are a 
homogeneous mixture. Leave at room temperature for 3min. 
20. Put on MPC until clear and transfer the supernatants to new 0.2ml tubes. Make sure no beads are transferred. 
4.4. Library quality control and quantification. 
Library quality control is performed by capillary gel electrophoresis on a Bioanalyzer High sense labchip. The result 
is displayed as an electropherogram (EPG) showing intensity in function of fragment-size distribution. The library 
should contain DNA fragments of ±300 bp. Figure 1a shows an EPG of a good quality library. The other two smaller 
peaks represent the internal standards (upper and lower marker). The intensity of the library informs about the 
concentration of the library (Note 25). A peak visible around 85bp, as the one shown in figure 1b, indicates the 
presence of primer-dimers (Note 26).  
The quantification of adapter-ligated fragments in the library is performed by qPCR. Only fragments carrying an 
adapter will bind to the flowcell, and therefore will be sequenced (Note 27). QPCR is performed as recommended 
by Illumina. Make sure the libraries are diluted to fit the standard curve used for qPCR. The concentration measured 
after qPCR reflects the amount of DNA that can be sequenced. 
9 cycli (Note 22) 





Figure 1: Library quality control.  
A) An electropherogram of a good quality library with a fragment length of ±300bp. (1) Lower marker, (2) Library, (3) Upper marker. B) 
An electropherogram of a library with primer-dimers (4). 
The libraries are further prepared for sequencing using the standard Illumina protocols. Sequencing is performed 
on a NextSeq500 using a high output flowcell for single read and 75 cycles. The sequencing run will last for about 
11 hours.  
4.5. Data analysis 
Several tools and programs are available to detect CNAs using shallow, genome-wide massively parallel 
sequencing data (172, 189). However, most of these tools only handle a certain part of the analysis. It requires 
bioinformatics knowledge to handle and combine these different tools to perform CNA detection starting from raw 
sequencing data. Recently, ViVar (182) was developed to provide a user-friendly web-based analysis platform that 
handles all necessary steps in a comprehensive way. This platform is freely available at https://www.cmgg.be/ViVar/. 
Download and installation instructions are also provided at this web URL.  
ViVar offers an easy-to-use and straightforward interface which enables the analysis from raw sequencing data, 
obtained from the sequencer as .fastq files, for detection of CNAs:  
1. Select ‘Projects’ from the top navigation bar (Figure 2). 
2. Click the ‘New project’ button to create a new project (Figure 2). 
3. Click the ‘Save’ button after filling out the project’s information to save the new project. 




4. One can now find the new project in the list, which is accessed by selecting ‘Projects’ from the top navigation 
bar (Figure 2). 
5. By clicking on the new project’s name, a page containing the experiments for that project will be loaded. In 
ViVar, each experiment consists of a single sample.  
6. To create a new experiment, click the ‘New experiment’ button. 
 
Figure 2: Creating a new project in ViVar.  
First, select ‘Projects’ from the top navigation bar (1), then click the ‘New project’ button to create a new project (2). After filling out the 
project’s information, the newly created project will appear in the projects list (3). 
7. Choose ‘Sequencing data’ by clicking the ‘Next’ button in the ‘Sequencing data’ field (Figure 3). 
 
Figure 3: Starting a new sequencing experiment on ViVar.  
A new experiment/analysis based on massively parallel sequencing data can be started by clicking the ‘Next’ button in the 
‘Sequencing data’ field (red circle).  
8. From the drop-down list select the project you want to add a new experiment to (Figure 4). 
9. Add data to an experiment by selecting the samples you want to analyze. You can select multiple samples at 
once (Figure 4). 
10. Next, choose the organism from which the samples originate (Figure 4).  
11. Then, also select the version of the reference genome you want to use for the analysis from the drop-down 
list (Figure 4). 
12. Finally, in the ‘Depth of Coverage’ field, select the bin size you want to use for the analysis (see description of 
this parameter below), switch the tumble button from ‘OFF’ to ‘ON’ and click the ‘Next…’ button to start the 
analysis (Figure 4).  





Figure 4: Setting the parameters for a new analysis in ViVar. 
 Once a new analysis based on massively parallel sequencing data has been created, parameters for the analysis can be specified: the 
project to which the experiment should be added, the sample(s) which should be analyzed, the reference genome which should be 
used in the analysis, and the bin size (1). Analysis can be started by switching the tumble button from ‘OFF’ to ‘ON’ (2) and clicking the 
‘Next…’ button (3). 
ViVar will now analyze the data in a fully automated manner. Briefly, it first uses Bowtie  (190) to place the 
sequencing reads onto the reference genome. Then, using these mapped reads, it performs CNA detection using the 
QDNAseq algorithm (160). To this end, the genome is divided in non-overlapping fixed size parts, so called 
bins/windows. The size of these bins will determine the minimum size of the CNAs which can be detected. Generally, 
CNAs three to five times the size of the bins can be detected. The number of reads mapped to each bin will be 
determined. This number is influenced by certain factors, such as GC-content and mappability, for which the number 
of reads mapped per bin is normalized. After GC-content and mappability normalization, read counts are median-
normalized by dividing the number of reads in each bin by the median number of reads across all bins. As CNAs are 
assumed to be rare, the median number of reads across all bins is a fair estimate of the expected number of reads 
per window for a perfectly diploid genome. As such, the median-normalized read counts represent a measure for 
the deviation from diploidy for each window and a copy number (CN) estimate is calculated using the following 
formula: CN= 2(read count/median read count). Then, a circular binary segmentation (CBS) algorithm (161) is applied 
which groups bins into larger contiguous regions with an equal CN. The mean of read counts of the windows 
contained in the segments are used as an estimator of the copy number of the whole segment. After this 
segmentation, CNAs are called when the segment’s log2(CN/2) surpasses a certain threshold. This threshold can be 
specified by the user in ViVar (see further). Based on literature review and own experience a threshold of +/- 0.35 
performs well.  




After the analysis has been finished, ViVar offers some powerful visualizations of the data: line profile plots, karyo 
plots, genome heatmaps, etc. (Figure 5). The procedure to obtain these visualizations is always similar: 
- Select ‘Projects’ from the top navigation bar 
- Click on the project of interest. A list of experiments within the project is now shown. 
- Select the experiment you want to visualize by ticking the checkbox in front of the experiments name 
(Figure 6).  
- Select, from the dropdown list at the top of the screen, the visualization of interest. 
- Some visualizations, such as the karyo plots, can handle multiple simultaneous experiments.  
- Finally, certain visualization and analysis settings, such as color schemes and thresholds for calling CNAs 
can be adjusted by clicking on ‘criteria’ in the upper right corner of the visualization screen.  
 
Figure 5: Some of the visualizations possible with ViVar.  
Karyo plot (A); line view plot (B); genome heatmap (C); and chromosome view (D). 
 
Figure 6: Visualizing results in ViVar.  
Results can be visualized in ViVar by ticking the checkbox in front of the name of the experiment you want to visualize (1) and choosing 
the visualization of interest from the dropdown list (2). 
5. Notes 
1. The amount of DNA in the positive control is equivalent to 5 cells. 
2. All buffers used during the downstream protocol are derived from this kit. Buffers must be vortexed before 
use, but never vortex enzymes. Always keep enzymes on ice. 




3. Another library preparation method for Illumina, without the enrichment PCR step, is a valid alternative for 
the described method. Omitting the PCR-step will lead to a more uniform coverage of the genome (187) 
(Chapter III). However, this TruSeq PCR-free library prep kit requires more input material, which might pose a 
limitation for some applications. Replacing the NEBNext Ultra II kit with the NEBNext Ultra 1 version, will not 
change the outcome. 
4. The type of kit depends on the number of samples and the coverage aimed. Here: Illumina NextSeq500 high 
output kit v2 (75 cycles).  
5. A) Blastocysts are kept at -20°C after biopsy until genetic analyses. Cells isolated from a cell culture are snap 
frozen in N2 immediately after collection and stored at -80°C until further use. 
      B) Other start material, such as fixed or microdissected cells, might lead to different results and might need 
some optimization. 
6. This mix can be stored at -80°C. However, it is recommended to proceed immediately.  
7. To avoid pipetting errors when pipetting very small volumes, prepare the mix for at least 5 samples.  
8. To avoid the loss of cell material, do not touch the liquid already present in the tube while adding the cocktail. 
9. To increase binding of the DNA, add 5 X Binding buffer (ratio 1:5). 
10. Make sure no residual wash buffer/ethanol is left, because this might lead to a suboptimal elution of the DNA. 
Centrifuge again if necessary. 
11. Elution with pre-warmed water will lead to a better elution of the DNA. The elution volume depends on the 
downstream application. Make sure to get rid of the air-bubbles in your tip that arise because of the 
temperature difference. Pipet the water straight on top of the column.  
12. Other assays based on fluorescent DNA stains can also be used to measure the concentration. However, 
spectrophotometric techniques such as Nanodrop are less accurate because the UV signal is not specific to 
DNA.  
13. If the negative control shows a similar result on Qubit and Agilent as the samples, some contamination might 
have occurred during the WGA procedure. In this case, samples might contain more amplified contaminated 
material than amplified template. If both samples and positive control show negative results, the PCR reaction 
during WGA might have failed.  If the positive control looks fine, but one (or more) of the samples is negative, 
that specific sample probably lacked template at the start. 
14. The treatment time might need to be slightly adjusted depending on the specific instrument and water bath 
temperature. 
15. The dilution needs to be made fresh. 




16. Do not mix the three components in advance, since this might create adapter-dimers. The adapter ligation 
could be suboptimal, since a large part of the adapters are already ligated to each other. Add the three 
components sequentially to one sample, then add the three components sequentially to the next sample, etc. 
Avoid a big time difference between the first and last sample, since the reaction already starts at room 
temperature.  
17. The elution volume is important for the next step.  
18. At this point, the sample could be stored at -20°C. However, long time storage might negatively affect the 
concentration of library with intact sequencing adapters. 
19. Make sure to change scalpel between each sample. If DNA concentrations are low, samples might be nearly 
invisible under the dark reader. Retrieve the samples between 200 to 400bp. 
20. Make sure each sample is assigned a unique index. The specific combination of indexes is only important if 
less than 7 samples are pooled (see kit documentation). Dual-indexing is used when more than 24 samples 
are pooled.  
21. In samples were template DNA concentrations are rather low, tRNA is added as a carrier that will adsorb to 
most of the tube wall, resulting in more concentrated template DNA in the rest of the tube. Higher 
concentration increases the efficiency of primer annealing to the template. More template will be efficiently 
amplified and the amount of primer-dimers will decrease.  
22. The number of cycles depends on the input amount of DNA. Decrease the number of cycles if possible, to 
decrease amplification bias. 
23. Make sure the beads are well mixed before use. When removing supernatant, check your tip for beads. If beads 
are visible, transfer the liquid back into the right tube and wait again until the liquid is clear.  
24. The protocol states not to dry the beads until they are cracked. Nevertheless, based on our experience, the 
elution efficiency increases when the ethanol is completely evaporated. 
25. The intensity of both internal standards should be similar. If this is not the case, the concentration 
measurements are not reliable.  
26. Intense primer-dimer peaks should be removed from the library. They will skew qPCR results, because they 
also contain the binding place for the qPCR primers and thus yield an unreliable quantification of adapter-
ligated fragments.  The dimers are removed by size selection on gel, as described before. The bright band of 
200-400bp is cut from the gel and the dimers are left behind nearly at the end of the gel. Primer-dimers 
might also be avoided by decreasing the primer input during enrichment PCR or decreasing the amount of 
samples prepared simultaneously. They will compete with the library-fragments for binding places on the 
flowcell. Only fragments carrying the correct adapters on both ends will bind to the flowcell. A peak at ±125bp 




on the EPG indicates the presence of adapter-dimers. Measuring the amount of DNA from the library that will 
actually bind to the flowcell is essential to overcome over- or underclustering during the sequencing run and 
can only be achieved using qPCR. 
27. When the fragment length between the samples and PhiX is different, a size correction is performed on the 
measured concentration after qPCR. PhiX has a fragment length of 500bp, whereas the samples have 
fragment lengths of only 300 bp. For size correction, the measured concentration is multiplied by the ratio of 
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Starting from only a few cells, current whole genome amplification (WGA) methods provide enough DNA to perform 
massively parallel sequencing (MPS). Unfortunately, all current WGA methods introduce representation bias which 
limits detection of copy number aberrations smaller than 3Mb. A recent WGA method, called TruePrime single cell 
WGA, uses a recently discovered DNA primase, TthPrimPol, instead of artificial primers to initiate DNA amplification. 
This method could lead to a lower representation bias, and consequently to a better detection of CNAs. The enzyme 
requires no complementarity and thus should generate random primers, equally distributed across the genome. 
The performance of TruePrime WGA was assessed for aneuploidy screening and CNA analysis after MPS, starting 
from 1, 3 or 5 cells. Although the method looks promising, the single cell TruePrime WGA kit v1 is not suited for high 
resolution CNA detection after MPS because too much representation bias is introduced. 
2. Introduction 
Several whole genome amplification (WGA) methods exist to amplify DNA extracted from a limited number of cells, 
yielding the necessary amount of DNA required to perform massively parallel sequencing (MPS) (130, 191). The 
different WGA methods each have their advantages and disadvantages in terms of genome coverage, 
representation bias, error rates, yield and robustness. The most appropriate method should be selected based on 
its intended application. A recent study suggests that multiple displacement amplification (MDA) methods are 
better suited for single nucleotide polymorphism (SNP) detection while PCR-based methods are the better option 
for copy number aberration detection (130). MDA methods use the high-fidelity phi29 polymerase, leading to less 
nucleotide errors in the amplified sequences, while PCR-based methods tend to give a more balanced genomic 
amplification. In Chapter III, we compared two state-of-the-art PCR-based WGA methods to study their applicability 
for CNA detection using MPS (187). In that study, PicoPLEX/SurePlex (Rubicon Genomics Inc., MI 48108, USA / 
BlueGnome Ltd., Mill Court, Great Shelford, Cambridge, UK) proved to be more suitable for CNA detection compared 
to Multiple Annealing and Looping Based Amplification Cycles (MALBAC) (Yikon Genomics, Beijing, China). MALBAC 
amplified samples showed a less uniform read distribution across the genome (i.e. more representation bias), 
leading to more false positive and false negative CNA detections. SurePlex amplified samples lead to accurate 
detection of CNAs with a resolution of 3Mb. In another study, SurePlex WGA proved its efficient amplification of DNA 
from 4-6 blastocyst cells for downstream MPS with a reliable detection of chromosomal aberrations down to 3Mb 
(30) (Chapter IV). Nevertheless, results show that the WGA representation bias is still a limiting factor in achieving 
higher resolution copy number profiles when starting from a single or a limited number of cells (30). In order not 
to call over- or underamplified regions as CNAs, the read counts need to be averaged out in genomics windows of 
at least 500kb (30) (Chapter IV), leading to a 3Mb resolution for CNA detection (see also Methods section). With 
less representation bias, smaller windows and a higher resolution could be used. Accurate detection of CNAs from 




amplified DNA is of importance for applications such as preimplantation genetic diagnosis (PGD), in which day-5 
embryos are screened for CNA using of 4-6 trophectoderm cells (30) (Chapter IV). Cell-based liquid biopsy both in 
cancer and prenatal diagnosis, is another emerging field where accurate, high resolution CNA detection starting 
from a limited number of cells is invaluable. 
A WGA method called TruePrime single cell WGA (Sygnis, Heidelberg, Germany) uses a DNA primase, TthPrimPol, 
which synthesizes primers for Phi29 DNA polymerase, so that no artificial primers need to be added to the reaction 
(192). After primer synthesis by TthPrimPol, Phi29 polymerase performs polymerization and strand displacement 
as in a classical MDA. The non-artificial primers, which could lead to a lower representation bias, combined with 
the high-fidelity of Phi29, could theoretically lead to an ideal WGA method.   
The goal of the present study was to assess the performance of TruePrime WGA for aneuploidy screening and high 
resolution copy number analysis, starting from a limited number of cells, using MPS. The variability in distribution 
of the reads across the genome and the ability to correctly detect chromosomal aneuploidies and large CNAs was 
assessed and the results were compared to the study of Chapter III (187), in which the performance of 
PicoPLEX/SurePlex and MALBAC WGA was studied in a similar setting. 
3. Material & Methods 
3.1. Experimental design 
This study was performed on cells derived from the female Loucy cell line (DSMZ, ACC394) (169) . A reference 180K 
aCGH profile (Agilent Technologies) was obtained from unamplified genomic DNA from this cell line (Figure 1). 
According to the 180K aCGH profile, the following chromosomal aneuploidies and CNAs were called within the 
resolution range (≥3Mb) of the subsequent sequencing results: a deletion of an entire X-chromosome, a distal 
deletion of ±72Mb on 5q21.3q35.3, a distal deletion of ±45Mb on 6q22.31q27, a ±26Mb duplication of 13q33-q33.3 
and deletions of respectively 13Mb and 3Mb on 16p13.3-p13.12 and 16q24.2q24.3. These CNAs were used as a 
reference for comparing with the MPS analyses. The cell line was grown in suspension which allowed for isolation 
of individual cells. Samples consisting of 1, 3 or 5 cells, in triplicate, were collected using micromanipulation. These 
samples were used to perform TruePrime WGA, Illumina library preparation with enrichment PCR and sequencing. 
In parallel, triplicate samples consisting of 3 cells were subjected to TruePrime WGA, PCR-free Illumina library 
preparation and sequencing to comparatively study the effect of enrichment PCR on representation bias (Figure 2). 





Figure 1: 180 K aCGH of genomic DNA from the female Loucy cell line.  
This profile shows all CNAs detected in the female Loucy cell line up to a resolution of 50 kb. Red bars indicate deletions and blue bars 
indicate insertions. The deletions in chromosomes X, 5, 6, and 16 and duplication in chromosome 13, all with a size of ≥3 Mb, were the 
CNAs expected to be detected by the sequencing results.  
A negative control was used during WGA to control for contamination of the samples. A sample containing 26pg 
high quality DNA was used as a positive control during WGA. This positive control was performed to check the yield 
of the WGA procedure on a sample with high quality input DNA, excluding possible suboptimal conditions due to 
the cell manipulation and extraction steps. The positive control serves as reference of the optimal WGA product 
yield and could be used as a troubleshooting tool in case the cell samples would yield no (or low) amounts of WGA 
product. Library preparation, sequencing and data analysis were performed in parallel with other similar samples 
(routine samples amplified with SurePlex WGA, not belonging to present study) to rule out failing steps after WGA 
amplification. 
 
Figure 2: Experimental design.  
Schematic overview of the experimental design of the study. Samples containing 1, 3 and 5 cells were taken from the Loucy cell line 
using micromanipulation. Next, the DNA of these individual samples was amplified with the TruePrime WGA kit. The WGA product of 1, 3 
and 5 cell samples was used to perform an Illumina library preparation with enrichment PCR. In parallel, WGA product of 3 cell samples 
was used to perform a PCR-free Illumina library preparation. This experiment was done in triplicate for all sample types.  
3.2. Growth and isolation of cells 
The cells were grown in Roswell Park Memorial Institute (RPMI-1640) medium (Life Technologies, Carlsbad, USA), 
supplemented with 10% fetal bovine serum (Life Technologies, Carlsbad, USA). For optimal growth, they were kept 
at a temperature of 37°C and a 5% CO2 level. A known amount of cells was isolated with an ergonomic denuding 




handle from STRIPPER (Origio, Måløv, Denmark) and MXL3-100 needles with a diameter of 100 µm (Origio, Måløv, 
Denmark). A serial dilution with sterile phosphate buffered saline (PBS) (Life Technologies, Carlsbad, USA) spots 
was performed on a Petri dish (5.5cm) under an Axiovert 25 light microscope (Zeiss, Jena, Germany), until the 
desired amount of cells for isolation was obtained. All cells were collected in a maximum volume of 2.5µl. All 
samples were snap frozen in liquid N2, immediately after collection. 
3.3. TruePrime WGA 
Cell lysis and amplification was performed using the TruePrime Single cell WGA kit (Sygnis, Heidelberg, Germany), 
following manufacturer’s instructions. As a positive control, 1µl of 26pg/µl single-source male control DNA (NIST 
2391C Component C DNA) was used. As a negative control, 1µl of PBS was used as input material. All samples were 
purified according to the manufacturer’s protocol of the Genomic DNA Clean & Concentrator kit (version 1.0.0, Zymo 
Research, Irvine, USA) with 5X binding buffer. Concentration was measured using Qubit dsDNA High Sensitivity Assay 
kit (Life Technologies, Carlsbad, USA). The quality of the different samples was assessed with the Agilent 12000 
(12K) DNA Assay kit (Bioanalyser, Agilent Technologies, California, USA). 
3.4. Illumina library preparation 
One hundred ng of the WGA product was fragmented to an average size distribution of 200bp with the S2 Focused 
Ultrasonicator with Adaptive Focused Acoustics (AFA) technology (Covaris, Woburn, USA). All samples were diluted 
in 1/5X Tris-EDTA buffer (TE-buffer; stock 1X) to a volume of 130µl in microTUBES (Covaris, Woburn, USA). The 
programmed guidelines for fragmentation to 200bp were followed (Duty cycle of 10%, Intensity of 5 and 200 
cycles/burst), but the fragmentation time was prolonged to 190s based on previous experience.  
Subsequently, libraries of the fragmented samples were created using NEBNext Ultra DNA Library Prep (PCR 1.4A, 
New England Biolabs, Ipswich, USA), following manufacturer’s protocol, with the exception of some minor 
modifications. After incubation with the USER enzyme, a DNA purification step (Zymo Genomic DNA Clean & 
Concentrator) was included before the size selection step. Size selection was performed with the E-Gel iBase Power 
system (Invitrogen) using an E-gel EX 2% agarose gel and a 1kb Plus DNA ladder (Thermo Fisher Scientific, Waltham, 
USA). For all samples, fragments with a size of ±300bp were cut from the gel, and DNA was recovered using the 
Zymoclean gel DNA recovery kit (Zymo Research). The size selected DNA samples were then subjected to an 
enrichment PCR using NEBNext Multiplex Oligos for Illumina (Index Primers Set 1 and 2 version 3.0) according to 
the protocol. tRNA was added to the reaction to minimize the loss of DNA via tube interaction. The quality of the 
different libraries was assessed with the Agilent High-Sensitivity DNA kit (Bioanalyser, Agilent Technologies, 
California, USA). 




The PCR-free libraries were created entirely according to the TruSeq DNA PCR-free HT sample preparation kit 
(Illumina), which does not require an enrichment PCR. For each sample, 1µg of WGA product was used as input. From 
here onwards, these samples will be referred to as ‘PCR-free’ samples. 
Before sequencing the samples, a library quantification was performed using a Sequencing Library qPCR 
Quantification kit (Illumina, San Diego, USA) to quantify the sequence-able DNA fragments containing the correct 
adapters. The control template used for the standard curve was a PhiX control library (10nM). The libraries from 
the different samples were equimolarly pooled, denatured and diluted to a final loading concentration of 2.1pM for 
sequencing. Finally, single-end index 75bp sequencing was performed on a high-output flowcell on a NextSeq500 
(Illumina, California, USA).  
3.5. Data analysis 
Fastq files of the samples were automatically analyzed using the ViVar software (182). The ViVar software performs 
CNA detection using the QDNAseq algorithm (160). After removal of poorly mapped reads, this algorithm normalizes 
the number of reads, mapped in non-overlapping, fixed size windows, for bias in GC-content and mappability 
simultaneously. In addition, QDNAseq excludes anomalous genetic regions from the analysis making use of a 
‘‘blacklist’’ based on information from the ENCODE Project Consortium (185). The blacklist contains chromosomal 
regions with known repeat elements, such as satellites, centromeres, and telomeres. After GC-content and 
mappability normalization, read counts were median-normalized by dividing the number of reads in each window 
by the median number of reads across all windows. As chromosomal aberrations were assumed to be rare, the 
median number of reads across all windows is a fair estimate of the expected number of reads per window for a 
perfectly diploid genome. As such, the median-normalized read counts represent a measure for the deviation from 
diploidy for each window and a copy number (CN) estimate is calculated using following formula: CN= 2(read 
count/median read count). Then, a circular binary segmentation (CBS) algorithm was applied which detects 
breakpoints between the windows, and groups them between breakpoints into larger contiguous regions with an 
equal CN. To this end, the CBS algorithm starts with the whole chromosome and segments it recursively by testing 
for change-points between such regions. The two-sample t-statistic is then applied to compare the mean of the 
read counts of the windows contained in one segment to the read counts of the windows in its adjourning segment. 
The mean of read counts of the windows contained in the segments, are used as an estimator of the CN of the 
whole segment. After this segmentation, CNAs are called when the segment’s log2(CN/2) surpasses a threshold of 
+/- 0.35, corresponding to a CN greater than 2.55 or less than 1.57. These thresholds were chosen based on literature 
review and own experience (161). From previous experience, a window size of 1Mb should be ideal to detect 
chromosomal aberrations of 3 Mb and bigger (187) (Chapter III). Analyzed data was visualized as line plots, in which 
windows are ordered along the x-axis by their genomic positions, and the y-axis shows the median normalized log2 




transformed read counts, i.e. the log2(CN/2). Chromosomes are identified along the x-axis by an alternating white 
and blue background color. Each dot on the profiles represents a different window and the horizontal lines refer 
to the segments. Each genomic profile was manually checked for aberrations. 
3.6. Read distribution analysis 
The read distribution in the samples was further analyzed using Integrative Genomics Viewer (IGV) (193). The BAM 
file of a sample was uploaded and hg19 was selected as the human reference genome. Next, a region was selected 
to zoom-in until the individual reads were visible. The selected regions covered a 1Mb window or one dot on a line 
profile on ViVar. Windows with a very high, low or average CN were investigated.   
3.7. Data dereplication 
Reads of which the start is mapped to the same genome position were dereplicated from the BAM files (containing 
the mapped reads) using a Python script. From a group of reads with an identical start position, only one is kept. 
Reads with an identical sequence are thus also dereplicated.  
3.8. Sensitivity and positive predictive value 
The sensitivity was defined as the number of true positive calls divided by all CNAs present in the reference (See 
details in Experimental design section). The positive predictive value (PPV) was defined as the number of true 
positive calls divided by the total number of calls (true positive + false positive). True positives are CNA calls that 
refer to a chromosome region that differs at most 10% in size from the corresponding CNA in the reference: When 
e.g. a complete chromosome is called, and only a part of that chromosome has a CNA in the reference, the call 
counts as a false positive. 
3.9. Statistical analysis of the read count variance 
For each sample, the read count variance observed between the windows across the whole genome is calculated 












 where ‘N’ is the number of windows, ‘xi’ the read count in window i,  ‘xi+1 ’ the 
read count in the next window i+1 and ‘a’ the average of the read counts in all windows (160, 193). In this formula, 
the read count in each window is scaled by factor ‘a’, normalizing the result for the total number of reads that was 
sequenced for the sample. This measure was calculated for each sample. A Welch’s t-test for unequal variances 
was performed to compare all 12 (3 repeats each of 1-, 3- and 5-cell samples + 3 3-cell PCR-free samples) TruePrime 
amplified samples versus all 12 analogous SurePlex amplified samples reported in Chapter III (187). A similar 
analysis was performed using the dereplicated TruePrime data. P-values smaller than 0.05 were considered 
statistically significant. 




4. Results  
4.1. Sample quality and yield after WGA 
All samples had a similar electropherogram (EPG) on a 12K chip after WGA (Supplementary File 1). The DNA 
fragments resulting from amplification had an average length of 5kb. The negative control showed a flat EPG and 
the positive control an EPG similar to 5 cell samples.  
The WGA yield increased with increased amounts of DNA input material. The average output after WGA on 1, 3 and 
5 cells was respectively 1684±120.4 ng (mean ± standard deviation), 2470±88.6 ng and 2629±38.7 ng. The positive 
control yielded an output of 2387 ng, while the negative control had an output of 22 ng. This small amount of WGA 
product in the negative control is considered normal for negative control WGA products. 
4.2. Sequencing run statistics 
The quality control parameters of the sequencing libraries were flawless. Supplementary File 2 shows the Agilent 
Bioanalyser 2100 results of the individual libraries (A), as well as the qPCR library quantification results (B). The 
Bioanalyser results have a library size distributions within the range of 200-1000 bp, which is suitable for clustering 
on the Illumina flowcell. The qPCR results show a variable but adequate amount of sequence-able library within 
the expected yield range for NEBNext Ultra library preparations. Based on these results the libraries were 
equimolarly pooled. The overall sequencing run quality was good: a Q30 of 90.1±0.5, a density of 269.25±1.3 K/mm2 
and a full width at half maximum (FWHM) of 3. On average 34 million passed filter reads were obtained per sample, 
corresponding with an average read depth of 0.8 per sample, if all reads could be mapped. This number of reads is 
a multitude of what is needed to perform CNA detection at a 3 Mb resolution (30) (Chapter IV). Supplementary File 
3 shows an elaborate sequencing run-statistics quality control report. On average 96.3% of the reads mapped to 
the reference human genome, of which 97.8% mapped uniquely to the reference. The actual average read depth 
and coverage, calculated after mapping, are 0.77 and 0.04 respectively. Raw sequencing data (FASTQ files) has been 
deposited in the NCBI Sequence Read Archive under project accession number PRJNA318625. 
4.3. Visualization of the data on ViVar 
The results of the data analysis workflow were plotted on a graphical line profile using the ViVar software. A 
uniform distribution of the reads over the windows across the genome (except for the parts with a CNA) would be 
the preferred result. However, the read counts per window from our samples were extremely irregular across the 
genome (Figure 3a). Although all profiles were similar within and between the 1, 3 and 5-cell samples, the exact 
regions showing over- or under-representation were different from sample to sample. The line plots of all samples 
are available in Supplementary File 4. A consequence of the uneven distribution of the reads is that a lot of window 
segments had a CN greater than 2.55 or less than 1.57, leading to falsely called CNA in regions where the Loucy 




genome is known to be diploid. The expected chromosomal abnormalities could also not be deduced from the line 
profiles. The sensitivity for TruePrime amplified samples was 18.5% ± 5.6% (mean ± standard deviation), whereas 
for SurePlex amplified samples this was 94.4% ± 11.8%2. Except for the deletion of chromosome X, which was called 
correctly in all samples, only one other CNA was called correctly in one of the TruePrime samples. Most often, 
complete chromosome aneuploidies were called instead of only the chromosomal parts that show a CNA in the 
reference. Both WGA methods, also resulted in a significantly different PPV of 8.43% ± 3.16% and 77.7% ± 11.8% for 
TruePrime and SurePlex respectively. The distinctive difference between the PPV of TruePrime and SurePlex is due 
to the presence of a lot more false positives after TruePrime WGA than after SurePlex WGA. 
 
Figure 3: CNA profiles before and after dereplication of the data. 
a) A line profile of sample ‘3 cells, replicate 1’, before dereplication, including the ‘outlier’ windows such as the one in the red circle. b) 
The same line profile after dereplication shows some improvement. High outliers such as the one in the red circle are no longer present. 
However, windows with a very low CN were still observed and the CNA profile is still littered with deletions and insertions. The blue 
color indicates a duplication or trisomy, whereas the red color indicates a deletion or monosomy.  
4.4. Statistical analysis of the read count variance 
The variance of the read counts per window across the genome for the current TruePrime samples is a lot higher 
compared to the variance in the SurePlex samples from Chapter III (187) (p= 0.015; Figure 4). A similar observation 
was made when comparing the dereplicated TruePrime data with the SurePlex data (p= 0.052; Figure 4). A table 
containing the calculated variances for SurePlex and TruePrime amplified samples can be found in Supplementary 
File 5.   





Figure 4: Boxplots of the variances in read counts per window across the genome.  
Boxplots are shown for all TruePrime samples, the dereplicated TruePrime samples and SurePlex samples reported in Chapter III (187). 
4.5. Visualization of read alignment in IGV 
To explain why some windows had extremely high read counts, a better insight into the read distribution within 
these windows was needed. Two windows were analyzed in detail using IGV, one having a CN close to 2 (CN= 1.9) 
and one ‘outlier’ (CN= 89.9) on chromosome 3 of a 5-cell sample amplified with TruePrime. The first window did 
not show the random equal distribution of reads expected from a low-pass sequencing. A lot of regions, larger than 
could be expected for a random distribution of reads across the window, showed a complete lack of reads (Figure 
5a), whereas other regions showed small clusters of reads (Figure 5b). The ‘outlier’ window showed a massive 
buildup of reads over a region of 48 kb, halfway the window (Figure 5c).  
Supplementary File 6 shows the read distribution of a few representative regions, comparing the previously studied 
SurePlex WGA and the currently studied TruePrime WGA. SurePlex WGA shows a much more even distribution of the 
reads compared to TruePrime WGA. 
 





Figure 5: Read alignment in IGV. 
A print-screen is shown for 3 different 14kb regions on chromosome 3 of sample ‘5 cells replicate 2’. The read alignment to the reference 
genome hg19 is illustrated for these regions. a) A region in a window close to the baseline (CN= 1.9) with a complete lack of reads. b)  A 
small clustering of reads in another region of this window. c) A massively buildup of reads in a 48kb wide region in an ‘outlier’ window 
with a CN of 89.9. Only a part of this buildup is shown here.  
4.6. Read distribution across the genome and CNA detection on dereplicated data  
When sequencing at an average read depth below 1, only a minor fraction (< 1%) of the reads should have the same 
starting position when there is no representation bias. When the number of mapped reads obtained for the 
individual samples (ranging between 2.2E+07 and 5.5E+07) in this study, would be randomly distributed over the 
genome, approximately 0.4 to 0.9% of the reads would not have a unique starting position. A lot of the 
representation bias introduced during TruePrime sequencing is caused by regions which are highly covered with 
duplicate or overlapping reads. We explored if the analysis could benefit from the removal of reads with the same 
starting position. Only 22% ± 12% of the originally mapped reads were left after dereplication. The dereplicated data 
resulted in a lower read count variability across the genome and a reduced number of positive outliers (Figure 3b). 
Still, the variability is higher in the TruePrime results compared to the SurePlex results (Figure 4). As a consequence, 
the CNAs could still not be correctly deduced from the profile. The sensitivity and PPV did not change substantially. 




4.7. Library preparation without enrichment PCR 
Omitting the enrichment PCR during library preparation did not influence our results. The results showed very 
similar profiles to the samples that were amplified, including the large read variability and the inadequacy to detect 
the CNAs (Supplementary File 4). Also after dereplication, the results were similar to the enriched samples.   
5. Discussion 
The new TruePrime WGA kit looks very promising from a theoretical point of view and should introduce less 
representation bias. However, during this study the advantage of this kit over other WGA methods for the detection 
of CNAs could not be demonstrated. A proper CNA detection using MPS was not possible on samples amplified with 
this kit. In Chapter III, SurePlex WGA was considered most suitable for this application (187). The results from the 
current study were compared to these previously generated SurePlex WGA results.   
Several factors, other than the TruePrime WGA, that could lead to representation bias were ruled out. The setup of 
this study was equal to the study in Chapter III (187), except for the WGA method used. The same cell line and cell 
isolation techniques were used. All EPG profiles of the WGA samples were similar and showed the expected pattern 
according to the manufacturer. No contamination was introduced during the preparation of the samples, as 
indicated by the flat EPG of the negative control. The WGA amplification was successful in terms of yield, as all 
samples and the positive control produced adequate amounts (> 1µg) of WGA product. Library preparation, 
sequencing and data analysis were performed in parallel with other similar samples (routine samples amplified 
with SurePlex WGA, not belonging to present study). These samples yielded the expected results  with a 
representation bias as reported in Chapter III (187) (data not shown), ruling out that steps following the WGA are 
introducing the observed representation bias. The kit was stored at -20°C, as recommended by the manufacturer, 
and this for two months. The use of a kit derived from an exceptional bad batch was excluded, as a second kit from 
a different batch led to the same results. 
The yield after amplification was quite high: Compared to the SurePlex study, the lowest yield was 1.4 times higher 
than the lowest yield with SurePlex WGA (1684±120.4 ng vs 1212.1±99.9 ng). The high TruePrime WGA yields would 
enable the use of this WGA material for multiple simultaneous applications.  
The sequencing run from these samples was of high quality and the created reads were almost exclusively 
composed of human genomic material, as on average 96.3% mapped to the human genome of which 97.8% mapped 
uniquely. In this respect, the TruePrime amplified samples perform better than samples amplified with SurePlex or 
MALBAC. However, these mapping results disclose no information regarding the uniformity of read distribution. A 
high mapping rate does not implicate an equal distribution of these reads across the genome. This was already 
clear in a previous study, where MALBAC had significantly higher mapping rates compared to SurePlex, but the read 




distribution for MALBAC was less uniform compared to SurePlex. Unfortunately, TruePrime WGA causes an even less 
uniform read distribution compared to this previous study. The per-window read count shows extreme outliers. As 
a consequence of this non-uniform read distribution, the expected CNA profile of the Loucy cell line could not be 
detected.  
A thorough data review in IGV led to a better understanding of the read distribution within these ‘outlier’ windows. 
The reads of these outliers clustered together in some regions within the window. Although windows with ‘normal’ 
CN values did not show such clustering, the read distribution was still highly non-uniform within these windows. 
When low-pass sequencing is performed, reads should be uniformly distributed across the genome, with regular 
intervals and without clustering. A uniform, unbiased read distribution is necessary for a reliable CNA determination, 
because over- and underrepresentation due to the WGA will disturb the CNA determination. 
In an effort to make the data more suitable for CNA detection, the outliers were filtered from the data by removing 
reads with the same starting position from the data. Hereby, identical sequences, commonly caused by enrichment 
PCR, are dereplicated. Reads with the same genomic mapping position, but that do not necessarily have the same 
length, are also dereplicated. This could have been caused by preferential binding of the TthPrimPol primase to 
certain regions. After dereplication, only 22% of the reads remained, highlighting the magnitude of the problem of 
duplicated reads in a situation were almost no reads with the same starting position were expected. Nevertheless, 
a highly non-uniform read distribution remained after dereplication, albeit with slight improvements. As a 
consequence of this non-uniform read distribution, the expected CNA profile for the Loucy cell line could still not 
be detected. It is of concern that true positive duplications could also be removed when reads with the same 
starting position are removed. This is not be the case in shallow whole genome sequencing with a coverage below 
1x.  When the reads would be randomly distributed over the genome, less than 1% of the reads would have the same 
starting position. Even in duplicated regions, very few reads with the same starting position are to be expected.  
Enrichment PCR and PCR-free libraries yielded the same results, showing that the enrichment PCR during library 
prep was not causing the representation bias. The amount of input DNA for the WGA was also not influencing the 
results, as the results for 1-, 3- and 5-cell were similar. 
It is not clear what is causing the representation bias. The main difference between the TruePrime WGA and other 
WGA methods is the use of TthPrimPol primase instead of primers. A primase should randomly bind to the DNA, 
because no complementarity is required. If this primase favors some regions over others, this could lead to over- 
and under amplification of these regions, exactly as in our results. We, however, see that the overrepresented 
regions are different from sample to sample, suggesting that the primase is not systematically favoring the same 
DNA regions. Possibly, too few (random) primers are formed, leading to underrepresented regions. The ones that 




are formed, are heavily amplified and lead to extremely overrepresented regions. We hope that our study can 
provide insights that can help to improve this technology, leading to WGA with less representation bias. 
6. Conclusion 
The single cell TruePrime WGA kit version 1 is not suited for CNA detection after MPS. Representation bias seemed 
to be introduced during amplification, resulting in over-and underrepresentation of genomic regions. 
7. Supplementary information 
 
Supplementary file 1: Agilent Bioanalyser 2100 12K electropherograms of TruePrime WGA products from all samples. 
 
All samples have a similar profile, with an average fragment length of ± 5kb. The negative control, in which the template was 
substituted with PBS, the electropherogram signal is a flat line, indicating the absence of DNA amplification. The positive 
control showed a similar profile to the other samples. In this positive control, the template was 26pg of DNA from the 2391C 
Component C. The Y-as shows the fluorescence intensity, which is an indicator for the amount of DNA present. The X-as shows 
the fragment length in base pairs. 
 
 




Supplementary file 2: Agilent Bioanalyser 2100 electropherograms (A) and qPCR library quantification results (B) of the 
sequencing libraries. 
Samples 1 to 9 were prepped using the NEBNext ultra library preparation kit. The last 3 samples were prepped using the 
TruSeq DNA PCR-free HT library preparation kit. Sample 5cell repl 2 shows a high primer-dimer peak, which has subsequently 
been removed using a 2% EX E-gel size selection.  
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diluted library (nM) 
1cell repl 1 3.7 
1cell repl 2 9.4 
1cell repl 3 7.9 
3cell repl 1 5.7 
3cell repl 2 6.3 
3cell repl 3 8.9 
5cell repl 1 9.6 
5cell repl 2 4.7 
5cell repl 3 15.7 
PCR-free3cell repl 1 5.8 
PCR-free3cell repl 2 5.4 
PCR-free3cell repl 3 6.1 
 
Supplementary file 3:   
Sequencing quality control report and read mapping statistics. The information in the table displays the average over the 4 





Density (K/mm2) 269.25±1.3     
Clusters past filter (%) 83.2±0.7     
Reads past filter/lane (x106) 145±1.8     
Total read count past 
filter( x106) 
581.63     
Reads/sample ( x106) 29.1     
Q30 (%) 90.1±0.5     








1 cell replicate 1 26,876,572 26,485,659 0.62 181.35 0.017038 
1 cells  replicate  2 21,931,292 21,690,048 0.51 38.87 0.021864 
1 cells  replicate  3 28,375,813 26,675,758 0.61 227.65 0.029697 
3 cells  replicate  1 36,862,692 36,145,552 0.84 228.08 0.034895 
3 cells  replicate  2 42,893,602 41,766,495 0.97 187.97 0.0236 
3 cells  replicate  3 30,007,070 29,259,675 0.68 134.71 0.042562 
5 cells  replicate  1 58,193,351 54,676,410 1.25 661.60 0.058997 
5 cells  replicate  2 34,894,399 33,703,063 0.79 233.71 0.071542 
5 cells  replicate  3 29,382,392 28,768,667 0.68 91.36 0.060076 
PCR-free 3 cells  replicate  1 39,486,483 37,063,877 0.85 475.55 0.042761 
PCR-free 3 cells  replicate  2 33,362,926 32,478,336 0.76 146.33 0.021173 
PCR-free 3 cells  replicate  3 29,333,156 27,753,005 0.64 257.43 0.03613 
B 




Supplementary file 4: ViVar line plots of all samples 
TruePrime 1cell repl 1 
 
TruePrime 1cell repl 2 
 
TruePrime 1cell repl 3 
 




TruePrime 3cell repl 1 
 
TruePrime 3cell repl 2 
 
TruePrime 3cell repl 3 
 
 




TruePrime 5cell repl 1 
 
TruePrime 5cell repl 2 
 









PCR-free 3cell repl 1 
 
 
PCR-free 3cell repl 2 
 
 
PCR-free 3cell repl 3 
  








Supplementary file 6 Read distribution of a few representative regions, comparing the previously studied SurePlex WGA and 
the currently studied TruePrime WGA. 
a) In the SurePlex amplified sample were the reads uniformly distributed across the different windows. The TruePrime 
samples showed large empty regions alternated with regions of clustered reads. b) Some regions show massive clustering 
after TruePrime amplification.  
 SurePlex TruePrime TruePrime dereplicated 
1cell repl 1 4.84 1.24E+20 7.96E+09 
1cell repl 2 1.48 1.58E+14 5.43E+10 
1cell repl 3 7.79 1.91E+18 5.94E+11 
3cell repl 1 2.16 1.78E+21 9.14E+15 
3cell repl 2 3.00 5.29E+15 7.36E+12 
3cell repl 3 1.43 5.59E+14 2.41E+10 
5cell repl 1 3.39 3.64E+13 1.67E+06 
5cell repl 2 3.97 6.41E+10 6.69E+07 
5cell repl 3 1.52 4.78E+12 1.05E+09 
PCR-free 3cell repl 1 2.02 9.39E+10 7.35E+08 
PCR-free 3cell repl 2 1.36 2.87E+19 8.14E+12 
PCR-free 3cell repl 3 1.51 2.22E+15 2.26E+10 
TruePrime 
5 cell repl 3 
TruePrime 
5 cell repl 3 
SurePlex 
3 cell repl 1 
SurePlex 
3 cell repl 1 
a 
b 
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Whole genome amplification (WGA) has become an invaluable tool to perform copy number variant (CNV) detection 
in single, or a limited number of cells. Unfortunately, current WGA methods introduce representation bias that limits 
the detection of small CNVs. New WGA methods have been introduced that might have the potential to reduce this 
bias. We compared the performance of PicoPLEX DNA-Seq (Picoseq), DOPlify, REPLI-g and Ampli1 WGA for aneuploidy 
screening and copy number analysis using shallow whole genome massively parallel sequencing (MPS), starting 
from a single or a limited number of cells. Although the four WGA methods perform differently, they are all suited 
for this application.  
2. Introduction 
Whole genome amplification (WGA) has become an invaluable tool to perform massively parallel sequencing (MPS) 
in applications where only a limited number of cells is available. Well-known examples of such applications are: 
preimplantation genetic diagnosis (PGD), cell-based non-invasive prenatal testing (NIPT) (110) and liquid biopsy of 
circulating tumor cells (CTCs) (194-196) Several WGA methods exist to amplify DNA extracted from a limited number 
of cells, yielding the necessary amount of DNA required to perform MPS (130, 191). The different WGA methods each 
have their advantages and disadvantages in terms of genome coverage, representation bias, error rates, yield and 
robustness.  
The best WGA method per se does not exist, because the downstream application is also important to determine 
the ideal method (130). Some WGA methods have already been compared for specific applications (30, 130, 187, 
197-199). Multiple displacement amplification (MDA) methods are better suited for single nucleotide polymorphism 
(SNP) detection while PCR-based methods are the better option for copy number variant (CNV) detection (130). 
MDA methods use the high-fidelity phi29 polymerase, reducing nucleotide errors in the amplified sequences, while 
PCR-based methods tend to give a more uniform amplification across the genome. For the detection of CNVs, 
SurePlex WGA has proven its efficiency in clinical settings such as PGD (30, 32, 163). However, results show that the 
WGA representation bias is still a limiting factor, hampering higher resolution copy number profiles when starting 
from a single or a limited number of cells (30) (Chapter IV). Fortunately, new WGA methods are being introduced 
that might have the potential to reduce this bias. In this study, we compared four different commercially available 
WGA methods for their suitability to detect CNVs after MPS. 
A first method, REPLI-g single cell WGA, is a well-established MDA method (130, 200). In a study comparing 5 
different WGA methods, REPLI-g had the lowest false positive rate and was well-suited for detection of CNVs and 
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single nucleotide variations (SNVs) (200). This two-step protocol includes an amplification step of 8h, but the 
hands-on time is short. 
A second method, Ampli1 WGA (Silicon Biosystems, Castel Maggiore, Italy), has already proven its efficiency for CNV 
and STR analysis in prenatal diagnosis (110). Ampli1 is based on a ligation-mediated PCR following a site-specific 
DNA digestion. Usage of non-random primers is one of the factors leading to a more homologous coverage. 
Unfortunately, the protocol consists of many different steps and is time consuming. 
PicoPLEX DNA-Seq (Picoseq) (Rubicon Genomics Inc., MI 48108, USA) and DOPlify WGA (Reproductive Health Science, 
Thebarton, Australia) are the two most recently developed methods. Picoseq is a method based on the 
PicoPLEX/SurePlex WGA technology (Rubicon Genomics Inc., MI 48108, USA/ BlueGnome Ltd., Mill Court, Great 
Shelford, Cambridge, UK) and does not only amplify the DNA of a sample but also results in an Illumina sequencing 
library for that sample. The amplification part is similar to PicoPLEX WGA, but during the second amplification step, 
Illumina adapters and barcodes are introduced. WGA and library preparation are performed in a single tube, 
decreasing possible handling errors, contamination, turnaround time and costs. The second new method, DOPlify 
WGA, uses an advanced Degenerate Oligonucleotide Primed PCR (DOP-PCR). The classical DOP-PCR does already 
exist for many years and was one of the first existing WGA technologies (201). It has two basic principles: 
degenerate base-pairing primers and a slowly increasing annealing temperature during PCR. The classical DOP-
PCR uses Taq polymerase with a high error rate, and uses primers that lead to an incomplete coverage (126). An 
advanced DOP-PCR, such as DOPlify might circumvent the disadvantages of previous DOP-PCR by using new 
polymerases or primers and might thereby out-perform other recent WGA technologies. DOPlify is a short and easy 
two-step protocol of only 3 hours.   
The objective of this study was to compare the performance of Ampli1, REPLI-g, Picoseq and DOPlify WGA in a 
shallow whole genome MPS workflow for CNV detection, starting from a limited number of cells. Samples of 1, 3 or 
5 cells were collected from the Loucy cell line in triplicate using micromanipulation. The samples were prepared 
using 4 different WGA methods followed by Illumina PCR-free MPS library preparation. The variability of the read 
distribution across the genome and the CNV detection performance were compared. 
3. Material & Methods 
3.1. Experimental design 
Figure 1 illustrates the experimental design of this study. Experiments were performed on cells from the 
lymphoblastoid Loucy cell line (DSMZ, ACC394) (169) . A CNV analysis has been performed on this cell line as part 
of the COSMIC project (202, 203). A reference 180K aCGH profile (Agilent Technologies) from unamplified DNA of a 
bulk sample of the cell line was available from a previous study (187) (Chapter III) (Supplementary Figure 1). The 
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following reference aneuploidies and CNVs (≥3Mb) were present: a deletion of an entire X-chromosome, two 
deletions of ±45Mb (consists of 6Mb and a 36.5Mb deletion interspersed by a 2.5Mb normal ploidy region) and 
30Mb on respectively 5q14.3-q31.1 and 5q33.1-q35.3, a deletion of ±60Mb on 6q21-q27, a deletion of 3Mb on 12p13.31-
p13.2, a ±26Mb duplication of 13q31.3-q34, and two deletions of 16Mb and 3Mb on respectively 16p13.3-p13.11 and 
16q24.2q24.3. The COSMIC and 180K aCGH CNV analyses are completely concordant regarding these >3Mb insertions 
and deletions.  
 
Figure 1: Experimental design.  
Samples consisting of 1, 3 or 5 cells were collected from the Loucy cell line using micromanipulation for each WGA method in triplicate. 
Cells were amplified with either Ampli1, REPLI-g or DOPlify, followed by PCR-free Illumina library preparation and sequencing. A fourth 
method, Picoseq, performs WGA and library preparation simultaneously, without the need for a separate library preparation. A bulk DNA 
sample was extracted from 5*106 Loucy cells using a column-based extraction method from Qiagen, also followed by PCR-free Illumina 
library preparation and sequencing. 
The cell line was grown in suspension, which allows collection of individual cells. Samples containing 1, 3 or 5 cells 
were collected in triplicate using micromanipulation. These samples were used to perform WGA, PCR-free Illumina 
library preparation and sequencing. This was performed in parallel for three types of WGA methods. A fourth 
method, Picoseq, performs WGA and library preparation simultaneously, without the need for the PCR-free Illumina 
library prep. A bulk DNA sample of the Loucy cell line was also included in the study. The bulk DNA was treated in 
same way as the other samples, except for the amplification step.  
A negative control, processed alongside the cell-containing samples, was used during all WGA methods to control 
for contamination. These negative controls contained the exact same reagents as the cell-containing samples, 
except that 1µl PBS instead of cells was added. A sample containing 1µl of male control DNA (Human Genomic DNA, 
Roche, stock solution of 0.2 mg/ml) with a concentration of 30pg/µl, was used as a positive control during each 
WGA method. This positive control was performed to check the yield of the WGA procedure on a sample with high 
quality input DNA, excluding possible suboptimal conditions due to the cell manipulation and extraction steps. This 
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sample could be used as a troubleshooting tool in case the cell samples would yield no (or low) amounts of WGA 
product.  
The different WGA methods were compared to assess their suitability for downstream CNV analysis using shallow 
whole genome MPS (see other Material & Methods sections for details): A comparison of the DNA yield after WGA, 
the mappability of the reads and the variance in read counts per window across the genome was performed within 
and between the WGA samples. The CNV calling accuracy after WGA was evaluated by comparing the CNV calls in 
WGA samples with those called in the bulk DNA sample. As the WGA samples and the bulk sample are processed 
and analyzed entirely in the same way, except for the WGA step, this allows a comparison in which the effect of the 
WGA on CNV calling accuracy/resolution can be studied. The resolution is configurable and should be set considering 
the extent of representation bias and considering the average sequencing depth. A lower resolution, meaning that 
smaller CNVs will not be detected, allows for a better averaging/smoothing of representation bias introduced by 
the WGA and sequencing, avoiding incorrect CNV calls. We have shown before that the representation bias 
introduced by current WGA and sequencing methods is the limiting factor that is necessitating a resolution of 3Mb 
(30, 187) (Chapters III & IV). For this reason, we compare the CNV calls in WGA samples with those called in the bulk 
DNA sample at a resolution of 3Mb. 
3.2. Growth and isolation of cells 
The cells were grown in Roswell Park Memorial Institute (RPMI-1640) medium (Life Technologies, Carlsbad, USA), 
supplemented with 10% fetal bovine serum (Life Technologies, Carlsbad, USA) at a temperature of 37°C and a 5% 
CO2 level. A known number of cells was collected with a denuding handle from STRIPPER (Origio, Måløv, Denmark) 
and MXL3-100 needles with a diameter of 100µm (Origio, Måløv, Denmark) from a serial dilution of medium with 
phosphate buffered saline (PBS).  All cells were collected in a maximum total volume of 2.5µl and snap frozen in 
liquid N2 immediately after collection. For the bulk DNA sample, DNA was extracted from 5*106 cells using the 
DNeasy Blood & Tissue kit (Qiagen Hilden, Germany).  
3.3. Ampli1 WGA, REPLI-g WGA, DOPlify WGA 
Cell lysis and amplification was performed, using the Ampli1 WGA kit (Silicon Biosystems, Castel Maggiore, Italy), 
the REPLI-g single cell kit (Qiagen Hilden, Germany) or the DOPlify WGA kit (Reproductive Health Science, Thebarton, 
Australia) as described in the respective manufacturer’s instructions. All samples were purified following the 
manufacturer’s protocol of the Genomic DNA Clean & Concentrator kit (version 1.0.0, Zymo Research, Irvine, USA) 
with 5X binding buffer. Concentration was measured using the Qubit dsDNA High Sensitivity Assay kit (Life 
technologies, Carlsbad, USA). 
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3.4. PicoPLEX DNA-Seq 
Cell lysis, amplification and library preparation was performed, using the PicoPLEX DNA-Seq kit (Rubicon Genomics 
Inc., MI 48108, USA) as stated in the manufacturer’s instructions. All samples were purified with 50µl of Agencourt 
AMPure XP beads. The quality of the libraries was assessed with the Agilent High-Sensitivity DNA kit (Bioanalyser, 
Agilent Technologies, California, USA). This method will further be referred to as Picoseq. 
3.5. TruSeq DNA PCR-free HT library preparation 
The WGA products from Ampli1, REPLI-g, DOPlify and the bulk sample were fragmented to an average size of 350bp 
using the S2 Focused Ultrasonicator (Covaris, Woburn, USA) following the manufacturer’s instructions (Duty cycle 
of 10%, Intensity of 5 and 200 cycles/burst, Duration 45 sec). Between 350ng and 1µg of WGA product was used as 
input for fragmentation. Sequencing libraries of the fragmented samples were prepared with the TruSeq DNA PCR-
free HT library preparation kit (Illumina) on the IP-Star Compact (Diagenode, Seraing, Belgium). Library 
quantification was performed using a Sequencing Library qPCR Quantification kit (Illumina, San Diego, USA) to 
quantify the sequence-able DNA fragments containing the correct adapters (this was performed on the samples of 
all four methods). The libraries from the different samples were pooled equimolarly, denatured and diluted to a 
final loading concentration of 2.5pM for sequencing. Finally, single-end indexed 75bp sequencing was performed 
on a high-output NextSeq500 flow-cell (Illumina, California, USA). 
3.6. Data analysis 
Fastq files of the samples were automatically analyzed using the ViVar software (182). The ViVar software maps 
the reads using bowtie2 (190) with very sensitive-local setting and performs CNV detection using the QDNAseq 
algorithm (160). This algorithm divides the genome in equally sized windows (configurable; see below). The reads 
that map in these windows are counted and normalized for bias in GC-content and mappability. In addition, 
QDNAseq excludes anomalous genetic regions from the analysis making use of a ‘‘blacklist’’ based on information 
from the ENCODE Project Consortium (185). The blacklist contains chromosomal regions with known repeat 
elements, such as satellites, centromeres, and telomeres. After GC-content and mappability normalization, read 
counts were median-normalized by dividing the number of reads in each window by the median number of reads 
across all windows. As chromosomal aberrations were assumed rare, the median number of reads across all 
windows is a fair estimate of the expected number of reads per window for a perfectly diploid genome. As such, 
the median-normalized read counts represent a measure for the deviation from diploidy for each window and a 
copy number (CN) estimate was calculated using following formula: CN= 2(read count per window/median read 
count per window). Then, a circular binary segmentation (CBS) algorithm was applied which detects breakpoints 
between the windows, and groups them between breakpoints into larger contiguous regions with an equal CN. To 
this end, the CBS algorithm started with the whole chromosome and segments it recursively by testing for change-
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points between such regions. The two-sample t-statistic was then applied to compare the mean of the read counts 
of the windows contained in one segment to the read counts of the windows in its adjourning segment. The mean 
read counts of the windows contained in the segments were used as an estimator for the CN of the whole segment. 
After this segmentation, CNVs were called when the segment’s log2(CN/2) surpasses a threshold of +/- 0.35, 
corresponding to a CN greater than 2.55 or less than 1.57. These thresholds were chosen based on literature review 
and own experience (161). From previous experience (Chapter IV), a window size of 1Mb should be ideal to detect 
chromosomal variants of 3Mb and bigger (30). Typically, 3 neighboring windows with a significantly higher or lower 
read count are required to call a CNV. When 3 consecutive windows of 1Mb are needed to call a CNV, the detection 
limit is thus 3Mb. As the WGA methods in the current study might perform better than previously tested methods, 
results were also generated using 500kb windows, possibly lowering the detection limit. Analyzed data were 
visualized as line plots, in which windows are ordered along the x-axis by their genomic positions, and the y-axis 
shows the median normalized log2 transformed read counts, i.e. the log2(CN/2). Chromosomes are identified along 
the x-axis by an alternating white and grey background color. Each dot on the profiles represents a different 
window and the horizontal lines refer to the segments. Each genomic profile was checked manually for variants. 
Raw sequencing data are deposited in the NCBI Sequence Read Archive under project accession number 
PRJNA362886. On ViVar they are available under the project: Comparing four WGAs 
(https://holmes.ugent.be:9090/ViVar/) 
3.7. Statistical analysis of the read count variance 
For each sample, the average read count variance observed between the windows across the whole genome was 












 where ‘N’ is the number of windows, ‘xi ’ the read count in 
window i,  ‘xi+1 ’ the read count in the next window i+1 and ‘a’ the median number of reads across all windows (160, 
193). In this formula, the read count in each window was scaled by factor ‘a’, normalizing the result for the total 
number of reads that was sequenced for the sample. This measure was calculated for each sample. A one-way 
ANOVA was performed between the average read count variances of the four WGA methods. P-values smaller than 
0.05 were considered statistically significant.  
3.8. True and false positives 
True positives are defined as the CNVs that are called in the bulk DNA aCGH & bulk DNA sequencing. Calls that are 
not present in these reference samples are considered false positives. Results of the WGA and the bulk DNA 
sequencing sample were compared using 1Mb windows and using 500Kb windows in the QDNAseq analysis. Within 
each comparison, the same window size is used for all samples. Individual cells from the same tissue or from the 
same cell line can show different CNVs (204, 205). Thus, some of the false positives and false negatives in the 
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individual cells (or in the limited number of cells samples) could have been caused by mosaicism in the Loucy cell 
line. 
4. Results 
4.1. DNA yield after WGA and DNA fragment-size  
DNA yield after WGA was compared between Ampli1, REPLI-g and DOPlify. Yields of the 1-, 3-, and 5-cell samples do 
not differ significantly per method and are reported here as an average ± standard deviation. Picoseq does not 
yield amplified fragments, but results in sequence-ready libraries. Therefore, only the yield of adaptor-ligated 
fragments and not the entire DNA yield is important for this method. Ampli1 and DOPlify WGA resulted in a 
comparable yield of 19.2±6.9 ng/µl and 21.1±2.6 ng/µl (in 30µl), respectively. REPLI-g WGA has a significantly higher 
yield of 900.7±255 ng/µl (in 30µl). All negative controls contained a negligible amount of DNA after WGA, except 
the one amplified with REPLI-g. The concentration of 1000ng/µl in the latter was expected: Phi29 DNA Polymerase 
has an extremely high processivity and will extend primer-dimers that may be present in the reaction in the 
absence of specific template in the reaction, leading to unspecific high molecular weight amplification products. 
Samples with template, yield approximately the same amount of DNA as non-template controls. For all WGA 
methods, the yield of the positive control sample was similar to the 5-cell samples. 
The average size of the DNA fragments after amplification varies between methods. REPLI-g has the longest 
fragments (> 10Kb), Picoseq the shortest (654±31.1 bp). Ampli1 and DOPlify result in fragments of respectively 
740.1±27.6 bp and 957.3±87.2 bp. The WGA product is fragmented to ±350bp by sonication prior to sequencing. 
4.2. Mapping statistics 
The average sequencing depth was similar for all samples and was around 0.3X. An average depth of 0.3X exceeds 
the required average depth to call CNVs with a resolution of 3Mb. It has been shown before that the average depth 
can be reduced to 0.03X without becoming the limiting factor for the resolution: The representation bias introduced 
by the WGA and sequencing is the limiting factor that is necessitating larger window sizes (and thus a lower 
resolution) (30, 187) (Chapter III & VI). For the REPLI-g, Ampli1, DOPlify and Picoseq amplified samples, respectively 
99.7±0.01%, 98.8±0.2%, 98.3±0.7% and 97±3.1% of the reads mapped to the human reference genome.  
4.3. Variance in read counts per window across the genome 
A uniform distribution of the reads over the windows across the genome (except for the parts with a CNV) is needed 
to be able to accurately call CNVs. Almost all the samples in this study had such uniform distribution. One 5-cell 
sample from Ampli1, as well as a 1-cell and 5-cell sample from DOPlify showed a distribution that cannot be used 
to call CNVs. The per-window read counts across the genome are so irregular that incorrect CNVs would be called 
across the entire genome (Supplementary Figure S2). Those three failures, as they are further referred to, were 
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excluded from any further analyses and are not included in the statistical analyses. Overall, the average variance 
in read counts per window across the genome was similar for all samples amplified with the same WGA method 
(Figure 2). Furthermore, this average variance was not significantly different between the four WGA methods 
(Figure 2). When the 1-cell, 3-cell and 5-cell samples were compared separately between all methods, they also 
showed no significantly different average variance (Supplementary Table S1; Figure 3). Although, statistically there 
was no difference, some observations were made. Picoseq seems to have a higher average read count variance for 
single cell amplification, with the highest difference in average variance between the three single cell samples 
amplified with this WGA (Supplementary Table 1; Figure 3A). For all WGA methods, the 3- and 5-cell samples tend 
to have a slightly lower average variance compared to single cell samples (Supplementary Table S1; Figure 3). 
 
Figure 2: Boxplots of the average variance in read counts per window across the genome.  
The boxplots show all samples per WGA method. A) Using 1Mb windows. B) Using 500Kb windows. The blue box contains the values 
between the first and third quartiles (Q1 and Q3). The black lines are the minimum and maximum, not considering outliers. Values that 
are more than 1.5 times the interquartile range (Q3-Q1) beyond the closest (Q1 or Q3) quartile were considered as outliers. 
4.4. CNV line profiles with 1Mb windows 
The 1Mb window line profiles of all samples are available online (https://holmes.ugent.be:9090/ViVar/) and in 
Supplementary Figure S3. One example of a 1Mb windows profile of a 3-cell sample is shown in Figure 4 for each 
WGA method. The 1Mb window profile of the sequenced bulk DNA reference sample (Figure 5A) showed all reference 
Chapter VII: Performance of four modern whole genome amplification methods for copy number variant detection in single cells 
128 
 
CNVs (>3Mb), except the 3Mb deletion near the start of chromosome 12 and the 3Mb deletion at the end of 
chromosome 16. The same CNVs were called in almost all WGA samples. Every Picoseq sample showed the same 
CNVs. After DOPlify WGA, two samples failed to show a usable CNV profile, as mentioned above. In the other DOPlify 
amplified samples, the same CNVs were called. One sample failed after Ampli1 WGA and was excluded from further 
analysis. Three out of the 8 remaining Ampli1 samples showed no call for the 26 Mb insertion on chromosome 13. 
Nevertheless, the line profiles of these three samples all showed a slightly increased CN at the position of the 
insertion. The insertion on chromosome 13 was also missed in 2 out of 9 REPLI-g samples.  
 
Figure 3: Boxplots of the variances in read counts per 1Mb window across the genome for 1-, 3- and 5-cell samples.  
A) All 1-cell samples per WGA method, except the failed one. B) All 3-cell samples per WGA method. C) All 5-cell samples per WGA 
method, except the failed ones. The blue box contains the values between the first and third quartiles (Q1 and Q3). The black lines are 
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the minimum and maximum, not considering outliers. Values that are more than 1.5 times the interquartile range (Q3-Q1) beyond the 
closest (Q1 or Q3) quartile were considered as outliers. 
 
Picoseq and DOPlify amplification did not only result in the same CNVs calls as the sequenced bulk sample, but did 
also result in no false positive calls. Analysis with Ampli1 and REPLI-g was slightly less accurate because some false 
positives were called. Only two Ampli1 amplified samples showed false positives, in contrast to five of the REPLI-g 
amplified samples. Overall, no specific trend in accuracy was observed in relation with the number of amplified 
cells. A table with the true and false positive calls per sample is shown in Supplementary Table S2.  
 
Figure 4: CNV line profiles generated with ViVar using 1Mb windows. 
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(A) A line profile of a 3-cell sample amplified with REPLI-g. (B) A line profile of an Ampli1 amplified 3-cell sample. C)  A line profile of a 
DOPlify amplified 3-cell sample. D) A line profile of a Picoseq amplified 3-cell sample. The blue color indicates a duplication or trisomy, 
whereas the red color indicates a deletion or monosomy. 
4.5. 1Mb window size versus 500kb window size 
By analyzing the data with smaller windows, smaller CNVs could be detected. Supplementary Figure S4 shows the 
500kb windows line profiles of all samples. The sequenced bulk reference sample showed all reference CNVs when 
the data was analyzed with a 500kb window size, except the 3Mb deletion near the start of chromosome 12 (Figure 
5B). Compared with this result, Picoseq and DOPlify amplified samples still showed 100% concordance. Two Ampli1 
amplified samples still missed the insertion on chromosome 13. One REPLI-g sample still missed the insertion on 
chromosome 13 and one other REPLI-g sample missed the 3Mb deletion at the end of chromosome 16.  
 
Figure 5: Line profile of the non-amplified bulk reference sample. 
 A) The line profile using 1Mb windows. B) The line profile using 500kb windows. The blue color indicates a duplication or trisomy, 
whereas the red color indicates a deletion or monosomy.  
The 180K aCGH reference shows a 3Mb deletion near the start of chromosome 12. Although this deletion was not 
called in the bulk reference sample, the 500kb line profile (Figure 5B) clearly shows windows with lower read 
counts at this position in the genome. This deletion is called in all but one of the Picoseq samples, 5 out of 7 DOPlify 
samples, 4 out of 9 REPLI-g samples and 4 out of 8 Ampli1 samples. The 180K aCGH reference shows also a 1.5Mb 
Chr9p and a 2.5Mb Chr9q deletion. Although not called in the bulk reference sample, the 500kb windows profile 
(Figure 5B) clearly shows windows with lower read counts at these positions in the genome. The 1.5Mb Chr9p 
deletion is only called in one REPLI-g sample. The Chr9q deletion is called in 5 out of 9 REPLI-g samples and 2 out 
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of 7 DOPlify samples. Finally, the aCGH reference shows a small insertion and a small deletion on Chr16q. The 500kb 
windows line profile of the bulk reflects this, albeit not clearly. However, this deletion is called in 4 out of 8 Ampli1 
samples and 1 out of 9 Picoseq samples.  
Considering all other calls as false positives, Picoseq and DOPlify did not introduce any false positives in the 500kb 
windows analysis. Ampli1 amplified samples showed almost 2 times as much false positives with 500Kb windows 
compared to 1Mb windows. REPLI-g even showed 3 times more false positives compared to the analysis with 1Mb 
windows. 
5. Discussion 
In the present study, the performance of 4 different WGA methods was investigated to examine if they generate a 
WGA product from a limited number of cells that is suitable for CNV detection after shallow whole genome 
sequencing. All four methods are suitable for this goal, showing only minor differences in the results. 
REPLI-g WGA resulted in the highest yield after amplification, enabling the use of this WGA material for multiple 
downstream applications. DOPlify and Ampli1 yielded only enough DNA to perform one PCR-free library preparation. 
Picoseq resulted in a sequencing-ready library, using a single-tube reaction. After library preparation, only the yield 
of adaptor-ligated, sequence-able fragments is of essence.  
All WGA methods showed a high percentage of reads mapping to the human genome. In this respect, the four WGA 
methods showed similar results. All methods showed a uniform distribution of reads across the genome with a 
similar average variance in read counts per window across the genome. Ampli1 failed to amplify one 5-cell sample 
and DOPlify failed to amplify a 1-cell and a 5-cell sample. The reason for this failure is unclear. It is possible that 
these protocols are less robust or the input material was of bad quality. The latter is unlikely since all cells were 
isolated simultaneously. The WGA products and sequencing libraries of these failed samples showed a similar size 
distribution as the successful samples during the quality check using an Agilent bioanalyser and could thus not be 
excluded before sequencing. As we are working with a cancer cell line, the occurrence of chromothripsis might also 
explain the results. Nevertheless, the true    
The accuracy to detect CNVs showed some discrepancies between the four tested methods. When using 1Mb 
windows, DOPlify and Picoseq samples detected 100% of the CNVs that were also detected in the sequenced bulk 
sample. The sensitivity to detect CNVs was lower for Ampli1 and REPLI-g. In some of these samples the 26Mb 
insertion on chromosome 13 was not called. Nevertheless, the size of this insertion is well above the threshold of 
3Mb which is approximately the detection limit when using 1 Mb windows. Using 1Mb windows, both DOPlify and 
Picoseq had a CNV profile with only the expected CNVs and without false positives. A few false positives were 
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detected in Ampli1 amplified samples and even more were detected in REPLI-g amplified samples. Although this is 
not obvious from the line profiles, nor the average variance in read counts in windows across the genome, the 
(local) CNV signal-to-noise ratio seems to be lower in the Ampli1 and REPLI-g amplified samples. The metric of the 
average variance in reads counts in windows across the whole genome is indeed not a good metric to show possible 
variance in specific smaller regions of the genome.  
In an effort to increase the resolution and to detect smaller CNVs, an analysis using 500kb windows was performed. 
Also in this analysis Picoseq and DOPlify excelled, leading to the highest number of detected true positives without 
detection of false positives. While additional true positives were also detected in the Ampli1 and REPLI-g amplified 
samples, the number of false positives increased substantially in the high-resolution analysis. 
6. Supplementary information 
Supplementary Figure S1: 180K aCGH of bulk DNA from the Loucy cell line.  
This profile shows all CNVs detected in the female Loucy cell line with a resolution of 50kb. Red bars indicate deletions and 
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Supplementary Figure S2: Failed samples with an unusable CNV profile.  



























  1Mb 500Kb 
 1 cell 0.025±0.001 0.029±0.003 
  Ampli-1 3 cell 0.022±0.004 0.026±0.002 
 5 cell 0.024±0.009 0.030±0.012 
 1 cell 0.035±0.150 0.034±0.015 
   REPLI-g 3 cell 0.034±0.110 0.048±0.012 
 5 cell 0.018±0.002 0.019±0.004 
 1 cell 0.029±0.009 0.045±0.014 
   DOPlify 3 cell 0.025±0.003 0.026±0.005 
 5 cell 0.019±0.004 0.021±0.003 
 1 cell 0.044±0.028 0.054±0.029 
   Picoseq 3 cell 0.021±0.007 0.032±0.110 
 5 cell 0.025±0.003 0.036±0.004 
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Supplementary Figure S3: CNV line profiles of all samples for a 1Mb window. REPLI-g CNV profiles 
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Supplementary Figure S3: CNV line profiles of all samples for a 1Mb window. Ampli-1 CNV profiles 
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Supplementary Figure S3: CNV line profiles of all samples for a 1Mb window. DOPlify CNV profiles 
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 Chr5q(1) Chr5q(2) Chr6q Chr13q Chr16p X-Chr Chr4p Chr5p Chr8p Chr10q Chr10q Chr14q Chr15q 
Bulk √ √ √ √ √ √        
Ampli-1   1c1 √ √ √  √ √      √  
                 1c2 √ √ √  √ √        
                 1c3 √ √ √ √ √ √        
                 3c1 √ √ √ √ √ √        
                 3c2 √ √ √ √ √ √        
                 3c3 √ √ √ √ √ √        
                 5c1 √ √ √ √ √ √        
                 5c2 √ √ √  √ √  √  √   √ 
REPLI-g    1c1 √ √ √ √ √ √   √     
                 1c2 √ √ √ √ √ √        
                 1c3 √ √ √ √ √ √ √       
                 3c1 √ √ √  √ √  √   √   
                 3c2 √ √ √  √ √        
                 3c3 √ √ √ √ √ √        
                 5c1 √ √ √ √ √ √        
                 5c2 √ √ √ √ √ √  √      
                 5c3 √ √ √ √ √ √  √      
DOPlify    1c2 √ √ √ √ √ √        
                 1c3 √ √ √ √ √ √        
                 3c1 √ √ √ √ √ √        
                 3c2 √ √ √ √ √ √        
                 3c3 √ √ √ √ √ √        
                 5c1 √ √ √ √ √ √        
                 5c3 √ √ √ √ √ √        
Picoseq   1c1 √ √ √ √ √ √        
                 1c2 √ √ √ √ √ √        
                 1c3 √ √ √ √ √ √        
                 3c1 √ √ √ √ √ √        
                 3c2 √ √ √ √ √ √        
                 3c3 √ √ √ √ √ √        
                 5c1 √ √ √ √ √ √        
                 5c2 √ √ √ √ √ √        
                 5c3 √ √ √ √ √ √        
 
Supplementary Table S2: True and false positives called by ViVar using 1Mb windows. The left side of the table contains all the true positives that are larger than 3Mb. The right side shows the false 
positives. The column headers indicate the location of the insertion (in bold) or the deletion. Two CNVs located on the same chromosomal arm are distinguished by subscript (1) or (2). 
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Supplementary Figure S4: CNV line profiles of all samples for a 500kb window. REPLI-g CNV profiles 
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Supplementary Figure S4: CNV line profiles of all samples for a 500kb window. Ampli-1 CNV profiles 
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Supplementary Figure S4: CNV line profiles of all samples for a 500kb window. DOPlify CNV profiles  
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Supplementary figure S4: CNV line profiles of all samples for a 500kb window. Picoseq CNV profiles 
  




 Chr5q(1) Chr5q(2) Chr6q Chr12p Chr13q Chr16p Chr16q X-Chr Chr9p Chr9q Chr16q(1)    Chr1p Chr1q   Chr2p  Chr2q 
Bulk √ √ √  √ √ √ √       
Ampli-1   1c1 √ √ √ √  √ √ √       
                 1c2 √ √ √ √  √ √ √   √    
                 1c3 √ √ √ √ √ √ √ √   √    
                 3c1 √ √ √ √ √ √ √ √   √    
                 3c2 √ √ √  √ √ √ √       
                 3c3 √ √ √  √ √ √ √       
                 5c1 √ √ √  √ √ √ √       
                 5c2 √ √ √  √ √ √ √   √     
REPLI-g    1c1 √ √ √  √ √ √ √       
                 1c2 √ √ √  √ √ √ √       
                 1c3 √ √ √  √ √  √    √   
                 3c1 √ √ √  √ √ √ √  √         √                 √ 
                 3c2 √ √ √   √ √ √  √     
                 3c3 √ √ √ √ √ √ √ √  √     
                 5c1 √ √ √ √ √ √ √ √       
                 5c2 √ √ √ √ √ √ √ √  √     
                 5c3 √ √ √ √ √ √ √ √  √ √     
DOPlify    1c2 √ √ √  √ √ √ √       
                 1c3 √ √ √ √ √ √ √ √       
                 3c1 √ √ √  √ √ √ √       
                 3c2 √ √ √ √ √ √ √ √  √   √  
                 3c3 √ √ √ √ √ √ √ √       
                 5c1 √ √ √ √ √ √ √ √       
                 5c3 √ √ √ √ √ √ √ √  √     
Picoseq   1c1 √ √ √  √ √ √ √   √    
                 1c2 √ √ √  √ √ √ √       
                 1c3 √ √ √ √ √ √ √ √       
                 3c1 √ √ √ √ √ √ √ √       
                 3c2 √ √ √ √ √ √ √ √       
                 3c3 √ √ √ √ √ √ √ √       
                 5c1 √ √ √ √ √ √ √ √       
                 5c2 √ √ √ √ √ √ √ √       
                 5c3 √ √ √ √ √ √ √ √       
Supplementary Table S3: True and false positives called by ViV r using 500Kb windows. From left to right, separated by a lack li e: all true positives that are larger than 3Mb; true positives smaller 
than 3Mb that are called in at least 1 sample; false positives. The column headers indicate the location of the insertion (in bold) or the deletion. Two CNVs located on the same chromosomal arm are 
distinguished by subscript (1) or (2). 




 Chr3p Chr3pq Chr3q Chr3q Chr4p Chr4q(1) Chr5p(1) Chr5p(2) Chr8p Chr9q(2) Chr10q(1) Chr10q(2) Chr12pq Chr12q(1) 
Ampli-1  1c1               
                1c2               
                 1c3               
                 3c1         √    √ √ 
                 3c2               
                 3c3               
                 5c1               
                 5c2   √    √   √        
REPLI-g   1c1               
                 1c2     √   √    √ √    
                 1c3              √     
                 3c1       √     √   
                 3c2 √          √       
                 3c3  √             
                 5c1       √     √   
                 5c2       √     √   
                 5c3       √        
DOPlify   1c2               
                 1c3               
                 3c1               
                 3c2               
                 3c3               
                 5c1               
                 5c3               
Picoseq   1c1               
                 1c2               
                 1c3               
                 3c1               
                 3c2               
                 3c3               
                 5c1               
                 5c2               
                 5c3               
Supplementary Table S3: cont. 




 Chr12q(2) Chr13q(1) Chr13q(2) Chr17q Chr18q(1) Chr18q(2) 
Ampli-1  1c1       
                 1c2       
                 1c3       
                 3c1       
                 3c2    √   
                 3c3       
                 5c1       
                 5c2       
REPLI-g   1c1       
                 1c2 √  √    
                 1c3       
                 3c1     √  
                 3c2     √  
                 3c3  √   √  
                 5c1      √ 
                 5c2      √ 
                 5c3       
DOPlify   1c2       
                 1c3       
                 3c1       
                 3c2       
                 3c3       
                 5c1       
                 5c3       
Picoseq   1c1       
                 1c2       
                 1c3       
                 3c1       
                 3c2       
                 3c3       
                 5c1       
                 5c2       
                 5c3       
 
Supplementary Table S3: Cont. 
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Preimplantation genetic diagnosis (PGD) is used during in-vitro fertilization to select an embryo for implantation, 
free of chromosomal aberrations or single gene disorders (SGDs) carried by the parents. Shallow whole-genome 
sequencing has recently become a standard for the genome-wide detection of chromosomal aberrations in PGD. 
In contrast, SGDs are still routinely diagnosed using PCR-based assays that need to be developed and validated for 
each individual disease-specific gene fragment. The TruSight One sequencing panel currently covers 12Mb of 
genomic content, including 4813 genes associated with a clinical phenotype. It has already been successfully 
applied for prenatal diagnosis of SGDs on DNA obtained from chorionic villi. In that setting, no whole genome 
amplification (WGA) was required, because enough fetal DNA was available. In PGD however, WGA is required prior 
to DNA target capture techniques, such as the TruSight One panel. In this study, we compared 4 different WGA 
methods in combination with the TruSight One sequencing panel to perform single nucleotide polymorphism (SNP) 
genotyping starting from 3 micro-manipulated cells. Bulk cell samples were processed alongside the WGA samples 
so serve as a performance reference. Target coverage, coverage uniformity and SNP calling accuracy obtained using 
any of the WGA methods, is inferior to the results obtained on bulk cell samples. However, results after REPLI-g 
come close. Compared to the other WGA methods, REPLI-g WGA results in a better coverage of the targeted genomic 
regions with a more uniform read depth. Consequently, this method also results in a more accurate SNP calling. 
2. Introduction 
Successful in-vitro fertilization (IVF) may require preimplantation genetic diagnosis (PGD) for the selection of an 
embryo free of chromosomal aberrations and single gene disorders (SGDs) carried by its parents. Recently, shallow 
whole genome sequencing has proven to be useful for the genome-wide detection of chromosomal aberrations in 
PGD (30, 32, 163). SGDs on the other hand, are still routinely diagnosed using PCR-based assays that are developed 
to target the specific gene fragment(s) involved in a single or a limited number of genetic diseases (39). 
Development and validated application of these methods is time consuming. Established protocols often require 
adjustments for couples carrying slightly different mutations (206). 
Whole Genome Amplification (WGA) can be used to amplify the DNA of the limited number of cells that can be 
biopsied from blastocysts for PGD. This pre-amplified DNA can be used to perform multiple PCR reactions, yielding 
multiple amplicons for the detection of disease-related mutations or insertions/deletions (indels). Massively 
parallel sequencing (MPS) can be used to sequence a pool of these different amplicons (207). The cost and 
timescale are reduced by multiplexing different patient samples on a single sequencing run. Still, this approach 
requires a specific PCR primer design for each disease-associated locus. WGA combined with MPS could also be 
used to sequence the entire genome of the embryo, allowing simultaneous screening for Single Nucleotide 
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Polymorphisms (SNPs) and chromosomal aberrations. However, whole genome SNP analysis will need sequencing 
at high coverage to accurately detect them, which currently is still too expensive for routine clinical applications.  
The TruSight One Sequencing Panel (Illumina) targets 4,813 genes associated with known clinical phenotypes and 
enables simultaneous screening for mutations in these genes on a single sequencing run. Since only the genomic 
regions of interest are sequenced, a high depth is obtained for a relatively low cost. This panel was already 
successfully applied to detect SGDs during a prenatal screening using DNA obtained from chorionic villi and 
amniotic fluid (46). Because only 4-6 trophoblasts can be biopsied in PGD, WGA is required to obtain a sufficient 
amount of DNA to start the TruSight One DNA capture. Unfortunately, WGA methods might introduce representation 
bias and nucleotide changes during amplification. Non-uniform amplification of regions across the genome may 
result in over- or underrepresentation of such genomic regions. Robust detection of mutations, more specifically 
SNPs, in insufficiently amplified (i.e. underrepresented) regions, can be problematic. Additionally, the introduction 
of errors in the sequence during amplification could result in mutations being obscured or introduced. The 
commercially available WGA methods all have their specific strengths and weaknesses and which one to use 
depends on the downstream application (130). WGA methods based on multiple displacement amplification (MDA) 
are better suited for SNP detection because they use the high-fidelity phi29 polymerase. Hybrid WGA methods use 
DNA polymerases lacking proofreading ability which introduces more errors, but yield a more balanced genomic 
amplification with less over- or underrepresented regions. Both accuracy and amplification uniformity are 
important for the accurate detection of SNPs and indels with the TruSight panel.   
In this study, four different WGA methods were used to amplify DNA isolated from 3 micro-manipulated cells of the 
well-characterized and extensively sequenced NA12882 cell line of the Illumina Platinum Genome project. The aim 
of this study is to show whether WGA amplified samples, in combination with the TruSight One Sequencing Panel, 
can be used to accurately and reproducibly detect SGD, which would encourage the use of this panel for detection 
of SGDs in PGD, and other applications in which a similar number of cells are obtained. Two semi-random primer 
mediated hybrid WGA methods (SurePlex and MALBAC) (133, 187, 208), a MDA method (REPLI-g) (33) and a ligation-
based WGA method (Ampli1) were assessed.  
As WGA methods based on MDA are reportedly better suited for SNP detection (33), because they use the high-
fidelity phi29 polymerase and amplify more regions of the genome compared to PCR-based or hybrid methods, it 
is to be expected that REPLI-g would outperform MALBAC, SurePlex and Ampli1 in this setting. It thus seems logical 
to choose an MDA based method to achieve a good amplification for downstream target capture and sequencing. 
If in doubt about which method to choose, a comparison of the different available MDA-based methods would be 
opportune, but REPLI-g is the MDA WGA method that is currently most widely used. 
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There are however several reasons why we choose to make the current comparison: The main reason to include 
the methods MALBAC, SurePlex and Ampli1 on top of REPLI-g is the fact that at the start of this study, no reports 
were published that show the performance of these WGA methods after target capture. It has been shown that 
MDA-based WGA methods show a better coverage of the genome when the WGA product is sequenced without 
previous capture and the resulting reads are mapped. But such results do not indicate that this would hold true 
when target capture is performed before sequencing. The latter requires a good accuracy on top of a uniform 
amplification. Our data brings evidence to this speculation. Interestingly, a paper was recently published by 
Borgström et al. (209), comparing the performance of the exact same 4 WGA methods for downstream exome 
capture sequencing. Their experimental setup is similar to ours, but they use the REPLI-g Mini kit instead of the 
REPLI-g single cell kit we use. Furthermore, the distinction between MDA-based and hybrid WGA methods is not 
unambiguous: e.g. MALBAC and SurePLEX use both strand displacement and PCR amplification. The 4 tested WGA 
methods are currently the most widely used WGA methods.  
3. Material & Methods 
3.1. Study design 
This study was performed on cells from the NA12882 lymphatic male cell line (Coriell Institute, New Jersey, USA). 
The DNA of this cell line has been sequenced extensively (50X depth on a HiSeq2000) and the sequencing data is 
available online (http://www.illumina.com/platinumgenomes/). As this data allows for robust SNP detection, the 
NA12882 genome will be considered the true control reference in this study. We prepared 14 genomic DNA samples, 
each one starting from 3 NA12882 cells. These were amplified by 4 different WGA methods, resulting in 3 or 5 
biological replicates per WGA method (5 for SurePlex, 3 for the others).  Additionally, 4 genomic DNA samples were 
prepared from larger cell numbers and not submitted to WGA (further referred to as bulk DNA samples). The bulk 
DNA samples were included in the study to evaluate the TruSight kit performance in samples mimicking current 
clinical application of the kit (46). Subsequent capture of gene regions with the TruSight One Sequencing panel 
(Illumina, San Diego, CA, USA) was performed on all samples (Figure 1). At the pooling step, four non-amplified bulk 
DNA samples and the WGA samples were randomly pooled per 3 to ascertain that variations observed after the 
capture step are caused either by the capture step or the preceding WGA. One MiSeq sequencing run was performed 
per pool of 3 samples.  




  Figure 1: Experimental design.  
Three cell samples from the NA12882 cell line were amplified with either Ampli1 (3 replicates), REPLI-g (3 replicates), SurePlex (5 
replicates) or MALBAC (3 replicates). Subsequently, samples were randomized for TruSight One capture in pools of 3 and those pools 
were sequenced on separate MiSeq runs. Four bulk DNA sample from the NA12882 cell line, not amplified before capture, were also 
randomly included in the pools.    
3.2. Growth and isolation of cells 
The NA12882 cell line was  grown  in  Roswell  Park  Memorial Institute  (RPMI-1640)  medium  (Life technologies,  
Carlsbad,  USA),  supplemented  with  15% fetal  bovine  serum  (Life technologies, Carlsbad, USA) and 2mM L-
Glutamine. For optimal growth it was incubated at a temperature of 37°C and a 5% CO2 level. A known amount of 
cells was isolated with an ergonomic denuding handle from STRIPPER (Origio,  Måløv,  Denmark)  and  MXL3-100  
needles  with a  diameter  of  100μm  (Origio,  Måløv, Denmark). The desired amount of cells was obtained by a 
serial dilution using spots of sterile phosphate buffered saline (PBS) (Life technologies, Carlsbad, USA) on a Petri 
dish (5.5cm), performed under an Axiovert 25 light microscope (Zeiss, Jena, Germany). For optimal lysis, all cells 
were collected in a maximum volume of 1μl. Immediately after collection, all samples were snap frozen in liquid 
nitrogen.  
For each bulk DNA sample, genomic DNA was extracted from 5x106 cells using the DNeasy Blood & Tissue kit (Qiagen 
Hilden, Germany).  
3.3. Whole genome amplification 
For MALBAC samples, lysis of the isolated cells and amplification of the genomic DNA was performed using the 
MALBAC kit (Yikon genomics YK001A/B version 1302.1, Jiangsu, China), following manufacturer’s instructions. As a 
positive control, 1µl of male control DNA (9948; Promega; 10ng/µl) was used at a concentration of 30pg/µl. The 
blank was 1µl of PBS.  
For the SurePlex samples, cell lysis and amplification was performed according to manufacturer‘s instructions using 
the SurePlex amplification system (Bluegnome, Cambridge, United Kingdom). As a positive control, 2.5µl of female 
control DNA (G1521; Promega; 187ng/µl) was used at a concentration of 25pg/µl. The blank consisted of 2.5µl PBS.  
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For the REPLI-g samples, cell lysis and amplification was performed following manufacturer‘s instructions using 
the REPLI-g single cell amplification system (Qiagen, Hilden, Germany). As a positive control, 1µl of female control 
DNA (Roche; 0.2mg/ml) was used at a concentration of 33.3pg/µl. A 3µl PBS blank was included.  
For the Ampli1 samples, cell lysis and amplification was performed following manufacturer‘s instructions using the 
Ampli1 WGA system (Silicon Biosystems, Castel Maggiore, Italy). As a positive control, 1µl of female control DNA 
(Roche; 0.2mg/ml) was used at a concentration of 33.3pg/µl. A blank consisting of 1µl PBS was included.  
All samples were purified using the Genomic DNA Clean & Concentrator kit (version 1.0.0, Zymo Research, Irvine, 
USA) according to the manufacturer’s instructions with 5 X binding buffer. Concentration was measured using the 
Qubit dsDNA High Sensitivity Assay kit (Life technologies, Carlsbad, USA). 
3.4. Library preparation and sequencing 
Sequencing libraries were prepared starting from 50ng of the WGA-amplified or bulk DNA using the TruSight One 
Sequencing Panel (Illumina, San Diego, CA, USA). Manufacturer’s instructions were followed, except for the 
enrichment wash step where a thermocycler was used instead of the SciGene TruTemp heating system. The samples 
were incubated for 30min at 42°C, with a heated lid at 100°C. Samples were fragmented using tagmentation, 
followed by addition of sequencing indexes during a first PCR amplification. After amplification, 3 samples were 
pooled equimolar before hybridization of the probes and subsequent capture. Probe hybridization and capture was 
performed two times. Finally, the captured fragments were enriched during a 2nd PCR.  
The amount of sequence-able library fragments was determined by performing a qPCR according to the Sequencing 
Library qPCR Quantification kit (Illumina, San Diego, USA). Sample pools were diluted to 10nM with elution buffer 
(EB buffer) (QIAGEN, Hilden, Germany). The control template used for the standard curve was a PhiX control library 
(10nM). Finally, dual-index, paired-end 150bp sequencing was performed on a MiSeq (Illumina). All sample pools 
were sequenced on separate MiSeq runs. 
3.5. Data analysis 
Sequencing read quality was checked using FastQC (v0.11.5) (210). Reads were aligned on the UCSC hg19 reference 
genome using bwa (v0.7.5) (211).  Mapping quality was evaluated using Qualimap (v2.2.1) (212). Duplicate read 
marking and all bam file manipulations were done using Picardtools (v2.6.0)(213). Reads from the NA12882 
Platinum Genome that aligned to the TruSight One Sequencing Panel regions were isolated using bedtools (v2.26) 
(171). SNP discovery in samples and the NA12882 reference was done using GATK (v3.6)(214) according to best 
practices instructions. Briefly, base quality scores were recalibrated in a two-pass covariation analysis 
supplemented with the dbSNP (release 135) (215) and Mills/1000 Genomes (216) data sets as a source of known 
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variants. SNP calling was then performed at base resolution in discovery mode using an emission confidence 
threshold of 10 and a call confidence threshold of 30. The final SNP's were obtained by applying the following filter 
criteria to discard low quality SNPs: QD < 2.0, FS > 60.0, MQ < 40, MQRankSum < -12.5, ReadPosRankSum < -8.0. 
VCFtools (v0.1.13) (217) and custom Python scripting were used for all SNP comparisons between sample replicates 
and the NA12882 reference. 
3.6. Sensitivity, false discovery rate (FDR) and Genotype concordance 
Variants were compared between samples and the reference dataset for positions where both had sequencing data 
(comparable SNP’s). Variants not detected in either the sample or the reference dataset due to lack of sequencing 
data were counted and labeled as 'no data in sample' and ‘no data in reference’ respectively. The comparable SNP's 
were categorized as follows: True positives are defined as variant positions found in both the sample and the 
reference dataset. False positives are variant positions found in the sample but not in the reference dataset. 
Positions called as variants in the reference set but not in the sample are labeled false negatives. The sensitivity 
for SNP calling in a sample was defined as the number of true positives, divided by the sum of true positives and 
false negatives. The FDR was defined as the number of false positives divided by the sum of true positives and false 
positives. 
4. Results and Discussion 
4.1. Coverage and depth 
To minimize run bias, samples amplified with the same WGA method were randomized over different MiSeq runs 
where possible (Table 1). The number of sequenced reads was variable between sample replicates. Two Ampli1 
samples had a substantial lower yield than the other samples. This is probably caused by random errors during 
quantification and equimolar pooling of the sequencing libraries, combined with a variable cluster formation and 
detection across different sequencing runs. The percentage of reads aligning to the hg19 reference genome was 
similar for all samples, including the bulk DNA samples (99.81±0.13%), as was the read alignment to the TruSight 
target regions (59.43±4.06%). This capture efficiency reflects the vendor’s performance specifications of the 
TruSight One kit. Mean depth across the targeted nucleotides correlated with the read yield and varied from 28X 
to 96X.  
The “coverage uniformity” (Table 1) is calculated as the percentage of targeted base positions for which the read 
depth is greater than 0.2 times the mean depth and thus is a measure for the number of bases that are not 
underrepresented in the read data. This coverage uniformity was different between the WGA methods, but similar 
for the repeats within a method. As expected, the coverage for the bulk DNA samples was most uniform 
(94.80±0.27%). REPLI-g amplified samples displayed a coverage uniformity closest to the bulk DNA samples 
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(88.41±1.01%). The other WGA methods showed a lower uniformity: Ampli1, MALBAC and SurePlex have a uniformity 
of respectively 49.26±1.33%, 47.23±0.33% and 49.77±1.42%. Figure 2 visualizes this uneven distribution of reads over 
the targeted regions by means of different plots. Figure 2a plots the read depth across the targeted regions for 
one representative sample of each method. Supplementary figure 1 shows the same plots for the other replicate 
samples. The plot allows to see larger regions with above or below average read depth. In terms of size of these 
alternating larger regions with high and low depth, there seems to be no pronounced difference between the 
different WGA methods. The over- and under-represented regions are not the same in the different methods, 
although there are some similarities: Bulk DNA, Ampli1, REPLI-g and Sureplex have a clear underrepresented region 
in common. Many of the over- and under-represented regions overlap between MALBAC and Sureplex. Figure 2b 
and 2c shows Lorenz curves and Gini indexes describing how sequenced bases are distributed over targeted (b) 
and covered bases (c). The plots clearly show that the distribution of the reads from bulk DNA is closest to the even 
distribution. Comparing the WGA methods, the read distribution after REPLI-g WGA is closest to the even distribution. 
 
Table 1: Mapping statistics 
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Figure 2: Read distribution.  
(a) Read depth calculated in 1 kb sliding windows across the concatenated target regions for one sample of each method. (b,c) 
Lorenz curves and Gini indexes describing how sequenced bases are distributed over targeted (b) and covered (c) regions. 
 
Table 1 also shows the percentages of target regions covered with a minimal depth of 1X, 10X or 20X. For bulk DNA 
and REPLI-g samples, target region coverage with a minimal depth of 1X was almost complete (99.61±0.01% and; 
98.92±0.20% respectively). This percentage was at least 20% lower in Ampli1, MALBAC and SurePlex amplified 
samples. Considering regions covered with a minimal depth of 10X and 20X, the coverage decreases for all methods. 
For bulk DNA, the decrease is however smaller compared to the WGA methods. For REPLI-g, the decrease is smaller 
compared to the other WGA methods. Figure 3 shows what percentage of targeted bases is covered at a minimal 
read depth range between 1 and 60. The plot shows again that more targeted bases are covered at a higher depth 
when sequencing bulk DNA. Comparing the WGA methods, REPLI-g results in the highest percentage of targeted 
bases that are covered at higher depth. The plot also shows the decline in covered targeted bases when considering 
higher depths. This decline is less steep for bulk DNA and REPLI-g compared to the other WGA methods. 
4.2. SNP analysis   
The online sequencing data for the Platinum Genome of the NA12882 cell line was mapped against the hg19 
reference genome.  An in-silico capture was performed on this mapping by isolating the reads aligning inside 
TruSight target regions. The SNPs called from this data are considered the reference set and were used to calculate 
the sensitivity and FDR for the samples (Table 2). The bulk DNA samples closely resembled the reference set, with 
a 96.8 ±0.2% sensitivity and a FDR of only 1.5±0.05%. This reflects a good performance of the capture kit when 
performed on unamplified DNA as specified in the kit’s manual. REPLI-g amplified samples, with a sensitivity of 
93.3±1.52% and FDR of 3.0±1.2%, were the only WGA samples that performed nearly as good as the bulk DNA samples. 
All other WGA methods had a low sensitivity and a high FDR, indicating unreliable results. MALBAC amplified 
samples had the lowest sensitivity (65.7±14.3%) and the highest FDR (49.6±15.8%).  Ampli1 and SurePlex were 
positioned somewhere in between. SurePlex amplification had a sensitivity of 74.2±2.2% and an FDR of 36.8±8.2%, 
while Ampli1 had a comparable sensitivity of 73.9±0.5% but a lower FDR of 20.7.±4.2%. SNP analysis reflects the 
representation bias observed for the Ampli1, MALBAC and SurePlex samples. REPLI-g is the only WGA method 
producing SNP discovery results close to the bulk DNA samples. 
The SNP calls were compared within the replicate samples for each WGA method.  The 3 REPLI-g replicates had 
6688 true positives and 67 false positives in common, comprising 93.7±1.80% and 32.8±12.05% respectively of the 
total number of true/false positives for each replicate. Of the common SNP calls, 99.01% are true positives, while 
0.99% are false positives. These results were similar to those of the 4 bulk samples, in which 99.2 % of the common 
SNP calls are true positives and 0.77% are false positives. This indicates that the detected false positives are not 
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consistent between all replicates, but are introduced more randomly than true positives. True positives on the other 
hand, are highly consistent between these replicates. These results, as well as those for the other WGA methods 
are included in Supplementary Table 1. 
 
            Figure 3: Percent target coverage at various minimum read depths. 
 









Sensitivity (%) FDR (%) No data in 
sample 
No data in 
reference 
Bulk DNA-1 7480 252 111 96.7 1.5 32 0 
Bulk DNA-2 7477 256 108 96.7 1.4 31 0 
Bulk DNA-3 7501 226 118 97.1 1.5 37 1 
Bulk DNA-4 7479 253 116 96.7 1.5 32 0 
Ampli1-1 4415 1517 1501 74.4 25.4 1832 0 
Ampli1-2 3762 1327 904 73.9 19.4 2675 0 
Ampli1-3 3642 1311 768 73.5 17.4 2811 0 
MALBAC-1 3057 3169 6076 49.1 66.5 1538 2 
MALBAC-2 4647 1624 2527 74.1 35.2 1493 0 
MALBAC-3 4665 1659 4177 73.8 47.2 1440 0 
REPLI-g-1 6980 643 325 91.6 4.4 141 4 
REPLI-g-2 7199 452 202 94.1 2.7 113 3 
REPLI-g-3 7229 438 150 94.3 2.0 97 1 
SurePlex-1 4755 1528 3350 75.7 41.3 1481 0 
SurePlex-2 4381 1711 3486 71.9 44.3 1672 0 
SurePlex-3 4679 1556 2862 75.0 38.0 1529 0 
SurePlex-4 4979 1524 1479 76.6 22.9 1261 0 
SurePlex-5 4729 1850 2808 71.9 37.3 1185 0 
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Unamplified samples are already being analyzed using TruSight One in a clinical setting. Our analysis shows similar 
results when performing TruSight One after REPLI-g WGA on 3 cells. This shows the potential to perform this 
analysis on biopsied trophoblast cells in a PGD setting. A thorough clinical validation of this technique will be 
essential to reveal if REPLI-g WGA combined with target capture panels such as TruSight One can be used in PGD 
for SGD diagnosis. 
5. Supplementary information 
Supplementary figure 1: Read distribution. 
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% of total 
FP 
Bulk DNA-1 1 7591 7383 97.3 7480 7326 97.9 111 57 51.4 
Bulk DNA-2 2 7585 7383 97.3 7477 7326 98.0 108 57 52.8 
Bulk DNA-3 3 7619 7383 96.9 7501 7326 97.7 118 57 48.3 
Bulk DNA-4 4 7595 7383 97.2 7479 7326 98.0 116 57 49.1 
Average±SD    97.2±0.19   97.9±0.14   50.4±2.07 
Ampli1-1 1 5916 3053 51.6 4415 2979 67.5 1501 74 4.9 
Ampli1-2 2 4666 3053 65.4 3762 2979 79.2 904 74 8.2 
Ampli1-3 3 4410 3053 69.2 3642 2979 81.8 768 74 9.6 
Average±SD    62.1±9.26   76.2±7.61   7.6±2.41 
Malbac-1 1 9133 2339 25.6 3057 2316 75.8 6076 23 0.4 
Malbac-2 2 7174 2339 32.6 4647 2316 49.8 2527 23 0.9 
Malbac-3 3 8842 2339 26.5 4665 2316 49.6 4177 23 0.6 
Average±SD    28.2±3.81   58.4±15.07   0.6±0.25 
RepliG-1 1 7305 6755 92.5 6980 6688 95.8 325 67 20.6 
RepliG-2 2 7401 6755 91.3 7199 6688 92.9 202 67 33.2 
RepliG-3 3 7379 6755 91.5 7229 6688 92.5 150 67 44.7 
Average±SD    91.8±0.64   93.7±1.80   32.8±12.05 
SurePlex-1 1 8105 3393 41.9 4755 3376 71.0 3350 17 0.5 
SurePlex-2 2 7867 3393 43.1 4381 3376 77.1 3486 17 0.5 
SurePlex-3 3 7541 3393 45.0 4679 3376 72.2 2862 17 0.6 
SurePlex-4 4 6458 3393 52.5 4979 3376 67.8 1479 17 1.1 
SurePlex-5 5 7537 3393 45.0 4729 3376 71.4 2808 17 0.6 
Average±SD    45.5±4.13   71.9±3.35   0.7±0.25 
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To allow multiple genetic analyses on a single cell, whole genome amplification (WGA) is required. Unfortunately, 
studies comparing different WGA methods for downstream human identification STR analysis remain absent. 
Therefore, the aim of this work was to assess the performance of four commercially available WGA kits for 
downstream human identification STR profiling. The performance was assessed using single or three cells as input. 
REPLI-g showed a very low dropout rate, as it was the only WGA method in this study that could provide a complete 
STR profile in some of its samples. Although Ampli1, DOPlify and PicoPLEX do not detect all selected STR markers, 
they seem suitable for genetic identification in single-cell clinical applications. 
2. Introduction 
Whole genome amplification (WGA) is unavoidable to allow multiple genetic analyses on single or a low number 
of cells. WGA increases the amount of input-DNA from pg-level up to ng- or µg-level. However, it is well known that 
a lot of WGA methods introduce bias during amplification and thereby influence the results of downstream genetic 
analyses (218, 219). The specific type of bias that is introduced, depends on the WGA method used. Therefore, the 
WGA method must be chosen according to the downstream application. Some methods will result in a non-uniform 
coverage, while others will introduce more nucleotide errors (130). A lot of research has already been performed 
on the influence of WGA on copy number variant (CNV) analysis (187, 197, 199, 209, 220, 221) and targeted 
genotyping analysis (209). However, studies comparing different WGA methods for human identification short 
tandem repeat (STR) analysis of a single or a limited number of cells have not been performed so far. 
The growing interest in single-cell analysis for clinical applications raises the need to identify single cells. STR 
analysis for human identification DNA profiling is such a genetic analysis that is often performed on only a limited 
number of cells. STRs are short DNA-fragments with different lengths (between 100 and 500 base pairs) within the 
population. A multiplex-PCR is performed to analyze a standard set of STR loci and to create an STR profile. Except 
for identical twins, each person has a unique STR profile. Single-cell DNA profiling is particularly valuable in the 
context of cell-based non-invasive prenatal testing. As no specific fetal cell marker has been discovered so far, after 
the isolation of a single fetal cell from a maternal blood sample, the fetal identity of this cell needs to be confirmed 
prior to further downstream procedures. This way, maternal cell contamination in the sample can be excluded. 
Other clinical applications, such as preimplantation genetic diagnosis (PGD), might also apply STR analysis, to 
assure the nature of the isolated cells (222). After fetal confirmation, genetic analysis such as CNV analysis is 
performed on this unique cell. Hence, to allow both STR and CNV analysis on a single cell, WGA is required. 
Unfortunately, a WGA method that is ideal for STR genotyping might be less suitable for CNV analysis. For example, 
previous research by Denis et al. demonstrates that multiple displacement amplification (MDA) WGA might be 
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applicable in forensic STR analysis (222). In contrast, MDA is not considered the most preferable WGA method for 
CNV analysis, as shown in Chapter VII (220). The aim of this work was to assess the performance of four 
commercially available WGA kits for downstream human identification STR. Ampli1 WGA Kit, DOPlify WGA, REPLI-g 
Single Cell Kit and PicoPLEX WGA Kit were compared in parallel for their ability to produce WGA product, adequate 
for human identification STR analysis. REPLI-g single cell kit (Qiagen, Hilden, Germany) is based on this MDA 
mechanism and has already been shown useful for STR analysis (222).  PicoPLEX WGA Kit (Rubicon Genomics Inc., 
MI 48108, USA) is a hybrid MDA-PCR based WGA method that uses self-inert degenerate primers. During the multiple 
displacement pre-amplification, an in vitro hairpin template library is created, which can then be amplified in a PCR 
reaction using flanking universal priming sites. PicoPLEX WGA kit has been widely used and the suitability of this 
kit for CNV analysis on a limited number of cells has been proven by several studies. Ampli1 WGA Kit (Silicon 
Biosystems, Castel Maggiore, Italy) is a ligation-adapter PCR based WGA method that utilizes a frequent cutter 
restriction enzyme for the initial fragmentation of the DNA template. One single highly specific primer, 
complementary to the adapters that are ligated on both sides of each DNA fragment, initiates the following PCR 
amplification reaction. This ligation based WGA method has already been successfully applied in a cell-based NIPT 
context. The most recently developed DOPlify WGA kit (Reproductive Health Science, Thebarton, Australia) uses an 
advanced Degenerate Oligonucleotide Primed PCR (DOP-PCR). In the past, the classical DOP-PCR did not result in 
reliable CNV or STR analysis (200). Nevertheless, DOPlify Reaction Kit is an advanced version of this classical DOP-
PCR and has recently shown promising results for CNV analysis, with minimal bias introduction (Chapter VII). This 
kit has not yet been tested in the context of STR profiling. 
Samples consisting of one or three cells, in triplicate, were collected from a B-lymphoblastoid cell line (B-LCL) using 
micromanipulation. As many clinical applications are based on single-cell analysis, single-cell samples are used as 
input in this study. Three-cell samples are included to detect possible differences in the performance of STR analysis 
after WGA on a few cells compared to a single cell. The lymphoblastoid cell line is representative for most human 
cells and is ideal as a reference for STR analysis, as it is diploid without any genomic aberrations. The samples were 
amplified using the four above-mentioned WGA kits and for each sample, a selection of 14 STR loci and the 
Amelogenin locus were amplified in a multiplex PCR reaction. A bulk DNA sample from the B-LCL was included in 
the STR-PCR reaction and used as a reference STR-profile against which all sample results were compared.   
3. Materials and methods 
3.1. Experimental design 
In this study, the performance of four WGA kits was examined for STR-genotyping of a limited number of cells from 
a male B-lymphoblastoid cell line (B-LCL), NA12882. This suspension cell line allowed for isolation of individual 
cells using micromanipulation. Samples consisting of 1-or 3- cells, in triplicate, were collected for each WGA method. 
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In parallel, a bulk DNA sample from the cell line was extracted. The 1- and 3-cell samples were amplified using the 
Ampli1 WGA Kit, DOPlify WGA, REPLI-g Single Cell Kit and PicoPLEX WGA Kit. STR-genotyping was performed on all 
WGA amplified DNA samples and the bulk sample. The STR-profile from the bulk DNA sample, served as a reference 
to which all STR-profiles were compared (Figure 1).  
 
Figure1: Schematic overview of experimental design 
A positive control containing saliva was included during STR-PCR to verify the success of the STR-multiplex PCR 
reaction. A negative control, consisting of H2O, was included to detect contamination introduced during the STR-
PCR. 
3.2. Cell culture and isolation  
The cells from the B-lymphoblastoid cell line (NA12882), acquired from Coriell Institute for Medical Research 
(Camden, USA), were grown in Roswell Park Memorial Insititute (RPMI-1640) medium (Life technologies, Carlsbad, 
USA). This cell medium was supplemented with 15% fetal bovine serum (Life Technologies, Carlsbad, USA), 2mM L-
glutamine (Life technologies, Carlsbad, USA) and a mix of penicillin at 100 units/mL and streptomycin at 100 µg/mL 
(Life technologies, Carlsbad, USA). Cells were cultured at a temperature of 37°C and a 5% CO2 level. For the 
micromanipulation of a limited number of cells, an ergonomic denuding handle from STRIPPER (Origio, Måløv, 
Denmark) and MXL3-100 needles with a diameter of 100µM (Origio, Måløv, Denmark) were used. Starting from a 
small 10µl spot of cell suspension, a serial dilution was made with sterile phosphate buffered saline (PBS) (Life 
technologies, Carlsbad, USA) on a Petri dish (5.5cm). Subsequently, the desired amount of cells were picked in a 
maximum volume of 2.5µL PBS under an Axiovert 25 light microscope (Zeiss, Jena, Germany) and were immediately 
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transferred to a 0.2mL PCR reaction tube on ice. A bulk DNA sample from the NA12882 cell line was prepared using 
the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) on ± 5*106 cells. 
3.3. Whole genome amplification 
Cell lysis and amplification for Ampli1 WGA Kit (Silicon Biosystems, Castel Maggiore, Italy), DOPlify WGA 
(Reproductive Health Science, Thebarton, Australia), REPLI-g Single Cell Kit (Qiagen, Hilden, Germany) and PicoPLEX 
(Rubicon Genomics Inc., MI 48108, USA) WGA Kit, was performed according to manufacturer’s recommendations. A 
positive control containing ±30pg high quality DNA (Human Genomic DNA, Roche, 100µg (500µl)) was included 
during each WGA reaction. This control sample was used to check the performance of the WGA kit, without the 
influences of cell isolation, cell lysis and DNA extraction. A negative control, consisting of 1µl of H2O, was added to 
detect contamination introduced during the WGA. The amplified DNA was purified using the Genomic DNA Clean & 
Concentrator kit (version 1.0.0, Zymo Research, Irvine, USA) using 5x binding buffer, following manufacturer’s 
instructions. DNA concentration was determined using the Qubit dsDNA High Sensitivity Assay kit (Life technologies, 
Carlsbad, USA). 
3.4. STR-genotyping 
Purified DNA samples were used as template for the in house multiplex STR-PCR, based on the Promega Powerplex. 
This multiplex-PCR was used to simultaneously amplify 14 STR loci across the human genome: D3S1358, TH01, D21S11, 
D18S51, vWA, D8S1179, TPOX, FGA, D5S818, D13S317, SE33, CD4, D7S820, D16S539, and Amelogenin for sex 
determination. The total volume in each reaction mix was 50µL, containing 2.5U Hotstar Taq polymerase (Qiagen, 
Hilden, Germany), 0.5 mM MgCl2 (Qiagen, Hilden, Germany), 0.4µg/µL albumin (Sigma-Aldrich, Saint Louis, USA), 1x 
PCR buffer (Qiagen, Hilden, Germany), 0.15µM-1µM of each primer and 30µL of purified DNA. Supplementary table 
S1 shows the exact concentrations used for each primer. Respectively 1ng, 1ng, 5ng and 4ng purified DNA from 
Ampli1, DOPlify, PicoPLEX and REPLI-g amplification product was added to the reaction mixture. The multiplex-PCR 
was performed in a SimpliAmp Thermal Cycler (Life Technologies, Carlsbad, USA) with an initial denaturation step 
at 95°C for 15 min, followed by 28 amplification cycles of 94°C for 1 min, 58°C for 1 min and 72°C for 1 min 20 s. A 
final elongation step at 72°C for 10 min was added. As a positive control, 30µL of a 1:10 dilution of saliva, was used, 
whereas for the negative control, the sample was replaced by 30µL of H2O.  
3.5. STR-Genotyping analysis 
STR profiles for all samples, including the bulk DNA sample, were generated with capillary electrophoresis using 
the ABI 3500 Genetic Analyzer equipped with GeneMapper ID-x 1.2 software (Applied Biosystems, Carlsbad, USA) 
following manufacturer’s recommendations. A detection threshold of 50 RFU was used to indicate allele peaks. The 
total dropout rate (DO%) was assessed for all samples and compared between the four WGA methods as well as 
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between the 1- and 3-cell samples per WGA method. The DO% indicates how many of the expected alleles are 
missing on the STR profile. The dropout rate was calculated based on the following formula: 
[1 − (
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑎𝑙𝑙𝑒𝑙𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑎𝑙𝑙𝑒𝑙𝑒𝑠
)] × 100% 
4. Results & Discussion 
4.1. DNA yield 
After WGA, the DNA yield was assessed and compared between the four WGA methods (Table 1). The yield was 
similar for Ampli1, DOPlify and PicoPlex, except for two single cell samples from Ampli1. All samples, except those 
two, contained ± 1000 ng of DNA. The yield after REPLI-g was considerably higher than the other WGA methods. 
Yields after either one- or three-cell amplification do not differ significantly for all tested WGA methods. 





Ampli1 WGA kit 
1-cell 
1 6.14 190.34 
2 37.80 1171.80 
3 18.04 559.24 
3-cell 
1 42.00 1302.00 
2 59.40 1841.40 




1 32.60 1010.60 
2 32.60 1010.60 
3 31.60 979.60 
3-cell 
1 30.60 948.60 
2 33.40 1035.40 
3 35.40 1097.40 
PicoPLEX WGA kit 
1-cell 
1 60.80 1884.80 
2 52.80 1636.80 
3 54.80 1698.80 
3-cell 
1 60.60 1878.60 
2 33.00 1023.00 




1 1200.00 37 200.00 
2 604.00 18 724.00 
3 690.00 21 390.00 
3-cell 
1 438.00 13 578.00 
2 384.00 11 904.00 
3 516.00 15 996.00 
Table 1: DNA yield after WGA amplification for each used method 
The absence of contamination after Ampli1, DOPlify and PicoPLEX WGA was proven by the negligible DNA yield in 
their respective negative control. However, the negative control from REPLI-g resulted in a concentration of more 
than 1000 ng/µl. According to the kit’s manual, the presence of high DNA yield in negative controls is caused by the 
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random extension of primer dimers in the absence of a template, generating high-molecular-weight product. The 
yield for all positive controls was similar to the yield of the cell samples of the corresponding WGA methods.   
Overall, the yield after WGA did not indicate any problems during amplification and was certainly high enough to 
perform both STR analysis and other conceivable downstream genetic analyses.  
4.2. Dropouts in STR profiles 
The STR profiles of the samples were compared to the reference STR profile of the bulk sample from the NA12882 
cell line. The reference profile and the profiles of all samples are shown in Supplementary Figure S1 and S2 
respectively. Figure 2 shows for each sample which loci were called in accordance to the reference. Green 
represents correctly called loci, orange represents an allelic dropout at a heterozygous locus (only one allele of 
two missing), and red indicates a complete locus dropout (complete locus is missing). The dropout rate was 
calculated for each sample. The average dropout rate and standard deviation for the different WGA methods is 
shown in Figure 3. 
For REPLI-g WGA, the generated STR profiles were almost identical to the reference profile. Consequently, the 
dropout rate for single- and three-cell samples amplified with REPLI-g was only 8.33 % ± 11.48 and 2.38 % ± 2.06, 
respectively. One single-cell sample showed two locus dropouts and three allelic dropouts, while the other REPLI-
g samples showed no or maximum one dropout in their STR profile. The dropout rate for samples amplified with 
Ampli1, DOPlify and PicoPLEX was distinctly higher compared to REPLI-g. In the Ampli1 samples, the dropout seems 
consistent for certain loci, as a recurrent locus dropout at the same 6 loci was observed in almost all samples. No 
alleles were detected in all Ampli1 samples for D18S51, AMEL, D8S1179, TPOX, FGA and D7S820 with exception of one 
single-cell sample showing an allelic dropout for FGA instead of a locus dropout. The dropout rate for single- and 
three-cell Ampli1 amplification was 60.71 % ± 22.30 and 44.05 % ± 2.06, respectively. The dropout after PicoPLEX 
and DOPlify WGA seemed more random across the different loci, although some consistency among the samples 
was noticeable. A dropout for the vWA and D5S818 locus was observed in almost all PicoPLEX samples, whereas for 
DOPlify almost all samples showed a dropout for TPOX, D7S820 and D16S539. After PicoPLEX WGA, one sample 
failed to show an STR profile. Therefore, this sample was omitted from the dropout rate calculation for PicoPLEX. 
Apart from this sample,  PicoPLEX samples showed less dropouts compared to both Ampli1 and DOPlify with a 
dropout rate of 35.71 % ± 3.57 after single-cell amplification and 16.07 % ± 0.00 after three-cell amplification. The 
dropout rate for DOPlify was 59.52 % ± 12.54 for single-cell samples, whereas for three-cell samples a dropout rate 
of 34.52 % ± 2.06 was calculated.  




Figure 2: Overview of dropouts in STR profile for each WGA method 
This figure illustrates which loci were called in each sample. Green represents correctly called loci; Orange represents an allelic dropout 
at a heterozygous locus; Red illustrates a complete locus dropout. 
Previous studies already indicated that MDA is suitable for STR analysis, but no comparison has been made with 
other modern WGA techniques. We observed that the MDA method used in this study, REPLI-g, was the only WGA 
that resulted in complete STR profiles for some of its samples. Because of the branched network formation during 
WGA, this MDA technology amplifies more regions. Therefore, it is more likely that all STR loci are included during 
amplification. The recurrent locus dropout of Ampli1 may also be related to its WGA working mechanism. The 
restriction enzyme might cleave at the STR primer binding sites of these loci, which inhibits their amplification. 
Therefore, the results for Ampli1 could possibly improve if other loci were selected for STR analysis. PicoPLEX 
showed slightly better results than both Ampli1 and DOPlify, but the amplification protocol seems less robust, as 
one of its samples failed to show an STR profile. The pre-amplification during the PicoPLEX amplification protocol 
uses the MDA technology, which might explain why PicoPLEX is the second best WGA for STR analysis. However, 
PicoPLEX uses another polymerase than the one used by REPLI-g and no large, branched network is formed during 
pre-amplification. The four WGA methods showed a slightly better STR profile and less variability between 
individual samples after three-cell amplification compared to single-cell amplification.  




Figure 3: Average Dropout rates per WGA 
Nevertheless, in the context of cell-based NIPT, fetal cell identification would also be possible from a partial STR 
profile. Therefore, Ampli1, PicoPLEX and DOPlify are also suitable for genetic identification in cell-based NIPT or 
other clinical genetic identification purposes, despite the fact that in most samples only half of the STR markers 
were detected. In cell-based NIPT or PGD, the WGA products are mainly intended for downstream genetic analysis, 
such as CNV detection. Therefore, beside STR analysis the WGA product must also be suitable for CNV analysis. REPLI-
g showed its suitability for CNV detection on a limited number of cells at a resolution of 3 Mb earlier, but did 
introduce some representation bias. DOPlify introduced almost no representation bias for CNV calling in that 
context, but its STR profiling resulted in more dropouts compared to REPLI-g. Both Ampli1 and PicoPLEX showed 
slightly more representation bias compared to DOPlify for CNV calling, but less compared to REPLI-g.  
5. Conclusion 
We can conclude that DNA from a limited number of cells is suited for STR profiling after WGA, but the quality of 
the results will depend on the selected WGA method. REPLI-g has a very low dropout rate, as it is the only method 
in this study that could provide, in at least some of the samples, a complete STR profile. Although Ampli1, DOPlify 
and PicoPLEX do not detect all selected STR markers, they seem suited for genetic identification in single-cell 
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6. Supplementary information 
Supplementary Table S1: Concentration of the STR primers in each PCR reaction mixture  
Primer Concentration 
SE33 F 0,5000 µM 
SE33 B 1,0000 µM 
D5S818 F 0,5000 µM 
D5S818 B 0,5000 µM 
FGA F 0,5000 µM 
FGA B 0,5000 µM 
D13S317 F 0,5000 µM 
D13S317 B 0,5000 µM 
vWA F 0,5000 µM 
vWA B 0,5000 µM 
D18S51F 0,5000 µM 
D18S51 B 0,5000 µM 
Amel F 0,5000 µM 
Amel B 0,5000 µM 
D21S11 F 0,5000 µM 
D21S11 B 0,5000 µM 
D3S1358 F 0,5000 µM 
D3S1358 B 0,5000 µM 
Tho1P16 F 0,5000 µM 
Tho1P16 B 0,5000 µM 
TPOX F 0,2500 µM 
TPOX B 0,2500 µM 
D7S820 F 0,6000 µM 
D7S820 B 0,6000 µM 
D16S539 F 0,8000 µM 
D16S539 B 0,8000 µM 
D8S1179 F 1,0000 µM 
D8S1179 B 1,0000 µM 
CD4 F 0,1500 µM 
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Supplementary Figure S1: STR profile from an unamplified bulk sample from the NA12882 cell line.  
One peak represents a homozygous locus, whereas two peaks represent a heterozygous locus. The colored box above the 
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The growing interest in liquid biopsies for cancer research and cell-based non-invasive prenatal testing (NIPT) 
invigorates the need for improved single cell analysis. In these applications, target cells are extremely rare and 
fragile in the peripheral circulation, which makes the genetic analysis very challenging. To overcome these 
challenges, cell stabilization and unbiased whole genome amplification (WGA) are required. This study investigates 
the performance of four WGA methods on single or a limited number of cells after 24 hour of Streck Cell-Free DNA 
BCT preservation. The suitability of the DNA, amplified with Ampli1, DOPlify, PicoPLEX and REPLI-g, was assessed for 
both short tandem repeat (STR) profiling and copy number variant (CNV) analysis after shallow whole genome 
massively parallel sequencing (MPS). Results demonstrate that Ampli1, DOPlify and PicoPLEX perform well for both 
applications, with some differences between the methods. Samples amplified with REPLI-g did not result in suitable 
STR or CNV profiles, indicating that this WGA method is not able to generate high quality DNA after Streck Cell-Free 
DNA BCT stabilization of the cells.   
2. Introduction 
In multiple fields of life sciences, single cell analysis is crucial to study the heterogeneity of cell populations or 
when only a limited number of cells is available (223). This is applicable for liquid biopsies in cancer research, cell-
based non-invasive prenatal testing (NIPT) and preimplantation genetic diagnosis (PGD). In the context of liquid 
cancer biopsies and cell-based NIPT, intact cells in the peripheral circulation are extremely rare and fragile (224, 
225). 
Considering a single human diploid cell contains only 6-7 pg of genomic DNA, whole genome amplification (WGA) 
is required to increase the amount of DNA up to ng- or µg-level when multiple genetic analyses or MPS are to be 
performed on a single cell. According to the manufacturer’s instructions, current MPS library preparation kits 
require a DNA input as low as 1 ng for Nextera XT library preparation and 500 ng for standard Illumina PCR-free 
library preparation. Recently, several research groups have been studying the performance of different WGA 
methods for specific applications. As some WGA methods only perform well in certain applications, an overall best 
performing WGA method does not exist (130, 187, 197, 198, 200, 220, 226). The suitability of a WGA method depends 
on the intended downstream application. Studies demonstrate that PCR-based methods result in a more balanced 
genome coverage, which makes them more suitable for CNV analysis, whereas multiple displacement amplification 
(MDA) based methods are preferred for single nucleotide polymorphism (SNP) detection (130).  
This study wants to investigate the performance of several state-of-the-art WGA methods in a setting mimicking 
cell-based NIPT and liquid cancer biopsy in which single cells are isolated from a patient blood sample. Cell isolation 
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and downstream application for genetic analysis cannot always be performed on-site and/or immediately upon 
blood retrieval. Therefore, the potential of transportation and longer storage without the loss of cell quality would 
be opportune in a clinical setting. The widely-used K2- or K3-EDTA blood tubes demand storage at 4°C and blood 
processing within 6 hours after venipuncture, before nucleated blood cell lysis occurs and cell-free DNA levels 
increase (227). Several alternative collection devices with cell- and/or DNA-stabilizing properties have emerged 
such as CellSave tubes, PAXgene tubes and Streck Cell-Free DNA BCT tubes (cfDNA BCTs). Comparative studies of 
their performance in the context of liquid cancer biopsy testing or cell-free NIPT, agreed that different stabilizing 
collection devices should be chosen according to the desired application (228-230). The cfDNA BCTs (Streck, 
Nebraska, USA) appeared best for this study, since the tubes are designed to prevent lysis of nucleated blood cells 
and circulating epithelial cells by stabilizing these cells and thereby preventing DNA release into the plasma for up 
to 7 days at temperatures between 15°C to 30°C (229, 230). In contrast to most fixatives, cfDNA BCT reagent claims 
to be a formalin-free preservative (231, 232). Formalin is known for its damage to DNA through the introduction of 
chemical modifications such as DNA protein denaturation, protein-DNA cross-linking and methylation of nucleic 
acids, which influences downstream genetic analyses (233). This formalin-free fixative might stabilize and thereby 
preserve desired cells without decreasing the DNA quality. As WGA performance depends on the input DNA quality, 
fixation might also influence the WGA. However, the exact effect on the amplification may possibly differ between 
the WGA methods.  
In this study, the influence of 24 hour Streck Cell-free DNA BCT preservation on four different WGA methods was 
determined. Samples consisting of 1 or 3 cells, in triplicate, were collected from a lymphoblastoid Loucy cell line 
after 24 hour preservation. This cell line is valuable for CNV detection performance studies, since it shows some 
known aneuploidies and CNVs (≥ 3 Mb), as studied and documented in the COSMIC project (203). Four WGA kits, 
each representing a different WGA method, were selected from earlier performance studies for CNV analysis on 
single, live cells (187, 220) (Chapters III & VII). The MDA-based WGA method, REPLI-g single cell kit (Qiagen, Hilden, 
Germany), uses the high-fidelity enzyme, Phi29 polymerase, which holds a proofreading activity and thereby 
reduces the introduction of nucleotide errors during WGA. The strand displacement activity of the polymerase 
creates a hyper-branched DNA structure and consequently exponential amplification occurs (234). The PicoPLEX 
WGA Kit (Rubicon Genomics Inc., MI 48108, USA) combines MDA with standard PCR amplification, utilizing self-inert 
degenerate primers, which causes semi-linear amplification. PicoPLEX WGA Kit has already proven its utility in 
clinical settings such as PGD for the detection of CNVs (30, 32). Other PCR-based WGA methods include Ampli1 WGA 
Kit (Silicon Biosystems, Castel Maggiore, Italy) and DOPlify WGA (Reproductive Health Science, Thebarton, Australia). 
Ampli1 is a ligation-adapter PCR-based WGA method, which is characterized by an initial restriction enzyme-based 
fragmentation of the DNA. Therefore, Ampli1 should be more robust for fragmented or degraded DNA templates. 
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Latest developed DOPlify WGA is based on the straightforward degenerate oligonucleotide primed PCR (DOP-PCR). 
DOPlify is an advanced DOP-PCR with possibly new primers and new generation polymerases with high fidelity and 
proofreading activity (201).   
As fetal cell isolation from the maternal blood stream is still prone to maternal cell contamination, a short tandem 
repeat (STR) profiling is often performed on each individual cell to exclude maternal contamination and confirm 
fetal identity (105). CNV analysis is necessarily for downstream genetic analysis in cell-based NIPT and liquid cancer 
biopsy. So, after the amplification with REPLI-g single cell kit, Ampli1 WGA Kit, DOPlify WGA and PicoPLEX WGA, both 
the suitability of the amplified DNA for STR genotyping and CNV detection was assessed. 
3. Materials and methods 
3.1. Experimental design 
In the present study, the performance of four WGA methods on a limited number of cells was examined after 24 
hour cell-free DNA BCT preservation (Figure 1). The suitability of the DNA for STR and CNV analysis was studied. A 
cell suspension from a female lymphoblastoid Loucy cell line (DSMZ, ACC394) was transferred to a cfDNA BCT tube 
and stored at room temperature for 24 hours (169). For each WGA method, samples consisting of 1 or 3 cells were 
collected, in triplicate, from this fixed cell suspension, using micromanipulation. In parallel, a bulk DNA sample from 
the cell line was obtained. This bulk DNA serves as a reference/golden standard to allow impartial conclusions when 
comparing the WGA methods. The 1- and 3-cell samples were amplified using four different WGA methods. 
Subsequently, human identification STR analysis, PCR-free Illumina library preparation and massively parallel 
sequencing (MPS) were performed on all WGA products. STR typing was also performed on the bulk DNA, in parallel, 
which was used as a reference profile. A reference 180K aCGH profile (Agilent Technologies) from unamplified DNA 
of a bulk sample of the cell line was available from a previous study (Supplementary Figure S1) (187) (Chapter III). 
The following reference aneuploidies and CNVs (≥ 3 Mb) were present: a deletion of an entire X-chromosome, two 
deletions of ±45 Mb (consists of 6 Mb and a 36.5 Mb deletion interspersed by a 2.5 Mb normal ploidy region) and 
30 Mb on respectively 5q14.3-q31.1 and 5q33.1-q35.3, a deletion of ±60 Mb on 6q21-q27, a deletion of 3 Mb on 
12p13.31-p13.2, a ±26 Mb duplication of 13q31.3-q34, and two deletions of 16 Mb and 3 Mb on respectively 16p13.3-
p13.11 and 16q24.2q24.3. CNV calling accuracy after WGA was evaluated in Chapter VII (220) by comparing the CNV 
calls in all WGA samples with those called in the earlier sequenced bulk DNA sample using 1Mb windows 
(Supplementary Figure S2). 




Figure 1: Experimental design.  
Cells from the Loucy cell line were preserved for 24 hours in Cell-Free DNA BCT reagent. Samples consisting of 1- or 3-cells were isolated 
from this fixed cell suspension for each WGA method. Ampli1, DOPlify, PicoPLEX and REPLI-g were used for amplification, followed by 
Illumina PCR-Free library preparation and next generation sequencing. In parallel, STR-PCR and capillary electrophoresis was performed 
on all samples, including a bulk sample from the cell line. 
A positive control containing 1µL of high quality male control DNA (Human Genomic DNA, Roche, 100 µg (500 µl)) 
in a concentration of 30 pg/µL was included during each WGA method. This control sample was used to evaluate 
the performance of the WGA kit, without the influences of cell isolation, cell lysis and DNA extraction. A negative 
control, consisting of 1µL H2O, was added to detect contamination introduced during the WGA.  
A positive control containing saliva was included during multiplex STR-PCR to verify the success of the PCR reaction. 
A no-template control (NTC) sample, consisting of H2O, was included to rule out any non-specific amplification 
during STR-PCR.  
3.2. Cell culture and isolation  
The cells from the lymphoblastoid Loucy cell line (DSMZ, ACC394) were grown in Roswell Park Memorial Institute 
(RPMI-1640) medium (Life technologies, Carlsbad, USA). This cell medium was supplemented with 10 % fetal bovine 
serum (Life Technologies, Carlsbad, USA) and a mix of penicillin at 100 units/mL and streptomycin at 100 µg/mL 
(Life technologies, Carlsbad, USA). Cells were cultured at a temperature of 37°C and a 5 % CO2 level.  A Phosphate-
buffered saline (PBS) suspension containing 1 * 106 cells in 10 mL was transferred to a cfDNA BCT tube and stored 
at room temperature for 24 hours. A known number of cells was isolated, using micromanipulation, in the same 
manner as previously described in Chapter VII (220). A bulk DNA sample from the Loucy cell line was prepared using 
the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) on ± 5 * 106 cells. 
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3.3. Whole genome amplification 
Cell lysis and amplification with Ampli1 WGA Kit (Silicon Biosystems, Castel Maggiore, Italy), DOPlify WGA 
(Reproductive Health Science, Thebarton, Australia), REPLI-g Single Cell Kit (Qiagen, Hilden, Germany),  and PicoPLEX 
WGA Kit (Rubicon Genomics Inc., MI 48108, USA) were performed according to manufacturer’s recommendations. 
The amplified DNA was purified using the Genomic DNA Clean & Concentrator kit (version 1.0.0, Zymo Research, 
Irvine, USA) using 5x binding buffer following manufacturer’s instructions. DNA concentration was determined using 
the Qubit dsDNA High Sensitivity Assay kit (Life technologies, Carlsbad, USA). 
3.4. STR-genotyping 
The purified DNA samples served as template for the in-house multiplex STR-PCR assay, based on the Promega 
Powerplex. This multiplex PCR was used to simultaneously amplify the Amelogenin locus and 14 tetrameric STR loci 
across the human genome: D3S1358, TH01, D21S11, D18S51, vWA, D8S1179, TPOX, FGA, D5S818, D13S317, SE33, CD4, 
D7S820, and D16S539. The total volume in each reaction mix was 50µL, containing 2.5 U Hotstar Taq polymerase 
(Qiagen, Hilden, Germany), 0.5 mM MgCl2 (Qiagen, Hilden, Germany), 0.4 µg/µL albumin (Sigma-Aldrich, Saint Louis, 
USA), 1x PCR buffer (Qiagen, Hilden, Germany), 0.15µM – 1µM of each primer and 30µL of purified DNA. 
Supplementary Table S1 shows the exact concentrations used for each primer. Respectively 1ng, 1ng, 5ng and 4ng 
purified DNA from Ampli1, DOPlify, PicoPLEX or REPLI-g amplification product was added to the reaction mixture. 
The multiplex PCR was performed in a SimpliAmp Thermal Cycler (Life Technologies, Carlsbad, USA) with an initial 
denaturation step at 95°C for 15 min, followed by 28 amplification cycles of 94°C for 1 min, 58°C for 1 min and 72°C 
for 1 min 20 s. A final elongation step at 72°C for 10 min was added. As a positive control, 30 µL of a 1:10 dilution of 
saliva was used, whereas for the non-template control the sample was replaced by 30 µL of H2O.  
3.5. STR-genotyping analysis 
STR profiles for all samples, including the bulk DNA sample, were generated with capillary electrophoresis. 
Separation and analysis of the amplified PCR fragments was performed using the ABI 3500 Genetic Analyzer 
equipped with GeneMapper ID-x 1.2 software (Applied Biosystems, Carlsbad, USA) following manufacturer’s 
recommendations. A detection threshold of 50 RFU was used to indicate allele peaks. The total dropout rate (DO%) 
was assessed for all samples and compared between the four WGA methods as well as between the 1- and 3-cell 
samples per WGA method. The dropout rate was calculated based on the following formula: 
[1 − (
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑎𝑙𝑙𝑒𝑙𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑎𝑙𝑙𝑒𝑙𝑒𝑠
)] × 100% 
In this study we analyzed the locus dropout and the allele dropout. The latter means only one allele has dropped 
out, whereas a locus dropout indicates the complete absence of that locus.  
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3.6. TruSeq DNA PCR-free HT library preparation  
Fragmentation of all WGA products to a mean size distribution of 350 bp was performed using the S2 Focused 
Ultrasonicator with Adaptive Focused Acoustics (AFA) technology (Covaris, Woburn, USA) according to 
manufacturer’s instructions. Resuspension buffer (provided in the TruSeq DNA PCR-free kit) was used to dilute all 
samples to a volume of 52.5 µL with a DNA input between 350 ng and 1 µg. Subsequently, library preparation, library 
quantification and single-end indexed 75 bp sequencing was performed as earlier clarified in Chapter VII (220), 
respectively using the TruSeq DNA PCR-free HT library preparation kit (Illumina, San Diego, USA), the Sequencing 
Library qPCR Quantification kit (Illumina, San Diego, USA) and a high-output NextSeq500 flow-cell (Illumina, San 
Diego, USA).   
3.7. CNV data analysis and statistical analysis of the read count variance 
CNV data analysis was performed as described in Chapter VII (220) using the ViVar Software (182). The CNV calls 
were detected based on the QDNAseq algorithm. The results were analyzed using 1Mb windows. The CNV profiles 
are visualized as line plots in which the windows are represented as dots, ordered based on their genomic position, 
as indicated by the x-axis. The horizontal lines refer to the segments. The alternating white and gray background 
identifies the chromosomes while the y-axis shows the median normalized log2 transformed read counts. Raw 
sequencing data are deposited in the NCBI Sequence Read Archive under project accession number PRJNA397729. 
On ViVar they are available under the project: Streck (https://holmes.ugent.be:9090/ViVar/) 
The statistical analysis of the average read count variance between the windows across the genome was performed 












 in which ‘N’ is the number 
of windows, ‘xi ’ the read count in window i,  ‘xi+1 ’ the read count in the next window i+1 and ‘a’ the median number 
of reads across all windows. In this formula, the read count in each window was scaled by factor ‘a’, normalizing 
the result for the total number of reads that was sequenced for the sample. To test for significant differences of 
this metric between groups of samples, a Kruskal-Wallis H test was performed. This way, following groups of 
samples were compared: Ampli1 versus DOPlify versus PicoPLEX for 1 cell samples (N=3), for 3 cells samples (N=3), 
and for the 1 cell and 3 cells samples taken together (N=6). Comparisons with p-values smaller than 0.05 were 
considered statistically significant. 
3.8. True and false positives 
All genomic line profiles were checked for accurate variants. Deletions or duplications in sample CNV profiles that 
were also called in the reference CNV profile from the bulk DNA sample, were defined as true positives. CNV calls 
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that are not present in the reference CNV profile were labelled as false positives. The results were compared using 
1Mb windows. 
4. Results 
4.1. Dropouts in STR profiles 
STR profiles of the amplified samples were compared with the reference STR profile from the cell line 
(Supplementary Figure S3). Figure 2 illustrates which loci were called in the 1- and 3-cell samples from all four WGA 
methods. A locus is called correctly if indicated in green. Orange squares represent allele dropouts in which only 
one allele of a heterozygous locus is called. A complete locus dropout is illustrated in red.  
Ampli1 showed no allele dropouts, but locus dropouts of the Amelogenin locus and the STR loci D18S51 and D7S820 
were present in all samples. A locus dropout of the loci D8S1179 and FGA occurred in 5 out of 6 samples whereas a 
locus dropout of TPOX was present in 4 out of 6 samples. The STR profiles of the 1- and 3-cell samples were very 
similar. DOPlify showed 0-4 allele dropouts per sample, mainly for the loci D3S1358 and SE33. All DOPlify samples 
demonstrated a locus dropout of the locus TPOX, whereas the D16S539 locus dropout was present in all samples 
except one. The CD-4 locus dropout was only seen in the 1-cell samples. No other substantial differences were 
observed between the 1- and 3-cell samples. The STR profiling of the first 1-cell sample from PicoPLEX was 
considered as a failure because only 3 out of 15 loci were called correctly. The remaining PicoPLEX 1-cell samples 
showed some randomly distributed allele dropouts and a few locus dropouts. The dropout of locus D5S818 was 
present in all but one sample. The 3-cell samples amplified with PicoPLEX resulted in remarkably more complete 
STR profiles. REPLI-g resulted in unsatisfactory STR profiles with a maximum of 5 correctly called loci per sample.   
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Figure 2: Overview of dropouts in STR profile for each WGA method.  
This figure illustrates which loci were called in the 1- and 3-cell samples for each WGA method. Correctly called loci are indicated in 
green. The orange squares represent allele dropouts, whereas a complete locus dropout is illustrated in red. 
Comparing the WGA methods based on the calculated dropout rate, DOPlify and PicoPLEX perform similar on 1-cell 
samples with a dropout rate of 28 ± 10.6 % and 28 ± 11.3 %.  Ampli1 has a dropout rate of 33.3 ± 11.6 %, whereas 
REPLI-g has the highest dropout rate of 77.3 ± 8.3 %. For 3-cell samples, PicoPLEX excels with a dropout rate of 10.7 
± 6.1 %, followed by DOPlify and Ampli1 with respectively 30.7 ± 14.1 % and 37.3 ± 4.6 %. Again, REPLI-g shows the 
highest dropout rate of 65.3 ± 2.3 %. PicoPLEX and REPLI-g clearly have a lower dropout rate for 3-cell samples, 
whereas the number of input cells has a minor impact on Ampli1 and DOPlify, which even show a slightly higher 
dropout rate for 3-cell samples (Supplementary Figure S4).   
4.2. Variance in read counts per window across the genome 
The variance in read counts per window across the genome gives an indication for the performance of each WGA 
method for CNV analysis. Only when the reads are distributed uniformly across the genome, CNVs can be called 
truthfully. All samples amplified with Ampli1, DOPlify and PicoPLEX showed this desired uniform distribution. 
Unfortunately, no conventional CNV profiles resulted from the samples amplified with REPLI-g, because the 
variance in read counts per window was very high, indicating the reads were distributed irregularly across the 
genome (Supplementary Figure S5). Therefore, no further downstream (statistical) analyses were performed for 
REPLI-g. Figure 3 illustrates the boxplots of the average variance in read counts per 1 Mb window across the genome 
for all 1-cell and 3-cell samples of Ampli1, DOPlify and PicoPLEX. Regarding the 3-cell samples, the average variance 
in read counts was similar within these three WGA methods. For the 1-cell samples, the average variance was also 
similar, but the boxplots show a bigger difference in variance between the three single cell samples, especially for 
PicoPLEX. One PicoPLEX single cell sample showed variance that is three times higher, compared to the other 
PicoPLEX samples. For the 1-cell samples (p = 0.511) and the 3-cell samples (p = 0.829), the average variance in 
read counts per window did not differ significantly between the different WGA methods. Moreover, including all 
samples per WGA method (N=6), no significant difference was observed between the three WGA methods (P = 
0.834). 




Figure 3: Boxplots of the average variance in read counts per 1 Mb windows across the genome.  
(A) Boxplots representing all 1-cell samples for Ampli1, DOPlify and PicoPLEX. (B) Boxplots representing all 3-cell samples for Ampli1, 
DOPlify and PicoPLEX. REPLI-g was omitted from this figure, because it showed a very high average variance in read counts, indicating 
that the reads were distributed irregularly across the genome. The red line is the median variance for each WGA. The blue box contains 
the first and third quartile, whereas the black lines represent the minimum and maximum variance. 
4.3. CNV analysis using a 1 Mb window 
Supplementary Figure S6 demonstrates the 1Mb window line profiles of all samples, except for REPLI-g. These are 
also available online (https://holmes.ugent.be:9090/ViVar/). As previously mentioned, REPLI-g was omitted from 
this CNV analysis. The CNV line profile of one representative 1-cell sample of Ampli1, DOPlify and PicoPLEX is 
represented in Figure 4. The expected duplications and deletions (≥ 3 Mb), as present in the reference 1Mb CNV line 
profile sequenced using a bulk sample from the Loucy cell line (as in Chapter VII) (220), were called in all WGA 
methods, except for one 3-cell sample from PicoPLEX. This sample shows no call for the Chr13q duplication, however, 
higher read counts per window at this genomic position are clearly notable. One DOPlify 1-cell sample called an 
extra deletion at the end of chromosome 10, whereas one PicoPLEX 3-cell sample called an extra deletion at the 
beginning of chromosome 5. Three samples showed an extra deletion at the end of chromosome 16, which is also 
present in the reference 180K aCGH profile. Supplementary Table S2 indicates the called CNVs per sample. CNV 
profiles from 1-cell samples showed no notable differences compared with 3-cell samples.  




Figure 4: CNV line profiles generated with ViVar using 1Mb windows. 
 Representative CNV line profile of a (A) 1-cell sample amplified with Ampli1. (B) 1-cell sample amplified with DOPlify. (C) 1-cell sample 
amplified with PicoPLEX. Segments in red represent deletions, whereas blue segments indicate duplications. As REPLI-g did not result in 
reliable CNV profiles, it was omitted from this figure. 
5. Discussion 
The goal of this study was to investigate the performance of four WGA methods on a limited number of cells after 
24 hour of Streck cfDNA BCT preservation. Both the suitability of the amplified DNA for STR genotyping and CNV 
analysis was assessed. It was observed that REPLI-g is not suitable to generate high quality DNA that allows STR 
genotyping or CNV calling in this specific set-up. The performance of Ampli1, DOPlify and PicoPLEX, on the other 
hand, was considered as suitable for both applications, with some differences between the three WGA methods.  
STR genotyping results in a remarkably high dropout rate for REPLI-g. Moreover, with a maximum of 5 correctly 
called STR loci per sample, the identity of a single cell is difficult to prove. PicoPLEX showed the lowest dropout 
rate and therefore performed best for STR genotyping. Still, one PicoPLEX 1-cell sample failed, and the reason for 
this failure was not clear. Possibly, this WGA protocol is less robust for STR analyses, which should be considered 
when choosing one over another WGA method. DOPlify and Ampli1 prove to be robust and reproducible WGA 
methods for STR genotyping of 1-cell and 3-cell samples but show a higher dropout rate than PicoPLEX. A consistent 
dropout of the same loci in each sample with Ampli1 is notable and can be related to the WGA working mechanism, 
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as restriction enzymes are used for the initial fragmentation of the DNA. Probably, the enzymes cleave at the STR 
primer binding sites. This way, PCR amplification of these specific loci is inhibited and consistent locus dropout 
occurs. If necessary, other STR primers can be selected for the DNA typing after Ampli1 WGA.  
The variance in read counts per window across the genome was similar for Ampli1, DOPlify and PicoPLEX. The 
uniform distribution of reads across the genome allows reliable CNV calling for these WGA methods. One single-
cell PicoPLEX sample, which failed to show a descent STR profile as well, now showed a higher variance in read 
counts per window compared to the others. Nevertheless, the CNV profile of this sample was similar to the others, 
indicating that the higher variance did not impede correct CNV analysis. As already mentioned above, we attribute 
these negative results to a lower robustness of the PicoPLEX WGA protocol. This might sporadically lead to a biased 
amplification, which seems to influence STR genotyping but not CNV analysis. Samples amplified with REPLI-g did 
not result in CNV profiles, due to the irregular distribution of reads across the genome. The poor performance of 
REPLI-g might be the result of the exposure of the cells to the cfDNA BCT preservative. Possibly, the preservation 
hampers the lysis of the cells in the REPLI-g WGA protocol. The assumption that the bad performance of REPLI-g is 
caused by the cfDNA BCT reagent is supported by the study from Chapter VII (220), which demonstrates a suitable 
performance of REPLI-g for CNV calling on 1-, 3- and 5-cell samples. This study followed the same experimental 
set-up, except for the cfDNA BCT preservation step. In both studies, similar boxplots are generated for Ampli1 and 
DOPlify, indicating that no negative effects on the distribution of reads result from the preservation step.   
Ampli1, DOPlify and PicoPLEX resulted in excellent 1Mb window CNV line profiles with only minor differences. Ampli1 
shows a 100 % sensitivity and specificity, which means that all expected CNVs are called and that no false positives 
were present. DOPlify shows almost a 100 % sensitivity, but an extra Chr10q deletion was called in one single cell 
sample. For this sample, a higher variance in read counts per window across the genome was noted, which might 
reduce the CNV calling reliability of the ViVar software and probably cause the calling of this incorrect deletion. For 
PicoPLEX, one sample showed a false-positive Chr5p deletion and a false-negative Chr13q duplication, which 
reduces the sensitivity and specificity of this method. However, the region corresponding with the Chr13q 
duplication clearly shows higher read counts. Compared to the other 3-cell samples from PicoPLEX with a 100% 
sensitivity and specificity, the average variance in read counts per window across the genome was higher, which 
might again reduce the CNV calling reliability of the ViVar software for this sample. Furthermore, two Ampli1 
samples and one PicoPLEX sample showed an extra deletion at Chr16q, which was not considered as a false positive, 
since this CNV is also present in the 180K aCGH reference profile from the cell line. Comparing this study with the 
study in Chapter VII (220), DOPlify performs very similar with or without cfDNA BCT preservation, whereas Ampli1 
results in a more complete CNV profile with less incorrect calls, when 24 hour cfDNA BCT stabilization of the cells 
is performed. 
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After Streck cfDNA BCT preservation, there is no overall best performing WGA method. The most suitable method 
must be selected based on the intended downstream application. However, REPLI-g can be omitted from the 
options after cfDNA BCT fixation.   
6. Supplementary information 
Supplementary Figure S1: 180K array CGH profile from a bulk sample from the Loucy cell line.  
All CNVs, as detected in the female Loucy cell line with a resolution of 50kb, are illustrated in this profile. Deletions are 
indicated as red bars, whereas blue bars indicate insertions. 
 
Supplementary Figure S2: 1Mb window CNV line profile from an unamplified bulk sample from the Loucy cell line. Segments 
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Supplementary Table S1: Concentration of the STR primers in each PCR reaction mixture. 
Primer Concentration 
SE33 F 0,5000 µM 
SE33 B 1,0000 µM 
D5S818 F 0,5000 µM 
D5S818 B 0,5000 µM 
FGA F 0,5000 µM 
FGA B 0,5000 µM 
D13S317 F 0,5000 µM 
D13S317 B 0,5000 µM 
vWA F 0,5000 µM 
vWA B 0,5000 µM 
D18S51F 0,5000 µM 
D18S51 B 0,5000 µM 
Amel F 0,5000 µM 
Amel B 0,5000 µM 
D21S11 F 0,5000 µM 
D21S11 B 0,5000 µM 
D3S1358 F 0,5000 µM 
D3S1358 B 0,5000 µM 
Tho1P16 F 0,5000 µM 
Tho1P16 B 0,5000 µM 
TPOX F 0,2500 µM 
TPOX B 0,2500 µM 
D7S820 F 0,6000 µM 
D7S820 B 0,6000 µM 
D16S539 F 0,8000 µM 
D16S539 B 0,8000 µM 
D8S1179 F 1,0000 µM 
D8S1179 B 1,0000 µM 
CD4 F 0,1500 µM 
CD4 B 0,6000 µM 
 
Supplementary Figure S3: STR profile from an unamplified bulk sample from the Loucy cell line.  
The Amelogenin locus and the 14 tetrameric STR loci are illustrated above the STR profile, indicating the called alleles. One 
peak represents a homozygous locus, whereas two peaks represent a heterozygous locus. 
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Supplementary Figure S4: Average dropout rate (%) for all 1- and 3-cell samples of the four WGA methods.  
 
Supplementary Figure S5: 1 Mb window CNV line profiles of REPLI-g samples.  
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Supplementary Figure S6: 1 Mb window CNV line profiles of all DOPlify samples: 
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Supplementary Figure S6: 1 Mb window CNV line profiles of all PicoPLEX samples:  
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Supplementary Table S2: CNVs called in ViVar using a 1Mb window. 
The column headers on the left side of the table show the genomic positions of all deletions or insertions (in bold), which are larger than 3 Mb and present in the reference 180 K aCGH profile. 
Called CNVs are indicated with a ‘ν’. The column headers on the right side show the location of the incorrectly called CNVs. Subscripts (1) and (2) indicate two different CNVs that are located on 
the same chromosomal arm.  
   Chr5q(1) Chr5q(2) Chr6q Chr13q Chr16p Chr16q X-Chr Chr5p Chr10q 
Bulk   ν ν ν ν ν   ν     
Ampli-1 1c1 ν ν ν ν ν ν ν   
  1c2 ν ν ν ν ν  ν   
  1c3 ν ν ν ν ν  ν   
  3c1 ν ν ν ν ν  ν   
  3c2 ν ν ν ν ν ν ν   
  3c3 ν ν ν ν ν   ν     
DOPlify 1c1 ν ν ν ν ν  ν  ν 
  1c2 ν ν ν ν ν  ν   
  1c3 ν ν ν ν ν  ν   
  3c1 ν ν ν ν ν  ν   
  3c2 ν ν ν ν ν  ν   
  3c3 ν ν ν ν ν   ν     
PicoPLEX 1c1 ν ν ν ν ν  ν   
  1c2 ν ν ν ν ν  ν   
  1c3 ν ν ν ν ν  ν   
  3c1 ν ν ν  ν  ν ν  
  3c2 ν ν ν ν ν  ν   













Chapter XI: General discussion & Summary  
 
The results of the individual studies have been discussed thoroughly in the discussion section of each chapter. In 
this chapter, we will summarize these results and discuss the general outcome of this dissertation.  
Our first main goal was the introduction of shallow MPS in PGD for CNV analysis as a possible substitute for aCGH. 
Before we could accomplish this, we developed a workflow, for CNV analysis after shallow MPS on a limited number 
of cells and chose a WGA method suitable for such analysis. In Chapter III we used such a workflow to demonstrate 
that SurePlex WGA is better suited for CNV detection after shallow MPS on a limited number of cells compared to 
MALBAC WGA. A WGA method well suited for CNV analysis should result in a uniform read distribution across the 
genome. A non-uniform read distribution indicates an over-or under-amplification of certain genomic regions. This 
would introduce CNVs not present in the original genome or mask real CNVs, and thereby result in a wrong 
interpretation of the genome. After MALBAC amplification, a non-uniform read distribution resulted in a biased CNV 
profile. A lot of CNVs were missed and other false positive CNVs were called. In contrast, SurePlex amplification 
resulted in a more uniform distribution and thereby a more complete CNV profile with less false positives. They are 
both hybrid PCR methods, using the same amplification mechanism, but with different primers. For MALBAC, these 
primers might have bound less uniform across the genome or the loop formation might have been suboptimal.  
In both methods, the false positive calls were not entirely consistent between the replicates. This indicates that the 
bias introduced during amplification is rather random and thereby more difficult to predict. The single cell samples 
showed more bias than the three or five cell samples. It is possible that the random bias is partially smoothed 
when multiple cells are amplified. The bias improved when using a PCR-free library preparation method, indicating 
that some bias was also introduced during the enrichment PCR step of library preparation. Nevertheless, some bias 
was still present after omitting the enrichment PCR, especially for MALBAC, indicating that both WGA and 
enrichment PCR were responsible for the bias. In general, SurePlex WGA should be suited for PGD on 3 and more 
cells for CNV detection after shallow MPS. 
Subsequently, we applied a similar workflow, using SurePlex WGA, to establish our first goal. In Chapter IV, we 
demonstrated that shallow MPS on trophectoderm biopsies is a preferable alternative for aCGH for the detection 
of chromosomal and structural abnormalities in PGD embryos. Shallow MPS showed a higher resolution and better 
signal-to-noise ratio than aCGH. In addition, the cost per sample should drop, as samples could be multiplexed or 
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combined with samples from other clinical applications (NIPT, exome sequencing) on a single sequencing run. These 
findings indicate that MPS is more precise and more flexible than aCGH. After MPS the resolution could be increased 
(by lowering the window size) for certain patients with known cryptic aberrations, yet restricting the analysis to 
the chromosomal segments of interest to avoid false-positive results genome-wide. ACGH is not that flexible, as 
the resolution is limited by the distance between the probes. Further, we showed for the first time that Illumina 
(NextSeq500) and Ion Torrent (Ion Proton) sequencing technologies are both applicable and even interchangeable 
in this setting. The detailed workflow for CNV detection in PGD has been described in Chapter V. In the meantime, 
shallow MPS has been successfully introduced for the detection of CNVs and aneuploidies in PGD at some genetic 
centers, such as the medical genetics center of Ghent. 
SurePlex WGA proved its value in this clinical setting for the amplification of 4-6 trophoblast cells and a subsequent 
CNV analysis at ≥3Mb resolution. However, a higher resolution in our study was hampered, probably by the 
representation bias introduced by our WGA. This representation bias would be even more pronounced if less cells 
were amplified (Chapter III). In settings, were the analysis of only a single cell is important (cell-based NIPT or 
heterogeneity detection in a cell population), a better WGA method might be suggested. Therefore, as requested 
by commercial partners, we tested some other WGA methods for CNV analysis after single cell sequencing, hoping 
to result in less bias. 
The first method tested was TruePrime WGA, which gave rather disappointing results (Chapter VI). The read 
distribution was extremely non-uniform and thereby no descent CNV analysis was possible. This method seemed 
not suited for CNV analysis after MPS on a limited number of cells. It is, therefore, not surprising that other research 
articles using this method remain absent. Only one paper, written by the company itself, came out shortly after our 
paper (192). We suspect that the possible instability of the TthPrimPl primase causes the representation bias during 
amplification. The stability might be better in house than after shipment to other locations. That would indicate 
that this version is not yet ready to be launched on the market. We have been contacted shortly after our publication 
to test their new version and although slightly improved, the results were still disappointing.  
In Chapter VII, we evaluated DOPlify and PicoPLEX DNA-Seq for their use for CNV detection after MPS on a limited 
number of cells, compared to Ampli1 and REPLI-g. This time, only using the PCR-free library preparation method. 
The four WGA methods seemed suitable for CNV detection after MPS on a limited number of cells, but DOPlify and 
PicoPLEX DNA-Seq excelled. The latter two detected all expected CNVs without false positives, at both a 1Mb and 
500kb window. Ampli1 and REPLI-g detected already some false positives at 1Mb and showed, respectively, two 
times and three times more when analyzed at 500kb. Nevertheless, some smaller CNVs were also more likely to 
be detected in those samples, suggesting that the local signal-to-noise ratio was lower after Ampli1 and REPLI-G 
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amplification. Therefore, for those two methods, one should decide between either a higher resolution or less false 
positives.  
DOPlify or PicoPLEX DNA-Seq might be able to replace SurePlex in a clinical PGD setting for chromosomal aberration 
detection. PicoPLEX DNA-Seq includes the same WGA technology as SurePlex, but without the need for a separate 
library preparation. In terms of cost, time, contamination risk and error susceptibility, this method might be 
preferred over conventional SurePlex in a PGD setting with Illumina sequencing. DOPlify is an advanced DOP-PCR, 
but more details about the advancement are not released. Most likely, Taq polymerase is no longer used, which 
would be an improvement over the amplification with SurePlex. When it comes to PicoPLEX DNA-Seq versus DOPlify: 
DOPlify seems to be better for single cell amplification, but two failed samples suggest the method might be less 
robust. PicoPLEX DNA-Seq is less flexible, as it always results in an Illumina library and is therefore not compatible 
with Ion Torrent sequencing.  
REPLI-g and Ampli1 seem to introduce more bias compared to SurePlex, as no false positives were observed at a 
1Mb window for the PCR-free SurePlex samples analyzed in Chapter III. However, this might have been a coincidence, 
as only three PCR-free SurePlex samples were available to compare. Nevertheless, REPLI-g uses the MDA 
technology and it is well-known that most hybrid WGA methods are better for CNV detection than the WGA methods 
based on MDA (130). The mechanism behind Ampli1 is highly depending on the availability of restriction sites. A 
non-uniform distribution of those sites across the genome, will lead to bias during amplification. REPLI-g 
amplification introduced more false positives and thereby showed a lower reproducibility than Ampli1. These 
findings were similar to previous research by Hou et al., where Ampli1 showed a lower amplification bias and a 
higher accuracy for single-cell CNV detection compared to REPLI-g (198).  
In Chapter VIII, we focused on an affordable analysis of SNVs across the genome using MPS. This could be another 
application in PGD, as to improve current detection methods for SGDs methods. Therefore, we applied the TruSight 
One sequencing panel to analyze multiple SNPs on a limited number of cells. The TruSight One sequencing panel is 
designed to screen for different SGDs at once in a prenatal setting using CVS. This panel simultaneously captures 
more than 4800 genomic regions associated with a clinical phenotype and analyzes them on a single sequencing 
run. As expected, the panel performed different on WGA DNA than on bulk DNA and this difference depended on the 
applied WGA method. Target coverage, coverage uniformity and SNP calling accuracy obtained using SurePLEX, 
Ampli1 and MALBAC, was inferior to the results obtained on bulk DNA. However, REPLI-g WGA came close to the 
results of the bulk DNA. REPLI-g resulted in better coverage of the targeted genomic regions with a more uniform 
read depth compared to the other WGA methods. Consequently, this method resulted in a more accurate SNP calling 
than the others. In contrast to CNV detection, MDA WGA methods are preferred over hybrid PCR methods for SNP 
detection (130), but it was never shown that this also holds true if a capture is performed before SNV detection. 
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MALBAC and SurePLex both use the Bst polymerase during their pre-amplification step, which has a lower fidelity 
than the Phi29 polymerase used by REPLI-g. The fidelity of a polymerase is more important for SNP detection than 
for CNV detection. In Ampli1 WGA it might have been possible that the targeted regions were cut by the restriction 
enzyme and thereby a lot of regions remained uncaptured. Again, the bias between the replicates in the four 
methods was not consistent, indicating that the bias was introduced rather random. A very recent study compared 
four WGA methods for SNP calling after exome sequencing, which is comparable to our setting (209). Their results 
for MALBAC, Ampli1, REPLI-g mini and SurePlex for variant calling and targeted coverage were comparable to our 
results.  
PicoPLEX DNA-Seq and DOPlify were not included in this study as we initiated this study before they were launched 
on to the market. Nevertheless, PicoPLEX DNA-Seq applies the SurePlex WGA technology and thereby the results 
are expected to be similar to SurePlex. Besides, the library formation included in the WGA, is probably not suited as 
starting material for the panel. It might, however, be interesting to test DOPlify for this application in the future.  
In the future, the TruSight One sequencing panel might be a substitute for state-of-the-art technologies for SGD 
analysis in PGD, if it performs well on amplified material. Although the results after REPLI-g amplification look 
promising, they do not match the bulk sample entirely. A thorough clinical validation of this panel combined with 
WGA will be essential before the panel could be applied in the clinic.  
For the last part of this dissertation we focused on STR analysis of WGA amplified single cell samples. The genetic 
identification of a cell might be important in an application, such as cell-based NIPT. In Chapter IX, SurePlex, Ampli1, 
REPLI-g and DOPlify were tested for STR analysis after the amplification of single or three fresh cells. Similar to 
SNV detection, REPLI-g was the best WGA method for STR detection on fresh cells in this study. REPLI-g was the 
only WGA in this study that could result in a complete STR profile for at least some of its samples. However, in a 
cell-based NIPT setting a complete STR profile should not be necessary to determine the genomic identity of a cell. 
In this setting, the maternal STR profile is compared to the STR profile of the cell. An STR profile, not equal to the 
maternal profile, but with one of the maternal alleles in each heterogeneous marker, must be fetal. The incomplete 
profiles of Ampli1, SurePlex and DOPlify could still predict potential fetal identity. After Ampli1 amplification, all 
samples showed a dropout of the same 6 STR markers, which might be related to the WGA working mechanism. 
The restriction enzyme probably cleaves at the STR primer binding sites of those regions, thereby PCR amplification 
at these loci is inhibited. Nevertheless, replacing these STR markers by others might improve STR analysis after 
Ampli1 WGA. SurePlex and DOPlify show a more random dropout. SurePlex showed a lower dropout rate than 
DOPlify and Ampli1, but one of its samples failed to show a descent profile. Therefore, DOPlify and Ampli1 seem 
more robust and reproducible methods.  
Chapter XI: General discussion & Summary 
199 
 
In cell-based NIPT, STR analysis is only performed to determine if the cell is fetal. The genetic analysis afterwards, 
such as CNV detection, is more important. Therefore, the applied WGA method should also be able to result in a 
reliable CNV profile. For instance, MALBAC did not perform well for CNV analysis and was therefore not tested in 
this study. DOPlify was one of the better methods for CNV detection and might therefore be a suitable candidate 
in a cell-based NIPT context on fresh cells.  
The results for STR analysis were very different when the cells were preserved before amplification, as 
demonstrated in Chapter X. All REPLI-g amplified samples showed a very high dropout rate and lacked thereby the 
ability to descent the genetic identity of a cell. In contrast, the other WGA methods showed some improvements. It 
has been described that a long heating step will be necessary to overcome chemical fixation. This might explain 
why REPLI-g, having the shortest lysis and performed at an overall low temperature, results in such bad results. 
This time, SurePlex showed the best results, but again one sample failed to show a descent profile. Thereby, it 
seems again less robust compared to DOPlify and Ampli1, but SurePlex had a lower dropout rate. It was even clearer, 
after preservation, that Ampli1 samples had a consistent dropout at 6 loci. The STR profiling after Ampli1 could 
probably be improved by selecting other STR markers. In a cell-based NIPT setting, CNV profiling will again be the 
most important determinant when deciding on a WGA method. Similar to the STR results after preservation, REPLI-
g amplified samples were not able to deduce a descent CNV profile. The other three methods were similar to each 
other, but Ampli1 was the only one without false positives. For the latter, the CNV detection seems to have improved 
over the analysis on fresh cells. The CNV profiles after DOPlify and SurePlex were also good, but not improved over 
fresh cell analysis. Therefore, for cell-based NIPT purposes, Ampli1 might be the preferred candidate. Our results 
prove that BCT preservation does not hamper DNA analysis, as long as it is combined with an appropriate WGA 
method.  
We can conclude that we laid the foundation to introduce shallow MPS as a substitute for aCGH for CNV and 
aneuploidy detection in PGD. Subsequently, we characterized the performance of most modern WGA methods in 
respect to downstream applications such as shallow whole genome sequencing CNV analysis and STR analysis of 
single fixed and unpreserved cells. Thus, we have the necessary tools ready to perform genetic analysis for cell-


































Chapter XII: Broader international context, relevance and future 
perspectives 
God blessed them; and God said to them, “Be fruitful and multiply” (Gen 1:28). Apparently, some couples have not 
been blessed that much, as one in six couples are unable to conceive by natural conception. Fortunately, a lot of 
these couples might still conceive using ART, and in particular IVF. 
The financial and emotional burden of ART, and PGD to lighten the load 
Before couples turn to ART, most of them have already been trying for some time to conceive naturally. When they 
finally turn to IVF/ICSI, most couples need on average 3 cycles before they get pregnant. The financial and emotional 
burden for those couples should not be underestimated. Every failed implantation can be emotionally very hard on 
the couple and the average cost per IVF cycle in Europe can vary between € 4000-5000 (ESHRE facts sheet 4; Jan 
2017). However, most countries in Europe provide full or partial reimbursement, lowering the financial burden 
(Figure 1). In the USA, no federal law regulates ART and therefore most treatments are performed within a private 
market system and can thereby rise up to $ 12400 per cycle (ESHRE facts sheet 4; Jan 2017). Nevertheless, even 
reimbursement is not unlimited and will stop after a certain amount of cycles. Therefore, it is important that the 
success rate for IVF/ICSI is high enough to minimize the failures and hence the financial and emotional burden.  
 
Figure 1: Reimbursement for IVF/ICSI in Europe (SANCO/2008/C6/051) 
Unfortunately, some embryos will suffer from genetic abnormalities without obvious abnormal morphological 
features (12, 19, 20). Without a genetic analysis, such embryos might fail to implant or result in abnormalities in the 
fetus. Due to PGD/PGS, a genetically normal embryo can be selected for transfer. Before PGD/PGS, the only options 
for couples producing too much genetically abnormal embryos were: remaining childless, prenatal diagnosis, 
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adoption or gamete donation. PGD/PGS has shown an added value to the ART outcome when using aCGH for analysis 
(20, 61). This demonstrates the relevance of PGD/PGS to lower the financial and emotional burden of IVF/ICSI. 
However, genetic selection of embryos is an ethically charged subject and is therefore not allowed in some 
countries in Europe (Figure 2). Even if it is prohibited, the costs for genetic analysis are extra on the already very 
expensive ART treatment. Less fortuned people will therefore still have no access to it. Some countries in Europe 
have a reimbursement policy for PGD (Figure 2), but not for PGS.  
 
Figure 2: Reimbursement situation for PGD treatment (SANCO/2008/C6/051) 
Belgium is one of those countries that is reimbursing PGD. The genetic centers get reimbursed per treatment by 
the health security system and the patients only have to pay a small personal contribution to the center per 
treatment. Nevertheless, the patient contribution and reimbursement still not completely cover the costs made by 
the genetic centers. As PGD will increase the cost and duration of the IVF/ICSI treatment, an efficient detection of 
the present abnormalities in the embryo is very important. The burden of the treatments on the health security 
system should also not be underestimated. The money going to failures could have been allocated to better a 
recourse. Therefore, it is very important that the technologies used for PGD are accurate, provide enough 
information and have an acceptable price.  
Current state-of-the art PGD/PGS technologies for CNV and aneuploidy detection, such as aCGH, proved their value, 
but the cost is relatively high and the resolution limited. This is where MPS has more room to optimize.  
We succeeded in developing a workflow to analyze chromosomal aberrations in PGD after MPS and were able to 
show a higher accuracy and flexibility of MPS over aCGH (Chapter IV). The quite large amount of research involving 
MPS in PGD, performed during and since our study, really stresses the relevance of this research worldwide (32, 
163, 179, 207). In the meantime, different genetic centers worldwide, among which the one at the UZ Ghent, have 
implemented MPS for chromosomal aberration detection in PGD. Some live births of healthy babies after MPS PGD 
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have even been reported already (31, 235, 236). Given the rather recent implementation, randomized controlled 
trials reporting the added value of MPS over aCGH to the PGD-outcome are still rather scarce (237). General 
assumptions on the financial benefit of MPS over aCGH also remain difficult, as this will depend on the sample 
throughput and the overall diagnostic setting. MPS allows not only for multiplexing PGD samples, but also for 
simultaneous sequencing of PGD samples with samples from other applications (NIPT, exome seq). This will most 
likely decrease the cost for PGD. However, centers with only a low sample throughput might not experience these 
financial benefits.     
Despite the observation that MPS is more flexible to increase the resolution in PGD compared to conventional 
techniques, we also observed that the WGA method is a limiting factor to further increase the resolution. A 
technique used for PGD must be very accurate to decrease financial and emotional burden of the patients. Therefore 
false positive or missed calls cannot be tolerated. We focused a big part of this dissertation on testing the most 
modern WGA methods in this context to possibly improve the accuracy of the DNA amplification. REPLI-g, GenomiPhi, 
GenomePLEX and MALBAC are the most widely applied WGA methods in publications (on average 23/method). The 
former three are older methods and as fewer WGA methods existed in the past, they were often used. The number 
of publications using these methods is however declining over time, except for REPLI-g. REPLI-g is still frequently 
used for SNV calling (Source: Web of Science; PubMed). MALBAC is a WGA method developed by an Asian company 
and therefore most publications using MALBAC are from that side of the world. Other more recent methods, such 
as SurePlex and Ampli1, have only been described sporadically. However, we were the first and only group using 
DOPlify and PicoPLEX DNA-Seq in a study. There is no consensus about the best WGA method, as the performance 
of a WGA is application dependent (130). Therefore, the choice of the WGA will be very important for the success of 
the application. Similar to us, others have also been comparing different WGA methods in a specific context (198, 
199, 209, 221). 
Even if the WGA was not limiting the resolution, the implementation of higher resolution analysis will be a matter 
of regulation. The regulation of ART and PGD differs around the world, even within Europe differences are observed. 
In the USA no regulations concerning the use of PGD exists. Therefore, PGD can be used for a variety of controversial 
purposes, including sex selection, selection for deafness and dwarfism or selection for a sibling who can serve as 
tissue donor for sick relatives (238). In Europe, all countries have their own specific regulation. For instance, the 
particular set of conditions for which PGD is permitted in Italy and Switzerland is not regulated as it is in France 
and the UK, which have a detailed regulatory framework. In the latter, certain authorities regulate when PGD can 
be offered. In Belgium, no detailed regulations for PGD are set either. Aside from eugenic selection and sex selection 
for non-medical reasons, the medical genetic centers can decide for themselves when PGD can be applied (239).  
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In terms of regulation and reimbursement, it is also important to make a distinction between PGD and PGS. PGS is 
applied in cases with unexplained ART failure, to screen for genetic abnormalities not explained by the parental 
karyotype. Although the technologies used for chromosomal aberration detection, such as aCGH and MPS, do not 
differ between PGD and PGS, most reimbursement policies will only apply in case of PGD. Therefore, costs for PGS 
can rise up to 2000 euros. One of the reasons PGS is still not reimbursed, is the ongoing discussion on the usefulness 
of PGS. Some European countries, such as Italy, do not even allow PGS (238). Nevertheless, in Chapter IV, we clearly 
detected aberrations not derived from the parental karyotype in most of the abnormal embryos. Although the 
evidence on the added value of PGS on ART is growing (30, 240), only very few randomized control trials are 
available on PGS. The accuracy of PGS is also compromised by the degree of mosaic embryos. Cases have been 
described where aneuploidy embryos resulted in euploid babies, which could question the accuracy of only one 
trophectoderm biopsy to predict the ploidy status of the embryo (241). Nevertheless, in most samples, the mosaic 
status of an embryo can be deduced from the aCGH or MPS CNV profile (242). Therefore, the issue lies not so much 
with PGS per see, but with the difficult interpretation of mosaic results.    
An even more complicated issue is the use of PGS in the case of SGDs. Research showed the value of aneuploidy 
screening in patients undergoing PGD for SGDs (243). Half of the patients in the study had at least one embryo that 
was SGD-unaffected but aneuploid. Nowadays, selection based on chromosomal abnormalities and SGDs are two 
separate tests and thereby two different biopsies.  
MPS has the potential to combine PGS for chromosomal aberrations and PGD for SGDs, which would imply only one 
biopsy to test both. Apart from the ethical discussion on whether to apply MPS for screening in this context, the 
state-of-the-art methods for SGD detection are time consuming as they are mutation and patient specific. Therefore, 
MPS might provide an alternative. Efforts have already been made to use MPS for SGDs or a combination of SGDs 
and aneuploidy detection (137, 207, 236, 244). Those studies use MPS as a targeted approach for one specific SGD. 
A targeted approach still requires some pre-testing concerning the specific mutation in the parents, which is again 
time consuming. Whole genome sequencing (WGS) for SNVs is still too expensive and a lot of unknown SNPs and 
multifactorial treats will be detected, which are difficult to interpret. Especially since some of these detected 
aberrations might be derived from WGA bias. Given ART is already very time consuming and expensive, another 
approach might be considered. In this respect, we tested the TruSight One Sequencing panel in this dissertation. By 
screening for more than 4800 possible disease-causing gene regions at once, we hope to avoid the need for pre-
testing. The panel captures only the DNA parts related to these mutations, avoiding WGS and thereby lowering the 
price and facilitate the interpretation. However, WGA remains necessary to generate enough DNA for the analysis 
and, more than for CNV detection, the WGA limited the application. Therefore, further research is needed before 
clinical implementation. This method would also enable the simultaneous analysis of CNVs at a reasonable 
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resolution as shown before on prenatal samples (46). However, as the combination of the panel with WGA is not 
yet optimized, we did not yet test CNV analysis with the panel.  
If such a panel would ever be applied in a pre-birth diagnostic setting, this would imply serious ethical regulations 
as it will involve PGS. The importance in combined chromosomal and SGD screening has already been discussed 
above. However, also de novo gene mutations are common in embryos (245, 246), also indicating the relevance of 
PGS. In each embryo, 44 to 82 de novo single-nucleotide mutations are expected, with one to two affecting the 
coding sequence (247-250). Still, concerns are raised about screening the genome for such small aberrations. It 
might lead to the discovery of variances of unknown significance (VOUS). Nevertheless, this risk is in part avoided 
by the use of a targeted panel, as the captured regions belong to known disease-causing gene regions. Another 
issue when using the panel for PGS, is the detection of the carrier status of the fetus. Clear regulations should be 
set to deal with such information, before implementing this type of screening in a diagnostic setting.  
The worldwide implementation of cell-free NIPT   
Lately, cell-free NIPT has been in the news a lot, as from the first of July, Belgium is the first country in Europe that 
reimburses cell-free NIPT. This test analyzes cell-free DNA in the blood of a pregnant woman after venipuncture. 
The way the media introduced the test to the people, wrongly assumes that this test can replace invasive prenatal 
testing. The technique is indeed safer than invasive techniques, but it has no diagnostic value. It will only test for 
Down syndrome (trisomy 21), Edwards syndrome (Trisomy 18) and Patau syndrome (trisomy 13). The test has only 
a 99% accuracy and is therefore only recommended as a screening test. Invasive testing is still strongly 
recommended after receiving a positive NIPT result. Nevertheless, cell-free NIPT screening is more accurate than 
current serum marker screening and ultrasound imaging (251, 252).  
Today, cell-free NIPT is a worldwide application. It was first introduced in Hong Kong in 2011 (NIFTY) and was soon 
after introduced commercially in the US (253-255). The global NIPT market is estimated to reach a value of $3.62 
billion by 2019 (256). MaterniT21Plus by Sequenom (San Diego, CA, USA) was the first commercially available cell-
free test in the US, followed by Verify (Verinata Health, Redwood City, CA, USA), Harmony (Ariosa Diagnostics, San 
Jose, CA, USA), Panorama (Natera, San Carlos, CA, USA), and ext. Those companies offer their tests worldwide in over 
60 countries, but North America accounts for more than half of their market (256). Other companies, such as 
LifeCodexx, are also located in Europe and have a mainly European market. The disadvantage of the 
commercialization, is the uncontrolled cost and the lack of counseling. CVS and amniocentesis are nearly always 
reimbursed in some way, but NIPT costs can rise up to $3000 in the US and €850 in Europe (254). However some 
private insurance companies start to include NIPT in their assortment. If such a test is performed independent of 
any clinician, the lack of counseling offered to the patient complicates the interpretation of the results. However, 
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nowadays NIPT is no longer solely offered by commercial companies, but also genetic centers often offer in-house 
optimized and validated tests (such as those in Belgium). Such centers can provide more information concerning 
the results. The increased accuracy over the current screening systems should lower the number of unnecessary 
invasive procedures. On the other hand, also a lot of couples will wrongly assume that the diagnostic value of this 
test is similar to invasive techniques. As a consequence, practitioners will have to perform less invasive procedures. 
As this is a rather delicate procedure, less practice might lower the quality of the tests. However, the decrease in 
reimbursement allocated to CVS and amniocentesis will probably not yet outweigh the extra burden introduced to 
our health security system by this test. There is need for a single, safe, accurate test, performed early in pregnancy 
that might replace both tests. 
A good non-invasive prenatal diagnosis (NIPD) test should be able to replace the invasive prenatal tests by a safe 
one, with the same diagnostic value. As the cell-free fetal DNA can never be physically separated from the 
abundance of maternal DNA, the genetic analysis will probably never parallel the invasive diagnosis (133). There is 
growing evidence that intact fetal cells can be isolated from the maternal blood circulation. Prenatal diagnosis on 
such cells, could probably replace invasive prenatal techniques. A cell-based NIPT workflow should be able to 
isolate rare, pure and intact fetal cells with well-preserved genomic DNA from a blood tube, to perform single cell 
genetic testing for fetal identity and abnormalities up to small CNVs. In this respect, we developed already a 
workflow during this dissertation to perform genetic testing for both fetal identity and chromosomal aberrations 
on single fresh or fixed cells.   
Cell-based NIPT: The holy grail in prenatal diagnosis? 
Since the discovery that fetal cells are present in the maternal blood circulation during pregnancy in 1959, people 
have been trying for years to isolate them. The research came to a slow start, as they had difficulties to prove the 
fetal nature and mainly focused on lymphocytes. After some initial promising studies with fetal nucleated red blood 
cells, the interest regarding these cells began to grow extensively, resulting in the ‘golden era’ of circulating fetal 
cell research between 1993 and 2003 (103, 257) (Figure 3). Nevertheless, failure to detect fetal cells in every 
pregnancy and an inability to obtain a correct diagnosis, dampened the initial enthusiasm for circulating fetal cells 
(103).  




Figure 3: Number of publications targeting fetal cells in maternal blood (257) 
The last couple of years, the interest for cell-based NIPT has raised again after some successful research with fetal 
trophoblasts (258-260). Technical evolutions over the recent years have further enhanced the development of 
isolation techniques around the world. The group from P. Paterlini-Brechot (Rarecells, Université Paris Descartes) 
was among the first to publish a successful prenatal diagnosis from fetal trophoblast cells isolated from maternal 
blood samples during pregnancy (105, 109, 261, 262). They used an in-house developed ISET system combined with 
laser microdissection to isolate trophoblasts based on size. Thereby, they were able to perform prenatal targeted 
diagnosis for cystic fibrosis and spinal muscular dystrophy (105, 109). Originally, their research focused on the size-
based isolation of CTCs from the blood of cancer patients (109, 263-265), but they soon discovered that the ISET 
could also be applied for trophoblast isolation. Tumor cells and trophoblast cells both show a distinct cell size 
compared to the surrounding blood cells. 
So far, only a few groups around the world were able to perform a genome-wide prenatal diagnosis from isolated 
fetal trophoblasts. This low number is probably caused by the challenges that this research faces. First of all, no 
specific fetal marker has been discovered yet. Therefore, antibody labeling will only enrich your sample for fetal 
cells, not result in a pure fetal cell sample. Second, due to the rarity of these cells, the initial enrichment step must 
be able to lose a large part of the unwanted cells, without losing too much of the targeted cells. The detection 
techniques after labeling/enrichment should be able to spot those target cells between large amounts of non-
target cells. Third, the cells should be isolated as single cells to first prove their fetal nature before genetic analysis. 
Fourth, a DNA amplification step will be obligatory due to the rarity of the cells. Finally, the DNA of the fetal cells 
must remain intact during all of these manipulations to provide a reliable diagnosis.  
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Researchers from Baylor College of Medicine (Houston, Texas, US) were the first ones to report a successful 
genome-wide diagnosis for small CNVs from fetal trophoblasts isolated from maternal blood samples (110). They 
did not rely on the trophoblast size for cell enrichment, but used antibody labeling combined with automatic single 
cell scanning and picking using the CyteFinder (RareCyte Inc.). Shortly thereafter, ARCEDI (Veijle, Denmark) 
published similar results, detecting large chromosomal aberrations, using a patented antibody mix for magnetic 
enrichment and automatic scanning using a MetaSystems scanner with an in-house developed cell classifier (259). 
Although, the group from Rarecells in Paris was among the first to report fetal cell isolation in the maternal blood 
circulation, they only reported results after a targeted diagnosis. Some time ago our research group started 
collaborating with them to perform genome-wide analysis on their single trophoblasts isolated from an ISET filter. 
As we already developed a workflow for CNV analysis in PGD, we believe this approach could also be applied to 
cells isolated from the maternal blood.  
Those three groups are among the most promising for cell-based NIPT so far. However, they are not ready to replace 
the invasive techniques in routine diagnostics. Baylor and ARCEDI still seem to lose a lot of cells during trophoblast 
enrichment, as their yield is only ±0.4 cells/ml of blood. According to previous reports one to six cells per milliliter 
of maternal blood should be present (107). Although Rarecells was able to enrich a bit more cells, they are not 
ready to perform a genome-wide analysis on the trophoblasts. The quality of the samples after laser 
microdissection limits the analysis possibilities. Our collaboration with Rarecells is still ongoing and we hope to be 
able to perform a genome-wide analysis in the near future.  
To implement cell-based NIPT in the routine genetic diagnostics, more than one cell per patient will be essential. 
Breman et al. suggests to have at least five cells per patient and in cases with possible confined placental 
mosaicism (CPM) a second blood sample with 10-20 cells might be necessary (110). Single cell analysis is always a 
bit tricky as WGA might have caused some bias in the DNA. When enough cells are analyzed, we could probably 
identify the bias. However, we could also consider to combine the DNA from the different WGA products and conduct 
a single analysis for the combined cells. As the amplification bias is rather random, the bias should be partially 
eliminated after combining different WGA samples. However, CPM will then be more difficult to detect. More 
research will be needed to define the frequency of CPM in cell-based NIPT from trophoblasts. Although, it will 
probably be similar to the 1-2% observed in CVS.  
Rarecells has already shown that their technique is applicable to both CTC and fetal cell isolation. The field of CTC 
research is a lot bigger than the small niche of researchers looking for fetal cells. Nevertheless, fetal cell research 
might profit from the fast technological developments for CTC enrichment. Our research group recently initiated 
the development of a workflow for cell-based NIPT based on a workflow for CTC enrichment.  As our group already 
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has a lot of experience with DNA analyses on a limited number of cells, we hope to be able to safeguard the DNA 
quality for a proper STR and CNV analysis after fixation, staining, enrichment, isolation and amplification. The 
influence of two of these factors, fixation and amplification, has already been studied in this dissertation. 
The implementation of a cell-based NIPT for prenatal diagnosis will lower the occurrence of miscarriages due to 
invasive technologies and might therefore lower the threshold for some couples to perform a genetic analysis on 
their fetus. In this respect, cell-based NIPT can lower the number of unprepared parents or decrease the burden on 
the health security system for the lifetime costs of an affected child (266). It might also decrease the number of 
unnecessary abortions performed due to false positive cell-free NIPT, as a lot of couples do not choose to perform 
a follow up invasive test after cell-free NIPT.  
Future technological evolutions might further complicate the interpretation of genetic data.  
Recent introduction of third generation sequencing might improve the analysis of single cells. Technologies, such 
as PacBio and NanoPore, do no longer need a clonal amplification step, which might partly reduce amplification 
bias. They are also able to create much longer reads than current technologies, which will improve the allocation 
of reads to their genomic location. However, they do not yet have the throughput and accuracy to sequence the 
complete human genome. Besides that, bias introduced during clonal amplification alone cannot explain the 
presence of all false CNVs we detected in our samples and omission will therefore not solve all bias. The possibility 
for long read sequencing will not even apply for whole genome amplified DNA, as the fragment length after WGA 
will still limit the read length.  
Nevertheless, newer sequencing technologies might further evolve towards immediate sequencing of unamplified 
single cells and therefore enable further drop in the resolution possible for genetic diagnosis. However, the 
interpretation of such results will be more complicated and needs to be accompanied by a strong regulation and 
genetic counseling possibilities. This even posed already problems for invasive microarray testing (267-269) and 
pediatric whole genome/exome sequencing (270).  There is currently no consensus on how to clinically manage 
VOUS (271) and when to return these incidental findings to patients (267, 268). A worldwide consensus will never 
be possible as too many difference exist between countries and even within some countries (ex. different states in 
the US). It is obvious that technical evolutions in genetic diagnostics will have to be accompanied with evolutions 
in counseling systems and genetic regulation. However, I believe that within the near future cell-based NIPT will 






























Algemene discussie & Samenvatting 
In de discussie sectie van ieder hoofdstuk werden de resultaten van de individuele studies reeds grondig besproken. 
In dit hoofdstuk zullen we deze resultaten samenvatten en de algemene bevindingen bespreken.  
Onze eerste doelstelling was om shallow MPS te introduceren in PGD als mogelijke vervanger voor array 
comparatieve genome hybridisatie (aCGH) voor de analyse van chromosomale aberraties. Vooraleer we dit konden 
bereiken, ontwikkelden we eerst een algemene workflow, om op een gelimiteerde hoeveelheid cellen kopie 
nummer variatie (CNV) analyse uit te voeren na shallow MPS en dit met behulp van de gepaste whole genome 
amplificatie (WGA) methode. In Hoofdstuk III gebruikten we deze workflow om aan te tonen dat SurePlex WGA, 
vergeleken met MALBAC, beter geschikt was voor CNV-analyse na ‘shallow MPS’ van een gelimiteerde hoeveelheid 
cellen. Een geschikte WGA-methode voor CNV-analyse moet resulteren in een uniforme read distributie over het 
volledige genoom. Een niet-uniforme distributie van de reads zou kunnen wijzen op een over- of onder-amplificatie 
van bepaalde genomische regio’s. Dit zou CNV’s introduceren die oorspronkelijk niet aanwezig waren in het genoom 
of bestaande CNV’s maskeren, wat zou leiden tot een verkeerde interpretatie van de genoomsequentie. Na 
amplificatie met MALBAC was de read distributie niet-uniform, resulterend in een biased CNV-profiel. Er werden 
een groot aantal CNVs gemist, terwijl er andere vals positieve CNV’s wel werden gecalled. SurePlex amplificatie 
resulteerde daarentegen in een meer uniforme read distributie, met als gevolge een min of meer compleet CNV-
profiel met minder vals positieven. Beide methoden zijn hybride PCR-methoden die, op de primers na, ongeveer 
hetzelfde amplificatie mechanisme gebruiken. Het is mogelijk dat de primers, gebruikt tijdens MALBAC-amplificatie, 
niet uniform binden aan het genoom of dat de loop vorming suboptimaal is doorgegaan.  
Na beide methoden waren de vals positieve calls niet volledig consistent tussen de verschillende replicaten. Dit 
wijst er mogelijks op dat de amplificatie bias random werd geïntroduceerd en daarbij dus moeilijk te voorspellen 
valt. De één-cel samples vertoonden meer bias dan de drie- en vijf-cel samples. We zagen de bias verminderen 
wanneer we gebruik maakten van de PCR-vrije library preparatie methode. Dit toont aan dat een deel van de bias 
waarschijnlijk veroorzaakt werd door de enrichment PCR-stap tijdens de library preparatie. Desalniettemin, een 
deel van de bias bleef toch aanwezig na het weglaten van de enrichment PCR, zeker voor MALBAC-samples. De bias 
was dus afkomstig van zowel de WGA, als de enrichment PCR. Deze studie toonde ons dat SurePlex WGA mogelijks 
kan gebruikt worden voor CNV-detectie in PGD na shallow MPS van drie of meer cellen.  
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Daaropvolgend hebben we een gelijkaardige workflow, gebruik makende van SurePlex WGA, aangewend om ons 
eerste doel te bereiken. In Hoofdstuk IV toonden we aan dat shallow MPS op trophectoderm biopsieën een voorkeur 
geniet op aCGH voor het detecteren van chromosomale en structurele abnormaliteiten in PGD-embryo’s. Met 
shallow MPS kon een hogere resolutie en een betere signal-to-noise ratio behaald worden in vergelijking met aCGH. 
Daarnaast kunnen veel stalen met elkaar en met stalen van andere applicaties (NIPT, exome sequencing) samen 
gesequeneerd worden op één run, waardoor de kost per sample zou moeten dalen. Deze bevindingen tonen aan 
dat MPS preciezer en flexibeler is dan aCGH. Voor bepaalde patiënten met een gekende kleinere afwijking kan de 
resolutie na MPS nog verlaagd worden (door de window size te verkleinen), specifiek voor dat chromosomale 
segment, zonder daarbij meer vals positieven te detecteren in de rest van het genoom. ACGH is hierin niet zo flexibel, 
want de resolutie is gelimiteerd tot de afstand tussen de probes. Vervolgens toonden we ook als één van de eersten 
aan dat de Illumina (NextSeq500) en Ion Torrent (Ion Proton) sequenerings-technologieën beiden toepasbaar 
waren in deze context en gelijkaardige resultaten vertoonden. De bovenstaande workflow werd in detail 
beschreven in Hoofdstuk V. Ondertussen wordt shallow MPS al succesvol toegepast voor CNV en aneuploidy detectie 
in PGD in verschillende genetische centra, waaronder het medisch genetisch centrum van Gent. 
In deze klinische setting was SurePlex WGA zeker geschikt voor de amplificatie van 4-6 trophoblast cellen en een 
CNV-analyse aan een ≥ 3Mb resolutie. Een hogere resolutie in deze studie werd echter wel verhinderd door de 
representatie bias geïntroduceerd door de WGA. Naarmate minder cellen geamplificeerd worden zal deze bias nog 
toenemen (Hoofdstuk III). Dit geeft aan dat in een setting waar single-cel analyse heel belangrijk is (cel-gebaseerde 
NIPT of de detectie van heterogeniteit in een cel-populatie), een betere WGA-methode zal moeten worden 
aangewend. Daarom hebben wij, op verzoek van een aantal commerciële partners, een aantal andere WGA-
methodes uitgetest voor CNV-analyse na single-cel sequenering, hopelijk resulterend in minder bias.  
De eerste methode die getest werd, TruePrime WGA, gaf teleurstellende resultaten (Hoofdstuk VI). De read 
distributie was absoluut niet uniform en maakte het onmogelijk om een deftig CNV-profiel te bepalen. Onze 
resultaten suggereren dat TruePrime WGA niet geschikt is voor CNV-detectie na MPS van een gelimiteerd aantal 
cellen. Het kan dan ook geen verrassing zijn dat tot nog toe geen artikels werden gepubliceerd waarin deze 
methode werd toegepast. Het enige artikel dat te vinden is, is er één van het bedrijf dat de kit produceert (192). Wij 
vermoeden dat de instabiliteit van het TthPrimPl primase aan de basis ligt van de representatie bias. Het is mogelijk 
dat de stabiliteit van het primase erop achteruit gaat tijdens het verschepen naar andere locaties. Dit zou aantonen 
dat deze versie van de kit nog niet klaar is voor distributie. Kort na het publiceren van onze resultaten werden wij 
gecontacteerd om de nieuwe versie van hun kit te testen. Jammer genoeg waren deze resultaten niet veel beter 
dan hun eerste versie.  
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In Hoofdstuk VII werden DOPlify en PicoPLEX DNA-Seq vergeleken met Ampli1 en REPLI-g voor CNV-detectie na MPS 
van een gelimiteerd aantal cellen. Deze keer werd enkel de PCR-vrije library preparatie techniek toegepast. Alle 
vier de WGA-methoden lijken toepasbaar voor CNV-detectie na MPS van een gelimiteerd aantal cellen, maar DOPlify 
en PicoPlex DNA-Seq blonken uit. Na deze laatste twee werden alle verwachte CNV’s gedetecteerd, zonder vals 
positieven en dit zowel bij een 1Mb als een 500kb window. Na Ampli1 en REPLI-g werden reeds vals positieven 
gedetecteerd bij een 1Mb window en steeg het aantal tot respectievelijk twee- en driemaal zoveel bij een 500kb 
window. Niettegenstaande werden sommige kleinere CNV’s wel beter gedetecteerd in deze samples, wat kan 
wijzen op een lagere lokale signal-to-noise ratio na Ampli1 en REPLI-g amplificatie. Om deze reden zal men, voor 
deze twee methoden, de afweging moeten maken tussen enerzijds een hogere resolutie en anderzijds minder vals 
positieven. 
DOPlify en PicoPLEX DNA-Seq zouden mogelijks SurePlex kunnen vervangen voor het detecteren van chromosomale 
aberraties in een klinische PGD-setting. PicoPLEX DNA-Seq gebruikt dezelfde WGA-technologie als SurePlex, maar 
de library preparatie is geïntegreerd tijdens de amplificatie. Dit maakt een aparte library preparatie onnodig. Qua 
kosten, tijd, contaminatierisico en gevoeligheid voor fouten, is deze methode te verkiezen boven SurePlex in een 
PGD-setting met Illumina sequenering. DOPlify is een geavanceerde DOP-PCR, maar meer details over de 
technologie werden niet vrijgegeven. Hoogstwaarschijnlijk werd het Taq polymerase vervangen, wat een 
verbetering zou zijn t.o.v. SurePlex. Als we DOPlify met PicoPLEX DNA-Seq vergelijken dan stellen we vast dat DOPlify 
beter is voor single-cel amplificatie, maar de twee gefaalde samples suggereren wel dat de methode minder 
robuust is dan PicoPLEX DNA-Seq. Aan de andere kant is PicoPLEX DNA-Seq minder flexibel, want deze resulteert 
altijd in een Illumina library en is dus niet compatibel met Ion Torrent sequencing.  
In vergelijking met SurePlex lijken REPLI-g en Ampli1 meer bias te introduceren. Er werden namelijk geen vals 
positieven gedetecteerd in de drie PCR-vrije SurePlex samples uit Hoofdstuk III. Echter, dit zou ook kunnen berusten 
op toeval, aangezien slechts drie PCR-vrije SurePlex samples beschikbaar zijn ter vergelijking. Toch, REPLI-g maakt 
gebruik van de MDA-technologie en het is gekend dat hybride WGA-methoden beter zijn voor CNV-‘detectie dan 
WGA-methoden met de MDA-technologie (130). Het mechanisme achter Ampli1 hangt dan weer af van de 
beschikbaarheid van restrictie sites. Een niet-uniforme distributie van deze sites langs het genoom zal leiden tot 
bias tijdens de amplificatie. Ampli1 vertoonde wel een iets hogere reproduceerbaarheid dan REPLI-g, daar die 
laatste meer vals positieven introduceerde. Deze bevindingen waren vergelijkbaar met een voorgaande studie door 
Hou et al., waarbij Ampli1 een lagere amplificatie bias en een accuratere single-cel CNV detectie vertoonde dan 
REPLI-g (198). 
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In Hoofdstuk VIII hebben we ons gefocusseerd op het vinden van een betaalbare genoom-wijde analyse voor single 
nucleotide variaties (SNV’s) gebruikmakende van MPS, die mogelijks een applicatie zou kunnen worden in PGD. 
Hiervoor hebben we het TruSight One sequencing panel getest om, vertrekkende van een gelimiteerd aantal cellen, 
meerdere SNV’s simultaan te analyseren. Het TruSight One sequencing panel werd oorspronkelijk ontwikkeld om 
te screenen voor verschillende monogenetische aandoeningen in een prenatale setting na de vlokkentest. Dit panel 
voert een simultane capture uit van 4800 genomische regio’s die geassocieerd zijn met bepaalde monogenetische 
aandoeningen en analyseert deze in één sequencing run. In een PGD-setting zal WGA nodig zijn om de kleine 
hoeveelheid startmateriaal te amplificeren. Zoals verwacht waren de resultaten verschillend voor WGA-DNA en 
bulk-DNA en we zagen dat dit verschil afhankelijk was van de gebruikte WGA-methode. De combinatie van SurePlex, 
Ampli1 en MALBAC WGA met het panel leek het niet goed te doen, want een groot aantal SNV’s werd gemist of 
verkeerd gecalled. De combinatie van REPLI-g WGA met het panel was beter en meer vergelijkbaar met de 
resultaten van een bulk sample. De targeted coverage en variant calling kwam dicht in de buurt van de resultaten 
van de bulk samples. REPLI-g maakt gebruik van de MDA WGA-technologie en zou dus beter geschikt zijn voor SNV 
calling vergeleken met hybride WGA methoden (130). Echter, werd nog niet aangetoond dat dit ook geldt wanneer 
een capture is uitgevoerd vóór de SNV-analyse. MALBAC en SurePlex gebruiken beide het Bst polymerase voor hun 
pre-amplificatie stap en dit heeft een lagere betrouwbaarheid dan Phi29 polymerase gebruikt door REPLI-g. De 
betrouwbaarheid van de polymerase is veel belangrijker in deze context dan bij CNV-detectie. Ampli1 kan mogelijk 
gefaald hebben door een samenloop van de target sites van het panel en de zones geknipt door het restrictie-
enzym, met als gevolg dat een aantal regio’s niet kunnen gecaptured worden. Opnieuw was de bias tussen de 
verschillende replicaten in de vier methoden niet consistent en zal de introductie van bias tijdens amplificatie dus 
hoogstwaarschijnlijk random verlopen.  
PicoPLEX DNA-Seq en DOPlify werden niet getest in deze studie want bij aanvang waren deze nog niet gelanceerd 
op de markt. Desalniettemin, PicoPLEX DNA-Seq gebruikt dezelfde WGA-technologie als SurePlex, waardoor we dus 
gelijkaardige resultaten kunnen verwachten. Bovendien resulteert deze WGA in een library die hoogstwaarschijnlijk 
niet kan gebruikt worden als startmateriaal voor het panel. In de toekomst kan het interessant zijn om eventueel 
nog DOPlify te testen in deze setting. Indien het panel goed zou werken op WGA-materiaal, zou het eventueel de 
state-of-the-art technologieën voor SGD-analyse in PGD kunnen vervangen. Hoewel de resultaten na REPLI-g 
amplificatie er veel belovend uitzien, zijn er toch nog grote verschillen met de bulk samples. Er zal dus nog een 
grondige klinische validatie nodig zijn van dit panel in combinatie met WGA vooraleer het kan toegepast worden 
in de kliniek.  
Het laatste deel van deze thesis focust op STR-analyse in WGA geamplificeerde single cel samples. De genetische 
identificatie van een cel kan belangrijk zijn in applicaties zoals cel-gebaseerde NIPT. In Hoofdstuk IX werd nagegaan 
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of STR-analyse mogelijk was na amplificatie van één of drie cellen met SurePlex, Ampli1, REPLI-g of DOPlify. 
Gelijkaardig met de resultaten voor SNV-analyse, was REPLI-g wederom de beste WGA-methode. REPLI-g was de 
enige WGA-methode in deze studie die een volledig STR-profiel kon bepalen van tenminste sommige van zijn stalen. 
Echter, een compleet STR-profiel is niet noodzakelijk om de genetische identiteit van een cel te bepalen in een cel-
gebaseerde NIPT-context. Een foetaal profiel zal bij heterogene merkers één allel van de moeder hebben en één 
allel van de vader. Het profiel van de moeder zal dus vergeleken worden met het nieuwe profiel en daaruit wordt 
dan afgeleid of het een zuiver maternale cel is of niet. Ampli1, SurePlex en DOPlify resulteerden meestal in een half 
STR-profiel, wat voldoende is om het foetale karakter van de cellen af te leiden. Na Ampli1 was de drop-out van 
een zestal regio’s consistent tussen de verschillende samples, wat zou kunnen gerelateerd zijn aan het 
werkingsmechanisme van Ampli1. Het restrictie-enzym zal waarschijnlijk knippen aan de STR-primerbindingsite in 
deze regio’s, waardoor hun amplificatie wordt geblokkeerd. Deze loci zouden kunnen vervangen worden door loci 
buiten de restricitezones, waardoor Ampli1 in een beter STR-profiel zou kunnen resulteren. De drop-out na SurePlex 
en DOPlify is meer random. SurePlex lijkt meer geschikt voor STR-analyse dan DOPlify en Ampli1, maar één van zijn 
samples vertoonde wel geen bruikbaar STR-profiel. Daardoor lijken DOPlify en Ampli1 robuuster en bijgevolg ook 
reproduceerbaarder.  
In een cel-gebaseerde NIPT-setting is STR-analyse enkel nodig om zeker te zijn dat de geanalyseerde cel foetaal is. 
De genetische analyse, zoals CNV-detectie, is veel belangrijker in deze diagnostische setting. Daardoor is het 
belangrijk dat de gebruikte WGA-methode ook leidt tot een betrouwbare CNV-analyse. Bijvoorbeeld, MALBAC 
resulteerde in een mindere CNV-analyse en werd daarom niet getest in deze studie. DOPlify was één van de betere 
voor CNV-detectie en zou dus weleens de meest geschikte kandidaat kunnen zijn in een cel-gebaseerde NIPT-
setting op verse cellen.  
De STR-resultaten zijn echter verschillend wanneer de cellen gepreserveerd zijn vóór amplificatie (Hoofdstuk X). 
Na REPLI-g amplificatie was er enorm veel drop-out en kon er dus geen genomisch profiel worden bepaald. Het 
werd al eerder aangetoond dat een voldoende lange heating-stap bij cel lyse belangrijk zal zijn bij het voorkomen 
van chemische fixatie. Dit kan verklaren waarom REPLI-g, met de kortste lyse stap en de lage temperatuur, zorgt 
voor de slechtste resultaten. In tegenstelling tot REPLI-g toonden de andere WGA-methoden een lichte verbetering 
na fixatie. SurePlex had de laagste drop-out rate, maar opnieuw viel één van de stalen uit. Daardoor lijkt deze 
opnieuw minder robuust dan DOPlify en Ampli1. Echter, in een cel-gebaseerde NIPT-setting zal CNV-analyse alweer 
een belangrijke determinant zijn bij het kiezen van een WGA-methode. Voor REPLI-g waren de CNV-resultaten even 
onbruikbaar als zijn STR-resultaten. De andere drie WGA-methoden toonden vergelijkbare CNV-profielen met elkaar, 
al was Ampli1 de enige zonder vals positieven. Voor deze laatste was zelf een kleine verbetering zichtbaar t.o.v. 
CNV-analyse op verse cellen. Het werd na fixatie nog duidelijker dat de drop-outs na Ampli1 niet random zijn en 
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dus mogelijks te verbeteren met een betere plaatsing van de gekozen loci. Onze resultaten suggereren dat Ampli1 
de meest geschikte kandidaat zou zijn voor cel-gebaseerde NIPT op gefixeerde cellen. We toonden in deze studie 
ook aan dat BCT-preservatie de DNA-analyse niet in de weg staat, zolang het gecombineerd worden met een 
geschikte WGA-methode. 
Uit deze thesis concluderen we dat we mee de fundering gelegd hebben voor de introductie van shallow MPS in 
PGD voor CNV en aneuploidy detectie, als een vervanger van aCGH. Verder hebben we ook de prestatie van de meest 
moderne WGA-methodes bestudeerd voor onder andere shallow MPS CNV-analyse en STR-analyse op single 
gefixeerde en niet-gepreserveerde cellen. Bijgevolg hebben we de nodige tools klaar voor een genetische analyse 
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